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SUMMARY
HSV-1 is a human pathogen which initially infects epithelial cells (usually causing 'cold 
sores' around the mouth) and then establishes life-long latent infection in sensory 
neurons. A knowledge of the mechanisms by which latent infection is established and 
by which reactivation occurs is likely to be a key factor in understanding the biology of 
the virus.
The HSV-1 virion contains a double stranded linear genome of 152kD which 
encodes at least 77 genes. These genes are expressed in a temporally regulated cascade 
during lytic infection in tissue culture. The five immediate-early genes are 
transactivated by a component of the virion tegument (Vmw65) in a complex with 
cellular proteins. The expression of at least three,Vmw 175, Vmw63 and Vmwl 10, is 
necessary for the efficient transactivation of early and late genes. Vmw 175 is the major 
viral transactivator and Vmw63 is thought to act at the post-transcriptional level. The 
mechanism of action of Vmwl 10 is unclear.
Vmwl 10 is a 775aa phosphoprotein which is localised to discrete domains in the 
nucleus, called ND10, at early times of infection. The protein is encoded by gene EE1 
which yields one of the five HSV-1 transcripts that are spliced. VmwllO is non- 
essential in tissue culture but deletion mutant viruses exhibit a cell type and multiplicity 
dependent defect in plaque formation as a result of inefficient induction of early and late 
gene expression. Whilst VmwllO is also non-essential for infection in mouse model 
systems, deletion mutant viruses reactivate inefficiently from latency. In an in vitro 
latency system, Vmwl 10 is both necessary and sufficient to reactivate quiescent viral 
genomes. In transfection assays, VmwllO has been shown to be a potent and 
promiscuous transactivator of gene expression, particularly in synergy with Vmw 175, 
and five functional regions have been identified on the basis of mutational analysis; one 
of these encompasses the RING finger and another the C-terminal end of Vmwl 10. The 
C-terminal end is important for the initial interaction of VmwllO with ND10; this 
provided circumstantial evidence for Vmwl 10 interacting with cellular proteins via C- 
terminal residues. Given the potential involvement of Vmwl 10 in the switch between 
lytic and latent infection, it was considered important to pursue any potential 
interactions between Vmwl 10 and cellular proteins.
To investigate the interactions of the C-terminal end of VmwllO with cellular 
proteins, a series of Vmwl 10 C-terminal GST fusion proteins were made and used in 
'pull-down' experiments with radiolabelled whole cell extracts. Vmwl 10 residues 594- 
775 (GEXE52) were found to bind strongly and specifically to a 135kD protein from all 
cell types tested and to a 150kD protein from some cell types. A shorter fusion protein 
containing VmwllO residues 633-775 (GEXE58) did not interact with the 135kD 
protein indicating that residues 594-633 of Vmwl 10 are necessary for the interaction in
this system. GEXE58 bound the 1501eD cellular protein whilst a fusion protein 
containing VmwllO residues 680-775 (GEXR5) did not, showing that VmwllO 
residues between 633 and 680 are necessary for this interaction.
Immune precipitation experiments carried out by other members of the group 
showed that purified, intact VmwllO bound a 135kD protein and a collaborative 
reciprocal depletion experiment indicated that the 135kD proteins in the two systems 
were likely to be the same. In order to further understand the mechanism by which 
Vmwl 10 acts during infection, it was considered important to purify the 135kD protein 
and attempt the cloning of a cDNA.
The 135kD protein was purified in a large scale GST 'pull-down' experiment and 
the fusion protein bound samples containing the 135kD protein were blotted onto a 
PVDF membrane. The 135kD protein band was isolated and submitted for 
microsequence analysis by Dr. P. Matsudaira (MIT). Six peptide sequences were 
obtained and the information employed in the design of redundant PCR primers for use 
in cloning a cDNA. This approach was unsuccessful and a long probe (53 bases) was 
designed based on one of the longer peptides, taking into account the optimum codon 
usage in the human genome (Lathe rules), for use in screening a cDNA library. This 
approach was also unsuccessful during the course of these studies but another member 
of the group was successful with this method later on.
Indirect evidence from another laboratory indicated that C-terminal residues of 
Vmwl 10 contain a multimerisation domain; it was possible that such a domain could 
include or overlap with the residues required for 135kD protein binding, so the 
multimeric nature of Vmwl 10 was examined more closely. The Vmwl 10 E52 and E58 
sequences were cloned into a T7 expression system and following expression, the 
Vmwl 10 peptides (T7E52 and T7E58) were purified by ion exchange chromatography. 
Analysis of the purified peptides by gel filtration chromatography, glycerol gradient 
centrifugation and glutaraldehyde cross-linking showed that both formed multimers of 
higher order than dimers although their precise nature could not be resolved. These 
experiments clearly separated the VmwllO residues required for 135kD binding (594- 
633) from those containing an independent multimerisation domain.
The significance of the VmwllO:135kD proteinrprotein interaction and the 
function of Vmwl 10 multimerisation during the life cycle of the virus are unknown,as 
yet, but undoubtably, this work has opened a new door for studying the mechanism of 
action of Vmwl 10 during HSV-1 infection.
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PAGE: polyacrylamide gel electrophoresis
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SDS: sodium dodecyl sulphate
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F Phe Phenylalanine TTC TTT
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V Val Valine GTA GTC GTG GTT
W Trp Tryptophan TGG
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CHAPTER 1 INTRODUCTION
The research presented in this Thesis concerns the interactions of the HSV-1 immediate- 
early protein Vmwl 10 with cellular proteins. In Sections 1A and IB, general features 
of the biology of herpesviruses and in particular an outline of the life-cycle of HSV-1 
are discussed. In Section 1C, the regulation of HSV-1 gene expression is discussed 
further and Section ID covers current knowledge of Vmwl 10 to date and the related 
cellular processes with which it may be involved.
1A Herpesviruses
1A1 Distribution and clinical aspects
The Herpesviridae form a large family of viruses; almost 100 members with diverse 
biological properties have been characterised. Most animal species examined have 
yielded at least one herpesvirus and the host range covers humans, horses, cattle, pigs 
and fowl. Thus, not only are these viruses relevant to the clinician but also to the 
veterinarian with particular reference to western economy. Molecular studies of these 
viruses have provided, and continue to provide, valuable insights into the molecular 
mechanisms of gene expression and its control. In addition, increasing interest has been 
taken recently in the use of human viruses as vectors for gene therapy.
Over recent years, human herpesvirus infections have become more relevant to the 
clinician with advances in organ transplantation techniques and with increased 
incidences of HIV infection. Infections are more prevalent in immune compromised 
individuals, whether this is dmg induced, such as in transplant patients, or if it occurs as 
a result of the onset of AIDS. Seven herpesviruses have been isolated from humans; 
herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), varicella 
zoster virus (VZV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), 
human herpes virus 6 (HHV6) and human herpes virus 7 (HHV7). Herpes virus-like 
sequences have been found in over 90% of AIDS-related Kaposi’s sarcoma tissue, 
indicating that an eighth human herpes virus may exist (Chang et al., 1994). More 
recently these sequences have also been found in Kaposi’s sarcomas of HIV negative 
individuals which has resulted in the speculation that a herpes virus, designated 
Kaposi’s sarcoma herpes virus (KSHV), may be involved in the pathogenesis of the 
tumour (Schalling et a l , 1995).
The herpes simplex viruses primarily infect epithelial tissue through the mucosa 
and abraded skin. Virions are transported to neuronal ganglia where latent infection is 
established. Of the two serotypes, HSV-1 is historically responsible for the common 
'cold-sore' and HSV-2 for genital lesions. However, this distinction is no longer valid as 
HSV-1 is now the causative agent of 30-50% of genital infections (Kinghom, 1993) and
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HSV-2 the causative agent of 5-20% of oral infections (Wiedbrauk and Johnston, 1993). 
HSV-1 is widespread and is usually acquired in childhood; over 90% of western 
populations are seropositive by the age of sixty (Nahamias et al., 1970). HSV-2 
infection occurs later in life and is generally acquired by sexual transmission (Johnson 
et a l , 1989; Kinghorn, 1993). The herpes simplex viruses also cause conjunctivitis, 
herpetic whitlow, keratitis and encephalitis. Neonatal infections are often life 
threatening and are acquired during birth from mothers with genital lesions.
Primary infection with varicella zoster virus (VZV) generally occurs in childhood 
with the appearance of a rash after 14-15 days which is often accompanied by fever. 
Herpes zoster, resulting from reactivation of latent virus from neuronal ganglia, is 
characterised by the appearance of lesions at the involved dermatome and is frequently 
accompanied by severe pain which can persist for months following healing of the 
lesions (reviwed by Gelb, 1990).
Human cytomegalovirus infection is widespread with up to 60% of western 
children and up to 100% of children in developing countries acquiring the virus before 
the age of six years. Primary infection is generally asymptomatic and cytomegaly 
(enlargement and fusion of macrophages) is a feature. As with other herpes viruses, 
persistent and recurrent infection can occur as a result of reactivation of latent virus. 
Reinfection with other genetically distinguishable isolates of differing serology is 
known to occur. Infection is a problem in immune compromised hosts and symptoms 
include gastroenteritis and retinitis. In severe infections, widespread cytomegaly occurs 
(cytomegalic inclusion disease) and whilst this can be asymptomatic to a degree, it can 
be fatal, particularly in the newborn (reviewed by Alford and Britt, 1990).
Epstein-Barr virus is usually acquired during childhood when infection is often 
asymptomatic. Primary infection in older children and adults results in infectious 
mononucleosis. The virus has been associated with the pathogenesis of Burkitt's 
lymphoma and nasopharyngeal carcinoma (reviewed by Kieff and Liebowitz, 1990).
In comparison with the human herpesviruses discussed above, little is known 
about human herpesvirus 6. It is clear that infection is widespread in the adult 
population and that it is acquired in childhood when it is associated with roseola 
(exanthem subitim). The virus may play a role in the pathogenesis of AIDS but this has 
yet to be verified (reviewed by Lopez and Honess, 1990).
Human herpesvirus 7 was isolated from T lymphocytes of a healthy individual 
(Frenkel et al., 1990) and, like human herpes virus 6, has been associated with roseola 
in infants (Burns et al., 1994; Hidaka et al., 1994; Tanaka et al., 1994; Ueda et al., 
1994; Ablashi etal., 1995).
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1A2 Herpesvirus classification and distinctive features
Under the Baltimore classification system, the Herpesviridae fall into group I as double 
stranded DNA viruses. Inclusion in the family is based on the structure of the virion 
(Figure lA2(i)) (reviewed by Dargan, 1986 and Rixon, 1993). Distinctive features are: 
the core containing a linear, double stranded genome of 100-230kb (these are among the 
largest DNA viruses) (Epstein, 1962a) within an approximately 125nm diameter 
icosahedral capsid made up of 162 capsomeres (Wildy et al., 1960); the tegument which 
is an amorphous structure surrounding the capsid (Roizman and Furlong, 1974); and the 
envelope containing viral glycoproteins (Spear and Roizman, 1972).
Figure 1A2(0 Electron micrograph of a herpes simplex virus type 1 virion. The 
micrograph shows the characteristic features of a herpes virus virion; the envelope 
containing viral glycoproteins and a central, inner capsid, which is 125nm diameter, are 
visible. The tegument is between the capsid and the envelope. The photograph is 
shown with the permission of Dr. F. Rixon.
On the basis of a number of early electron micrographs, the virion core was 
thought to contain the DNA arranged as a toroid around a central protein 'plug' (Furlong 
et al., 1972; Nazerian, 1974). It was later suggested that this was an artifact of 
specimen preparation (Puvion-Dutilleul et al., 1987) and there is now general agreement 
that the core contains only DNA which is present in a liquid crystalline state (Booy et 
al., 1991).
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Figure 1A2(ih A schematic diagram of the sequence arrangements in the six classes 
of genomes of the viruses comprising the family Herpesviridae. The six classes, A-F, 
are exemplified by channel catfish herpesvirus, herpesvirus saimiri, EBV, VZV, HSV 
and tupaia herpesvirus respectively. In the diagram, horizontal lines represent unique 
or quasi-unique regions. Reiterated domains are represented by rectangles, 
designated as follows; left and right terminal repeats (LTR and RTR) for class A; 
repeats R1 to R4 for the internal repeats of class C; and internal terminal repeats of 
class D. At the termini of classes B and C the repeats are reiterated numerous times. 
The termini of class E consist of two elements; one terminus contains 'n1 copies of 
sequence 'a' next to a larger sequence designated 'b*. The other terminus has one
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directly repeated 'a' sequence next to a sequence designated 'c'. The terminal 'ab' and 
'ca' sequences are inserted in reverse orientation internally in the genome (see primes) 
separating the unique sequences into long (UL) and short (Us ) domains. 
Recombination between repeated sequences results in the four combinations in 
orientation of UL and Us shown. Similarly, the short unique sequence of D type 
genomes can invert as shown.
An interesting feature of herpesvirus DNA is the variation in genome size of any 
one herpesvirus which arises as a result of the variation in the number of terminal and 
internal reiterated sequences. There are six different genome arrangements, designated 
A-F (Figure lA2(ii)). In group D genomes, for example VZV, the sequences of one 
terminus are repeated in an inverted orientation internally. The unique domain flanked 
by the inverted repeats can invert relative to the remaining sequences such that two 
populations of virus exist which differ only in their genome arrangements. The same is 
true of group E genomes, exemplified by the herpes simplex viruses. The genomes of 
this latter group of viruses exist as four different isomers.
Most investigations of the structure of the virion capsomere have been carried out 
with HSV-1 capsomeres, but the morphology of all herpesvirus capsids is similar. Of 
the 162 capsomeres making up the icosahedral capsid, 150 are hexameric and 12 
pentameric. The hexamers occupy the faces and edges of the capsid and the pentamers 
are at the vertices (Schrag et al., 1989; Baker et al., 1990; Booy et al., 1991). Studies of 
HSV-1 capsid assembly have become more amenable with the development of an in 
vitro assembly system (Newcomb et al., 1994) and a recombinant baculovirus assembly 
system in insect cells (Tatman et al., 1994).
The structure of the virion tegument and the process by which it is acquired is 
poorly understood. Viral structural proteins are assigned to the tegument if they are 
known not to be components of the capsid or envelope (Rixon, 1993). It is clear that 
whilst purified herpesvirus DNA is capable of initiating infection, certain tegument 
proteins can influence the process of infection. For example, the HSV-1 tegument 
protein Vmw65 (the gene product of UL48) is required for efficient expression of 
immediate-early (IE) genes. Vmw65 enhances productive infection at low multiplicities 
(Ace etal., 1989).
The virion envelope has a trilaminar appearance in electron micrographs (Epstein, 
1962b) and has been observed to be derived from cellular membranes (Armstrong et al., 
1961; Morgan et al., 1968). A number of viral glycoproteins present in the HSV-1 
envelope are known to be necessary for fusion of the virion envelope with the plasma 
membranes of host cells, a process which results in delivery of the capsid to the 
cytoplasm. At least ten distinct glycoproteins are present on the surface of HSV-1 
virions (reviewed by Spear, 1993).
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The herpesviruses have a number of biological features in common; they all 
encode enzymes for nucleic acid metabolism and DNA replication occurs in the nucleus 
of the infected cell. Capsid assembly also occurs in the nucleus and capsids bud from 
the nuclear membrane. In addition, virion production generally leads to cell death and 
all members investigated have the ability to cause latent infection, i.e. they may remain 
in a quiescent, undetected state within the host with the ability to be reactivated.
On the basis of differences in the biology of these viruses, the Herpesviridae 
family has been further subdivided into the alpha, beta and gamma herpesvirinae 
(Roizman et al., 1981). The alpha herpesvirinae are characterised by their short 
productive cycle (less than 24 hours in tissue culture) and their establishment of latency 
in sensory neurons. Examples include HSV-1 and HSV-2. The beta group have a longer 
productive cycle and include the human and murine cytomegaloviruses. Viruses in the 
gamma group infect B or T lymphocytes and all members replicate in lymphoblastoid 
cells in vitro. An example is EBV. As with any classification system, the divisions are 
not completely adequate and some viruses do not fit clearly into any one group. For 
example, HHV-6 is biologically a gamma herpesvirus but has been assigned to the beta 
subfamily on the basis of its genome structure and sequence.
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IB HSV-1 biology
HSV-1 was the first human herpesvirus to be discovered and has also been the most 
intensely investigated. The virus is usually acquired by close physical contact with an 
infected person during childhood. Infectious virus replicates in susceptible epithelial 
cells and initiates the formation of an inflamed lesion, usually around the mouth, called 
a 'cold-sore'. Virions enter sensory neuron endings and are transported to the cell bodies 
in sensory ganglia where latent infection is established.
In this Section, aspects of both lytic (productive) and latent infection are briefly 
described. Where information is relevant to HSV-1 and HSV-2, the term HSV is used.
1B1 The HSV genome
The HSV DNA genome is linear and double stranded (Becker et a l., 1968). It is 
approximately 150kbp with a G+C content of 68% (HSV-1) or 69% (HSV-2). HSV-1 
strain 17+ has a genome size of 152 kilo base pairs (McGeoch et al., 1986; McGeoch et 
al., 1988a; Perry and McGeoch, 1988). The structure is that of the class E genome and 
four isomers exist (see above and legend to Figure lA2(ii)). The HSV-1 genome 
encodes at least 77 genes, fifty nine mapping to U l, thirteen to Us and two copies of 
four genes to the repeated sequences.
1B2 The lytic life cycle
In tissue culture, the HSV-1 lytic life cycle is completed during a period of less than 24 
hours. The stages involved are: attachment (to the cell plasma membrane), viral 
envelope fusion with the plasma membrane and entry into the cell, transport to the 
nucleus and release of DNA, gene expression and DNA replication, and virion 
production. Cell death inevitably ensues.
1B2.1 Adsorption, penetration and uncoating
The initial stage of infection involves attachment of the virion to the cell surface. The 
cell surface receptors are heparan sulphate proteoglycans (reviewed in Spear, 1993; 
Shieh and Spear, 1994). Enzymatic removal of heparan sulphate from cell plasma 
membranes renders cells resistant to HSV infection. Chinese hamster ovary cells, 
which are defective in heparan sulphate synthesis, are also resistant to infection. The 
initial interaction of an HSV-1 virion with the cell is the binding of gC, one of at least 
ten virion glycoproteins present on the external surface of the virion, to heparan 
sulphate. This interaction can be inhibited and reversed by the addition of exogenous 
heparin. The non-essential nature of this interaction is demonstrated in gC null mutant 
viruses which still bind to the cell surface with only a slight reduction in binding 
efficiency and infectivity compared to wild-type virus. It is evident that another viral
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glycoprotein, gB, also mediates heparan sulphate binding; mutant viruses which express 
neither gC or gB bind to cells in tissue culture extremely inefficiently. Unlike gC 
mutant viruses, gB null mutant viruses fail to penetrate into the cell, despite the ability 
of the virions to interact with heparan sulphate (reviewed by Spear, 1993).
The initial and relatively non-specific interaction at the cell surface mediated by 
gC and gB is followed by a heparin resistant interaction which involves gD. 
Glycoprotein gD is essential for virus penetration; it has been shown that binding to 
cells of inactivated virions containing gD can inhibit the penetration but not the initial 
binding of a homologous challenge virus and that a truncated soluble form of gD which 
binds to cells can also inhibit HSV-1 entry but not binding to the cell surface. Cells 
expressing gD are resistant to HSV-1 penetration but virions bind to the cell surface. 
These results indicated that there is a specific cell receptor for gD; it has been shown 
that gD is modified by mannose-6-phosphate and can bind to two different mannose-6- 
phosphate receptors (Brunetti et al., 1994; 1995). Blockage of the mannose-6- 
phosphate receptors in tissue culture does not completely inhibit viral penetration, 
indicating that another cell surface receptor facilitates this activity. This is reflected in 
the necessity, not only for gB and gD in viral penetration, but gH also. Glycoprotein gH 
forms heterodimers with another glycoprotein, gL, an association that appears to be 
essential for the processing and intracellular transport of both proteins. It is therefore 
not surprising that gL null mutants are also non-viable. Viable gK null mutant viruses 
are unobtainable as well, indicating that this protein is also essential for penetration 
(reviewed by Spear, 1993).
Following envelope fusion with the plasma membrane and subsequent 
penetration, viral capsids are transported to the nuclear membrane and DNA is released 
into the nucleus through pores in the nuclear membrane in a process requiring a viral 
function (Tognon et al., 1981; Batterson et al., 1983). The transport process is thought 
to be mediated by the cellular cytoskeleton (Kristensson et al., 1986). Viral gene 
transcription and DNA replication occur in the nucleus.
1B2.2 Viral gene expression
HSV gene expression occurs in a temporally regulated cascade (Section 1C) and genes 
are classified as a, (3 and y (Honess and Roizman 1974, 1975) or immediate-early (IE), 
early (E) and late (L) (Clements et al., 1977). Genes are transcribed by cellular RNA 
polymerase II with the participation of viral factors (Ben-Zeev and Becker, 1977; 
Costanzo et al., 1977). The mRNAs produced are capped, methylated and 
polyadenylated and are translated on bound and free polyribosomes. Viral proteins can 
be extensively processed by cleavage, phosphorylation, sulphation or poly(ADP) 
ribosylation (reviewed in Roizman and Sears, 1990).
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The HSV-1 virion tegument protein, Vmw65, is required for transactivation of the 
five IE genes. As detailed later (Section 1C) the products of at least three IE genes are 
necessary for fully efficient expression of E and L genes. EE gene expression is 
necessary for efficient E gene expression which peaks 5-7 hours post infection, and L 
gene expression follows the onset of DNA replication at approximately 3 hours post 
infection. There are two classes of L gene; leaky-late (or y  1) genes are expressed at low 
levels prior to viral DNA replication and require the onset of replication for maximal 
expression and true late (or y2) genes are expressed only following the onset of 
replication. Specific aspects of the regulation of gene expression are discussed in 
Section 1C.
1B2.3 DNA Replication
HSV-1 DNA replication can be detected as early as 2 hours post infection and continues 
for at least 9-14 hours (Roizman et al., 1963; Roizman and Roane, 1964). Replication 
occurs by a rolling circle mechanism and head to tail concatemers accumulate in the 
nucleus (reviewed by Roizman and Sears, 1990) in so-called 'replication compartments' 
(Quinlan etal., 1984; de Bruyn Kops and Knipe, 1994).
There are three origins of replication in the HSV-1 genome and their positions 
were initially deduced from the structures of defective genomes. Two, designated orisi 
and oris2> are identical and map in the 'c' inverted repeat of the S component of the 
genome. The third, ori l, is found in the L component.
Seven genes have been found to be necessary and sufficient for origin dependent 
DNA synthesis. The products of UL5, UL8 and UL52 form a primase and helicase 
complex. The product of UL9 is an origin specific DNA binding protein and the UL29 
gene product binds single stranded DNA. The UL30 and UL42 genes encode the 
catalytic and accessory subunits of the viral DNA polymerase respectively (reviewed by 
Challberg, 1991). Other virally encoded enzymes are also involved in nucleic acid 
metabolism; for example, thymidine kinase, ribonucleotide reductase, uracil-DNA 
glycosylase and dUTPase (reviewed in Roizman and Sears, 1990).
1B2.4 Virion assembly
The mechanism of capsid assembly and DNA packaging in HSV-1 virion assembly is 
not fully understood. Three types of capsid can be isolated from infected cells 
designated A (empty), B (containing a proteinaceous core) and C (mature virions). It is 
thought that B capsids are the precursors of A and C capsids.
Capsids are made from seven viral proteins encoded by six genes (Table 1B2.4). 
During assembly, which occurs in the nucleus of infected cells, it is thought that the 
products of six genes assemble to form a B type capsid; the outer icosahedral shell is 
formed by VP5, VP19C, VP23 and VP26 and an internal scaffold is formed by VP22a
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and the product of gene UL26; the UL26 gene product undergoes autoproteolysis to 
give VP24 and VP21 and the proteolytic activity also modifies VP22a. DNA packaging 
then occurs with removal of VP21 and VP22a to generate C capsids. Type A capsids 
may be the products of abortive packaging events (reviewed in Rixon, 1993).
PROTEIN Mr(X10=2} GENE LOCATION
VP5 155 UL19 Icosahedral shell
VP19C 53 UL38 Icosahedral shell
VP21 42 UL26 Scaffold
VP22a 38 UL26.5 Scaffold
VP23 33 UL18 Icosahedral shell
VP24 25 UL26 Scaffold
VP26 12 UL35 Icosahedral shell
Table 1B2.4 Table showing the proteins involved in capsid assembly and their 
locations within the capsid.
Packaging of concatemeric DNA arising from replication (see above) occurs by a 
procedure during which concatemers are processed into genome length molecules by 
cleavage at 'a' sequences. There is evidence that cleavage and packaging are linked 
processes as viruses with mutations in the genes encoding VP5, VP19C, VP23 and the 
protease fail to cleave concatemeric DNA (reviewed by Roizman and Sears, 1990).
Little is known of the precise details by which the tegument and envelope are 
acquired. It is apparent from electron microscopy that there are two possible pathways. 
In the first model, capsids bud through the inner nuclear membrane and the newly 
acquired membrane fuses with the outer nuclear membrane and capsids are released into 
the cytoplasm. The tegument is then assembled and the capsids are enveloped as they 
bud through the plasma membrane, so releasing mature virions. In the second model, 
the tegument is acquired in the nucleus and capsids bud through the inner nuclear 
membrane and leave the perinuclear cisterna in a vacuole formed by the outer nuclear 
membrane. The vacuole and plasma membranes eventually fuse and mature virions are 
released from the cell. Both procedures involve a traverse through the Golgi apparatus 
(reviewed by Rixon, 1993).
1B2.5 The effect of HSV infection on the cell
Cells productively infected with HSV do not survive. Major structural alterations 
occur; the nucleolus disintegrates during the course of infection and host chromatin is 
dispersed to the edge of the nucleus and degraded. The nuclear envelope becomes 
distorted and multilobed as infection proceeds, and other cellular membranes form
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thickened patches along their surfaces. This could be due to the deposition of tegument 
proteins (reviewed by Roizman and Sears, 1990).
Immediately upon infection, a rapid shut-off of host macromolecular synthesis 
occurs. Host DNA synthesis is shut off (Roizman and Roane, 1964), host protein 
synthesis declines very rapidly (Sydiskis and Roizman, 1966; Read and Frenkel, 1983), 
host ribosomal RNA synthesis is reduced (Wagner and Roizman, 1969) and 
glycosylation of host proteins ceases (Spear et al., 1970). However, it is apparent that 
some cellular promoters are transactivated and that this requires the presence of 
Vmwl75 (Latchman et al. , 1987; Kemp and Latchman, 1988). VmwllO may also be 
involved (Everett, 1985).
HSV-1 host shut-off occurs in two stages. An early shut-off mechanism involves 
a protein present in the virion and a delayed mechanism requires viral protein synthesis 
(Nishioka and Silverstein, 1977, 1978a, 1978b; Fenwick and Walker, 1978; Fenwick 
and Clark, 1982).
The rapid shut-off function was mapped to the UL41 gene (whose product is vhs ) 
by studies of mutant viruses defective in the early shut-off process (Fenwick et al., 
1979; Kwong et al., 1988). The vhs protein is non-essential for replication in tissue 
culture and vhs mutants over-express viral proteins (Read and Frenkel, 1983) due to the 
stabilisation of viral RNA (Kwong and Frenkel, 1987; Oraskar and Read, 1987). Recent 
studies have shown that vhs forms a complex with VP 16 (a-TIF) and that this blocks 
the ability of VP 16 to form a transactivating multiprotein complex (see Section 
lC l.l(ii)) with cellular factors on immediate early gene promoters (Smibert e ta l , 1994). 
However, host factors bind VP 16 more avidly than vhs and it may be that early in 
infection, the host cell proteins Oct-1 or HCF displace vhs from VP 16 such that 
transactivation of immediate-early gene promoters is concomitant with early host shut- 
off.
There is also evidence that another virion protein, the product of the UL13 gene, is 
involved in host cell shut-off since UL13 mutants display a vhs-type phenotype 
(Overton etal., 1992; 1994).
1B3 The latent state
As well as productively infecting host epithelial cells in vivo, HSV-1 has the ability to 
latently infect host cell sensory neurons. Latent infection is characterised by the 
absence of viral antigens and infectious virus. There are three aspects of
latent infection; establishment, maintenance and reactivation.
Insights into the mode of establishment of latent infection have come mainly from 
studies with mutant viruses capable of latent infection but which do not replicate in 
ganglia during productive infection at the epithelia. Viral genomes, which are probably 
encapsidated, pass by fast retrograde axonal transport to sensory neuron cell bodies
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located in ganglia. Once in the ganglia, either viral replication, with production of 
progeny virus and neuronal cell death, or establishment of latent infection occurs. The 
precise mechanism for the latter situation is unclear. It has, however, been concluded 
that the decision to enter latent infection is made early in the virus:cell interaction, prior 
to high levels of expression of IE polypeptides. It is possible that cellular factors may 
be involved in repressing EE gene expression (reviewed by Stevens, 1989; Rock, 1993).
(i) Latency in mice
Early studies investigating the latency competence of mutant viruses in mouse models 
measured the ability of a virus to reactivate from latency. It was possible, however, that 
replication deficient viruses could establish latent infection which would not have been 
detectable in these experiments. A careful study to differentiate between the ability of 
mutant viruses to establish latent infection and to reactivate was carried out by Lieb et 
al. (1989). They examined the role of three EE proteins (Vmwl 10, Vmwl75, Vmw63) 
in latent infection in the mouse ocular model and they also addressed the question of 
whether or not viral replication at the initial site of infection is necessary for the 
establishment of latency. It was found that viral mutants in the genes encoding 
Vmwl75 and Vmw63 did not replicate in the eye, as detected by plating eye swab 
material onto complementing cell lines. In addition, these viruses could not be 
reactivated from explanted ganglia which were superinfected with a helper virus or 
ganglia which were explanted onto complementing cell lines. It was concluded that 
viruses which fail to replicate at the initial site of infection also fail to establish latent 
infection in this model. Vmwl 10 deficient viruses were found to replicate in the eye 
and also to establish reactivatable latent infection in the ganglia in these experiments, 
although at reduced efficiency compared with wild type virus.
The latency competence of a Vmw65 mutant virus, ml814, was also examined in 
the mouse ocular model (Steiner et al., 1990). The 12bp insertion in the gene encoding 
Vmw65 yields a product which is functional in its structural role in the virion but is 
incapable of transactivating IE gene promoters (Ace et al., 1989; Section lC l.l(ii)). 
The virus was shown to be avirulent in mice (Ace et al., 1989; Steiner et al., 1990) and 
also to establish latency in trigeminal ganglia in spite of its inability to replicate 
following corneal inoculation (Steiner et al., 1990). This contradiction with the results 
of Lieb et al. (1989) was explained by proposing that mutant viruses in the genes 
encoding Vmwl75 and Vmw63 had established a low level latent infection which was 
not detectable by the investigative methods utilised.
(ii) Host cell factors
Even though ml814 can reactivate from latency in mice, it has been proposed that the 
failure to express IE genes, as mediated via the TAATGARAT motif in EE promoters, is
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an important step in the establishment of latency. This suggestion has arisen as a result 
of a number of observations; Vahlne and Lycke (1977) showed that HSV-1 replication 
was restricted in the mouse neuroblastoma cell line C l300 and attributed this to a non­
interferon factor (Vahlne and Lycke, 1978). The block was overcome by pretreatment 
of cells with sodium butyrate which resulted in increased transcription of IE genes (Ash, 
1986; Kemp and Latchman, 1989). The repression was later found to be mediated via 
the TAATGARAT element (Kemp et a l., 1990).
The CAT gene under the control of an IE promoter in a plasmid construct was 
expressed weakly in the ND series of cell lines which are derived from immortalised 
primary rat dorsal root ganglion (DRG) neurons (Kemp et al., 1990). However, 
cotransfection of plasmids encoding isolated TAATGARAT elements or the octamer 
motifs of cellular promoters led to increased CAT gene expression (Kemp et al., 1990; 
Wheatley et al., 1991). This suggested that an inhibitor of IE gene expression is present 
in ND cell lines which is titrated out by the addition of excess TAATGARAT or 
octamer motifs. In contrast to fibroblasts which express the Oct-1 factor which forms a 
complex with VP 16 at the TAATGARAT motif (Section lC l.l(ii)), ND cells and DRG 
were shown to contain significant amounts of Oct-2 mRNA (Lillycrop et al., 1991) 
which had previously been shown to be present in the embryonic sensory ganglia and 
adult neuronal tissues of rats (He et a l., 1989) and in mouse brain extracts (Scholer et 
al., 1989). The octamer/TAATGARAT binding protein Oct-2 was found to be absent 
from cells permissive for HSV-1 replication and down regulation of IE gene expression 
could be achieved by transfection of plasmids expressing Oct-2, thus confirming the 
role of Oct-2 as a repressor of IE promoters in neuronal cells (Lillycrop et al., 1991). 
Latchman's group have hypothesised that although neuronal cells express limited 
amounts of Oct-1 (He et al., 1989), Oct-2 binds TAATGARAT motifs preventing the 
formation of the Vmw65/Oct-l mediated transactivation complex (a similar complex 
cannot form with Oct-2). This would lead to repression of EE gene expression and the 
switch from the lytic cycle to latency.
The Oct-2 repressor protein found in ND cell lines was shown to be related to that 
found in B-cells, in which it acts as an activator (Muller et al., 1988; Lillycrop et al., 
1991; Latchman et al., 1992). The RNA encoding Oct-2 is alternatively spliced in both 
B-cells (Wirth etal., 1991) and neuronal cells (Lillycrop and Latchman, 1992) to yield 
multiple protein isoforms when translated. The predominant isoforms in neuronal cell 
lines, Oct 2.4 and Oct 2.5, lack a C-terminal activation domain (Wirth et al., 1991) and 
it is feasible that they are unable to form a complex with Vmw65 due to the absence of 
specific contact amino acids necessary for complex formation (Section lC l.l(ii)). The 
predominant B-cell isoform, Oct 2.1, which possesses the C-terminal activation domain 
was found to activate IE promoters (Lillycrop and Latchman, 1992; Lillycrop eta l., 
1994). Lillycrop et al. (1994) have concluded that expression of Oct 2.4 and Oct 2.5
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renders neuronal cells non-permissive for the HSV-1 lytic cycle. The role of these 
isoforms in vivo has yet to be established.
(iii) Latent viral genomes
The lack of detectable viral genomic termini during latent infection has led investigators 
to suggest that the viral genome is maintained either as a circular molecule or as a linear 
concatamer (Efstathiou et al., 1986; Rock and Fraser, 1983; 1985). Density gradient 
centrifugation has indicated that it is not integrated into the host cell genome (Mellerick 
and Fraser, 1987). Deshmane and Fraser (1989) have reported that latent HSV-1 DNA 
is associated with nucleosomes in a chromatin structure in latently infected neurons.
There has been much debate as to the number of viral genomes present in latently 
infected neurons. Early DNA hybridisation experiments suggested the number is 
between 0.01 and 1.0 per neuron (Puga et al., 1978; Cabrera et al., 1980; Rock and 
Fraser, 1983; Efstathiou et al., 1986) but more recent in situ PCR experiments indicate 
that the number is much higher, although exact values have not been calculated 
(Ramakrishnan etal., 1994; Mehta et al., 1995). The higher values suggest either that 
the original multiplicity of infection for latently infected neurons is higher than 
previously thought or that replication of the viral genome occurs without destruction of 
the infected neurone. As HSV can be recovered from the central nervous system only at 
very low efficiency, it is possible that the majority of latent genomes are associated in a 
chromatin-like structure which confers on them an inability to reactivate; perhaps the 
low level of reactivation seen reflects viral genomes which are not associated with 
nucleosomes.
Viral gene expression during latent infection is restricted to the latency associated 
transcripts (Section 1C3).
(iv) In vitro latency models
Studies of reactivation have been carried out in in vitro latency systems as well as in 
animal models (reviewed in Stevens, 1989; Rock, 1993). The molecular processes are 
thought to involve the immediate-early protein Vmwl 10, as Vmwl 10 mutant viruses 
reactivate poorly from the latent state in vivo (Clements and Stow, 1989; Lieb et al., 
1989; Cai et al., 1993) and Vmwl 10 mutant viruses are unable to stimulate the 
reactivation of latent virus in an in vitro latency system (Russell et al., 1987; Harris et 
al., 1989). Interestingly, unlike the situation observed in in vivo latency systems, 
Preston’s group (Jamieson et al., 1995) has shown that the tk gene of a mutant virus in 
their in vitro latency system is not arranged into the regular structure characteristic of 
cellular chromatin.
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1C HSV-1 gene expression
1C1 The temporal regulation of HSV-1 gene expression
The analysis of viral mRNAs and polypeptides produced during the course of HSV-1 
infection led to the identification of three groups of HSV genes characterised by their 
specific temporal expression and sensitivity to metabolic inhibitors (Honess and 
Roizman, 1974; 1975; Clements et al., 1977); alpha (a ) or immediate-early (IE), beta 
(P) or early (E) and gamma (y) or late (L). Transcription of immediate-early (IE) genes 
occurs immediately upon infection, in the absence of de novo viral protein synthesis.
Early (E) polypeptides are detectable soon after infection and are present at their 
highest levels 5-7hr post infection. Many of these genes encode polypeptides involved 
in viral nucleic acid metabolism. Genes in this group are sometimes classified as (31 
and P2, indicating that that not all E genes are transcribed simultaneously during 
infection (Honess and Roizman, 1974).
The late genes can also be divided into two groups, 'leaky-late' and 'true-late' or yl 
and y2 respectively. Their products can be detected 2hr post infection and increase to a 
maximum at approximately 12hr post infection. 'Leaky-late' genes are expressed at low 
levels prior to viral DNA synthesis but require the onset of viral DNA replication for 
maximal expression. 'True-late' genes, require the onset of viral replication before 
expression occurs.
1C1.1 Activation of IE gene transcription
(i) Promoter sequences
Analysis of the four HSV-1 IE promoters led to the identification of two separable 
regions (Makem and Roizman, 1982a; 1982b; Cordingley et al., 1983; Kristie and 
Roizman, 1984; Preston et al., 1984; Bzik and Preston, 1986): (i) a minimal promoter 
region comprising a TATA box and proximal upstream sequences which direct basal 
transcription, and (ii) an upstream enhancer element to which host factors and a 
complex of viral and host factors bind. Sequence analysis identified a conserved motif, 
TAATGARAT, within the IE enhancer regions (Makem and Roizman, 1982b; Murchie 
andMcGeoch, 1982; Preston etal, 1984).
Early experiments indicated that IE promoters are stimulated by a component of 
the virion (Post et al., 1981). In a series of experiments in which cloned HSV-1 DNA 
fragments derived from various parts of the genome were cotransfected into BHK cells 
with chimaeric plasmids expressing the thymidine kinase ( tk) gene under IE control, the 
virion component was identified as Vmw65 (also known as VP 16 or a-TIF) (Campbell 
et al., 1984), a late gene product which is found in the tegument of the virion (Batterson 
and Roizman, 1983; Weinheimer et al., 1992). Further transfection experiments with
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mutant and chimaeric forms of HSV-1 IE and E promoters showed that the conserved 
TAATGARAT motif present in one or more copies in IE gene promoter regions was 
necessary for Vmw65-mediated transactivation (Kristie and Roizman, 1984; Preston et 
al., 1984). However, the transactivating function of Vmw65 is non-essential for lytic 
infection in tissue culture; a virus, ml814, which encodes a Vmw65 protein which is 
functional in its role in virion structure but cannot transactivate EE promoters, has a high 
particle:pfu ratio and enters the lytic cycle in tissue culture, although only at high 
multiplicities of infection. Virus m l814 is also avirulent in vivo (Ace e ta l ., 1989).
A GA-rich motif upstream of the the TAATGARAT motif in the IE3 promoter 
was shown to be necessary for optimum levels of transcription from this promoter (Bzik 
and Preston, 1986; Triezenberg et a l., 1988a; 1988b). The EE4/5 and IE2 promoters also 
contain similar GA-rich motifs. LaMarco and McKnight (1989) identified a cellular 
factor which binds to the GA-rich motif, IE facilitator or (IEF)ga activity, but it was 
found not to mediate its effect by interacting with Vmw65. Characterisation of (IEF)ga 
led to the identification of the cellular GA binding protein (GABP) which has two 
subunits (LaMarco et a l., 1991). It is thought that GABP mediates promoter induction 
by cooperating with the cellular factor Oct-1 to enhance the formation of a multiprotein 
complex, which includes Vmw65, on the TAATGARAT motif. Interestingly, GABP 
binds the GA repeats of interferon-inducible promoters, indicating that during activation 
of IE genes HSV-1 may exploit a mechanism employed by mammalian cells to combat 
infection.
Analysis of GC-rich sequences in IE promoters showed the presence of motifs 
which bind the cellular factor Sp-1 in vitro (Jones and Tijan, 1985). These may account 
for the constitutive activity of IE promoters (Kristie and Roizman, 1984; Preston etal., 
1984; Bzik and Preston, 1986).
(ii) Vmw65 transactivation
A number of groups showed that Vmw65 did not bind directly to DNA, thereby raising 
the question of the mechanism of transactivation induced through the TAATGARAT 
motif (Marsden etal., 1987; O'Hare et al., 1988; Preston etal., 1988). A hint came with 
the identification of a cellular factor, NF-III (also called Oct-1) which binds to the 
octamer element in the adenovirus type 2 origin of DNA replication (the Ad2 octamer 
element) (Pruijn et al., 1986). It was quickly found that a cellular factor bound to the 
HSV-1 TAATGARAT motif (Kristie and Roizman, 1987; Preston et al., 1988) and this 
was identified as NF-III (Oct-1) (O'Hare and Goding, 1988).
In a series of binding experiments with infected cell extracts it was found that the 
complex formed on the TAATGARAT motif was modified by virus infection (Preston 
et al., 1988; O'Hare etal., 1988), and use of an anti-Vmw65 antibody identified Vmw65 
as one of the components. Mutational analysis showed that the TAAT component of
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the motif was necessary for Oct-1 binding and that mutations in the GARAT region 
affected complex mediated transactivation of IE genes (O'Hare et al., 1988; O'Hare and 
Goding, 1988). Oct-1 is a ubiquitous octamer binding homeodomain protein containing 
a POU domain which is essential for DNA binding. The POU domain consists of two 
subdomains, a POU-specific domain and a POU homeo domain. Expression of these 
two subdomains in isolation has shown that the Ad2 octamer element can be divided 
into two regions; one is recognised by both the POU-specific domain and the POU 
homeo domain and the other only by the POU-specific domain. The differing sequence 
specificity of the Oct-1 POU-specific domain compared with that of the POU 
homeodomain adds to the overall sequence specificity of this homeodomain protein. 
Interestingly, it has been shown that the sequence preferences of the isolated POU- 
specific domain are distinct from those of the entire POU domain, suggesting that the 
POU domain binding site is more than a simple juxtaposition of the POU-specific and 
POU homeo domain target sequences (Verrijzer etal., 1990; 1992).
In vitro binding experiments have shown that Oct-1 and Vmw65 interact weakly 
and that an additional cellular factor, host cell factor (HCF), is necessary for efficient 
Vmw65-mediated transactivation (Gerster and Roeder, 1988; Kristie et al., 1989; Katan 
et al., 1990; Kristie and Sharp, 1990; Xiao and Capone, 1990; Stem and Herr, 1991; 
Walker et al., 1994). Purification of HCF showed that it consisted of six related and 
tightly but non-covalently linked polypeptides of 110-150kD with a minor 300kD 
protein (Wilson et al., 1993). Two cDNAs encoding these polypeptides have been 
isolated; a major species encoding a 2035 residue protein (approximately 300kD) and a 
minor species encoding a 1966 residue protein which is derived from the major species 
by alternative splicing (Wilson et al., 1993). The 300kD protein shows no homology 
with any known protein but contains eight 26 residue repeats at which proteolytic 
cleavage occurs to give the smaller polypeptides (Wilson et al., 1995a). The role of 
HCF in uninfected cells is unknown; it is most abundant in foetal and placental tissues 
and cell lines, suggesting that it may be involved in cell proliferation (Wilson et al., 
1995b).
More recently, it has been shown that Vmw65 interacts with residues in the POU 
domain of Oct-1 to form a complex which exhibits identical functional requirements to 
those of the complex formed in the presence of HCF; this includes the specificity of 
POU domain residues contacting Vmw65 and the requirement of the GARAT 
component of the octamer sequence (Walker et al., 1994). The fact that greater levels 
of the Vmw65 protein were required for the formation of the complex in the absence of 
HCF was interpreted as indicating that HCF stabilises the complex. In spite of the 
requirement of the GARAT element for Vmw65 recognition, no differences were found 
between the DNA contacts of the POU domain alone and the POU domain in a complex 
with Vmw65. Vmw65 does not seem to contact DNA in this complex; on its own it
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binds DNA weakly and non-specifically (Kristie and Sharp, 1990; Walker et al., 1994). 
Walker et al. suggested that the presence of the GARAT sequence in the TAATGARAT 
octamer induces a site specific conformational alteration in the nature of the POU 
domain of Oct-1 that is not seen when Oct-1 binds other octamer sites; this change 
enables Vmw65 to bind to Oct-1 and is the basis of selective recognition and subsequent 
transcriptional activation by Vmw65. The mechanism by which the GARAT element 
induces the conformational change in Oct-1 remains unknown.
Mutational analysis of Vmw65 has identified regions important for its 
transactivating capabilities (reviewed by O'Hare, 1993). Deletion of the acidic C- 
terminal domain (approximately 80 residues) of Vmw65 leads to loss of its 
transactivating function. Two important C-terminal regions (residues 412-456 and 452- 
490 of the 490 residue protein) have been identified as potent transcriptional activation 
domains during investigations using 'GAL-4-VP16' fusion proteins (these contained the 
GAL-4 DNA binding domain and the relevant residues of Vmw65). Residues 412-456 
have been reported to interact directly with the basal transcription factor TFIID (Lin et 
al., 1991). It has been shown that residues 457-490 are necessary and sufficient to 
mediate an interaction with TAFn40, a component of the TFIID complex that also 
interacts with TFIIB (Goodrich et al., 1993). It has been suggested that the interaction 
between Vmw65 and the basal transcription complex results in a change in 
conformation of the transcription machinery which promotes recruitment of other 
cellular factors to make a functional transcription complex (Hahn, 1993).
1C 1.2 Negative regulation of IE genes
From the results of early experiments carried out by Honess and Roizman (1974; 1975) 
it was evident that treatment of cells with cycloheximide, an inhibitor of protein 
synthesis, led to the overproduction of IE transcripts. This implied that during the 
normal course of virus infection, IE gene transcription is down-regulated. Infection 
with the tsK mutant virus resulted in a similar phenotype (in addition no E or L gene 
expression occurred) which suggested that Vmw l 75 may be a negative regulator of IE 
gene transcription. Quantitative Northern blotting experiments have shown that 
throughout the course of normal virus infection Vmwl 10 and Vmwl75 transcripts are 
present; however, compared with their peak levels of transcription, Vmwl75 transcripts 
remained at low levels whereas Vmwl 10 transcripts were present at high levels (Harris- 
Hamilton and Bachenheimer, 1985). In a more extensive analysis of the rates of IE 
mRNA transcription using nuclear run-on assays, Weinheimer and McKnight (1987) 
also showed that IE gene transcription persisted throughout infection. However, whilst 
IE1 and IE3 mRNAs were shown to accumulate with similar kinetics (increasing from 
l-6hr post infection) it was evident that the rate of transcription of the IE3 gene was 
reduced by 1 hr post infection. This study also showed that the rate of transcription from
18
Chapter 1 Introduction
the IE4/5 promoter was not down-regulated during infection. The conclusion from 
these studies was that transcription from the IE3 promoter was reduced during viral 
infection by a mechanism which involves Vmwl75.
The transactivating ability of Vmwl75 was examined in transient transfection 
assays using various combinations of plasmid-borne copies of HSV-1 IE genes and their 
promoters (reviewed by Everett, 1987b). Due to the nature of the systems used, the 
results varied, but the consensus was that Vmwl75 represses the IE3 promoter (DeLuca 
and Schaffer, 1985; O'Hare and Hayward, 1985b; Gelman and Silverstein, 1986). It has 
been shown that Vmwl75 binds to a consensus sequence at the mRNA capsite of the 
IE3 promoter and that this is necessary for Vmwl75-mediated repression (DeLuca and 
Schaffer, 1985; O'Hare and Hayward, 1985; Gu eta l., 1993; Michael and Roizman, 
1993). A similar consensus sequence is present in the EE 1 promoter, further upstream of 
the capsite; in transfection assays IE1 gene transcription was increased when this 
sequence was mutated (Resnik et al., 1989), but in the context of the virus there was no 
observable effect on DEI gene expression (Everett and Orr, 1991).
It has been suggested that Vmwl75 represses IE3 gene transcription by interfering 
with the basal transcription machinery (Didonato and Muller, 1989), although 
repression has been shown not to arise as a direct result of destabilisation of the 
transcription complex as Vmwl75, TFIIB and TFIID simultaneously (as a tripartite 
complex) and cooperatively occupy their binding sites on the IE promoter (Smith et al., 
1993). Gu et al. (1993) have shown that Vmwl75 has little effect on basal transcription 
but dramatically represses Sp-1 activated transcription from the IE3 promoter. An 
important aspect of Vmwl75 mediated repression of the IE3 promoter is the position of 
the Vmwl75 consensus binding site; it is necessary that it is present within 45bp 3' of 
the TATA box such that the tripartite complex can form (Gu et al., 1995). It is likely, 
therefore, that Vm wl75 masks or alters the preinitiation complex through specific 
proteinrprotein interactions so that activators communicate less efficiently with TFIID 
and the initiation of transcription is inhibited. As Vmwl75 is a potent transactivating 
protein, being essential for E and L gene expression, it is not surprising that its 
expression is regulated; autoregulation is an extremely efficient mechanism for ensuring 
that the protein is not over or under expressed.
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1C1.3 IE transcripts and proteins
The designated names of the five IE genes and their protein products are summarised in 
Table 1C 1.3. Figure 1C 1.3 shows the locations of the IE genes in the HSV-1 genome 
(Clements et al., 1979; Murchie and McGeoch, 1982; Rixon et al., 1982; McGeoch et 
al., 1985; 1986: 1988b; Perry et al., 1986). They are concentrated within the repeat 
regions, the only exception being LE2 which is found in the long unique segment (Ul). 
Of the five HSV-1 primary transcripts that are spliced, three are IE transcripts. Two of 
these are the IE4 and IE5 transcripts which are derived from identical promoters located 
in the short repeat region. Their splice sites are also derived from sequences in the 
repeat region (Watson et al., 1981; Rixon and Clements, 1982) whilst their individual 
coding sequences are present in the short unique segment (Us). The third spliced 
primary transcript is that of the IE 1 gene. This gene lies in the long repeat region and is 
therefore diploid (Perry et al., 1986). Gene IE3 is also diploid as it lies in the short 
repeat sequence. DE2 and IE3 gene transcripts are not spliced.
Glasgow nomenclature Chicago nomenclature
Gene* Gene’*' Product Gene Product
IE-1 RL2 Vmwl 10 a 0 ICP0
IE-2 UL54 Vmw63 a l l ICP27
DE-3 RSI Vmwl 75 a4 ICP4
EE-4 US1 Vmw68 a l l ICP22
EE-5 US 12 Vmwl2 oc47 ICP47
* Original nomenclature (Clements etal., 1979). 
t  Later nomenclature (McGeoch etal., 1988a).
Table 1C1.3 Table summarising the different terms used to identify the immediate- 
early genes and their products.
The analysis of ts mutants showed that Vmwl 75 is essential for the expression of 
E and L gene products (Courtney et al., 1976; Marsden et al., 1976; Watson and 
Clements, 1978; 1980; Preston, 1979a; Dixon and Schaffer, 1980; Preston, 1981; 
DeLuca et al., 1985). Moreover, its presence is required throughout the course of 
normal viral infection in tissue culture (Preston, 1979b; Watson and Clements, 1980). 
As the ts viruses over-expressed IE products, it was assumed that Vmwl75 represses IE 
gene expression (Preston, 1979a; Dixon and Schaffer, 1980; Watson and Clements, 
1980; Section 1C 1.2).
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Figure 1C1.3 A schematic diagram showing the locations of the IE genes on the HSV- 
1 genome and the regulation of gene expression by HSV-1 gene products. The 
approximate relative positions of the five HSV-1 IE genes on the HSV-1 genome are 
shown. The IE4 and IE5 genes are transcribed from a common promoter which is in 
the short repeat region of the genome. The role played by some of the IE gene 
products in infection is indicated. Vmw68 may play a role in regulating late gene 
expression and Vmw12 affects MHC class I presentation of peptides on infected cell 
plasma membranes. Early gene expression leading to replication is required for late 
gene expression.
Investigations of insertion and deletion mutant viruses which either do not express 
V m w llO  or express non-functional Vmwl 10, have shown that Vmwl 10 is non- 
essential in tissue culture. However, these viruses exhibit a cell type, cell cycle and 
multiplicity dependent defect during growth (Stow and Stow, 1986; Sacks and Schaffer, 
1987; Everett, 1989; Cai and Schaffer, 1991). It is possible that HSV-1 infection in vivo 
may be at low multiplicity and VmwllO may therefore play a role in the establishment 
of lytic infection in vivo. Vmwl 10 also appears to play a role in the reactivation of 
latent viral genomes. In an in vitro latency system, Vmwl 10 deficient viruses failed to 
reactivate latent virus (Russell et al., 1987; Harris et al., 1989). In vivo experiments 
with Vmwl 10 deletion mutant viruses showed that whilst these viruses replicated at the 
periphery and established latent infection, they reactivated poorly, indicating that
(replication DNA replication
enzymes)
d h
-»
IE1
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VmwllO plays a role in the reactivation of latent viral genomes (Sacks and Schaffer, 
1987; Clements and Stow, 1989; Lieb etal., 1989).
In transient transfection assays, VmwllO has been shown to be a potent and 
promiscuous transactivator of viral and cellular gene expression. In some systems it 
acts in synergy with Vmwl75 (Everett, 1984b; 1986; Gelman and Silverstein, 1985; 
1986; O'Hare and Hayward, 1985a; 1985b; Quinlan and Knipe, 1985). However, its 
mechanism of action is unknown. Vmwl 10 does not bind to DNA (Everett, 1991b), 
therefore, it must exert its effects through protein:protein interactions. A puzzling 
feature of Vmwl75 ts mutants is the inability of the virus to express early and late gene 
products, despite the presence of normal transactivation competent Vmwl 10. It has 
been proposed that this is due to a transdominant activity of mutant Vmwl75 (Gelman 
and Silverstein, 1986; Everett, 1987b). In support of this, some mutant Vmwl75 
proteins apparently interfere with the transport of Vmwl 10 into the nucleus (Knipe and 
Smith, 1986; Zhu et al., 1994; Mullen et al., 1995) and similar Vmwl75 mutants inhibit 
the transactivation activity of Vmwl 10 in transfection assays. However, this theory is 
unlikely to be the situation in reality as Vmwl75 deletion mutant viruses also show no 
evidence of Vmwl 10-induced transactivation (DeLuca et al., 1985; DeLuca and 
Schaffer, 1988; Shepard and DeLuca, 1989).
Studies of infections in tissue culture with Vmw63 ts or deletion mutant viruses 
have shown that Vmw63 is essential for normal virus growth (Sacks et al., 1985; 
McCarthy et al., 1989; Rice and Knipe, 1990). Vmw63 null mutant viruses over­
express some E gene products and induce reduced levels of L gene expression.
The activity of the protein has been examined in transient transfection assays by a 
number of groups with complex and sometimes contradictary results. The results 
showed that Vmw63 alone could transactivate gene expression from the gB promoter 
(Rice and Knipe, 1988). In the presence of Vmwl75 and Vmwl 10, Vmw63 was found 
to increase transactivation (late gB and VP5 promoters), decrease transactivation (early 
tk promoter) and also to have no effect on transcription levels (late gC promoter). 
(Everett, 1986; Rice and Knipe, 1988; Sekulovich et al., 1988; Su and Knipe, 1989). 
Closer analysis of Vmw63 revealed the presence of both repressor and activator 
domains in the C-terminal end of the protein (Hardwicke et al., 1989; Rice et al., 1989; 
McMahan and Schaffer, 1990): however, the mechanisms by which Vmw63 acts are 
unknown.
From experiments in which the accumulation of specific transcripts and their 
protein products were compared during infection with a Vmw63 ts mutant virus, it was 
concluded that Vmw63 probably functions at the post-transcriptional level (Smith et al.,
1992). It has been shown that Vmw63 causes a reduction in host cell pre-mRNA 
splicing (Sandri-Goldin and Mendoza, 1992), a property of the protein which is 
probably in part responsible for shut-off of host cell macromolecular synthesis. This
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may be connected with the observation that Vmw63 causes the redistribution of small 
nuclear ribonucleoprotein (snRNP) complexes, cellular structures involved in pre- 
mRNA splicing (Phelan et al., 1993). Recent analysis of the C-terminal region of the 
protein has shown that the repressor region is necessary for the redistribution of snRNPs 
but is not sufficient for the inhibition of host cell splicing (Sandri-Goldin et al., 1995). 
The relevance of these observations to the mechanism by which Vmw63 transactivates 
gene expression in the presence of Vmwl75 and Vmwl 10 is unclear.
The product of the IE4 gene, Vmw68, has been shown to be non-essential for 
infection in tissue culture (Post and Roizman, 1981). An early experiment with a partial 
deletion mutant virus showed that it did not grow efficiently on some cell types and was 
avirulent in mice (Sears et al., 1985). Sears et al. (1985) also concluded that Vmw68 is 
involved in stimulating late gene expression. This is supported by more recent work 
carried out by Poffenburger et al. (1994) who showed that a complete Vmw68 deletion 
mutant virus was impaired in its ability to cause death in mice following intracerebral, 
intraperitoneal or intravaginal inoculation. The Vmw68 null mutant virus produced no 
visible signs of infection in the cornea but was reactivated from explanted ganglia; 
reactivation from ganglia following intravaginal inoculation did not occur, even though 
PCR analysis showed the presence of latent viral genomes. Vmw68 is modified by the 
Ul13 kinase (a structural component of the virion) and the product of the Us3 gene 
(Purves et al., 1993); viruses with deletions in Ul13 or the gene encoding Vmw68 
express reduced levels of Vmwl 10 and some late viral proteins as a result of reduced 
levels of transcription from the genes encoding these proteins. Interestingly, Vmw68 
has recently been shown to be necessary for virus induced aberrant phosphorylation of 
the large subunit of cellular RNA polymerase II which occurs on HSV-1 infection. It is 
speculated that this results in the preferential transcription of viral genes by RNA 
polymerase II but this has yet to be shown (Rice etal., 1994; 1995).
Viruses with deletions in the IE5 gene, encoding Vm wl2, showed that Vmwl2 is 
non-essential in tissue culture (Longnecker and Roizman, 1986; Mavromara-Nazos et 
al., 1986). The protein is found in the cytoplasm, indicating that it is unlikely to play a 
role in the regulation of transcription. Indeed, it has recently been shown to play a role 
in rendering infected cells resistant to lysis by CD8+ cytotoxic T lymphocytes. One 
property of HSV-1 is the down-regulation of MHC class I and associated peptides on 
the cell surface, and it has been shown that Vmwl2 is both necessary and sufficient to 
cause the retention of MHC class I proteins in the endoplasmic reticulum and cis-Golgi 
(York et al., 1994). More recently it has been observed that V m w l2 binds to a 
transporter associated with antigen processing (TAP), preventing peptide translocation 
into the endoplasmic reticulum (Hill et al., 1995). As a result, MHC molecules do not 
become loaded with peptide which means that the MHC subunits are not stably 
associated and cannot be transported to the plasma membrane.
Chapter 1 Introduction
1C1.4 Activation of E gene expression
(i) Cis-acting elements
The discovery that Vmwl75 was essential for E and L gene expression and that it 
transactivated a number of E gene promoters in synergy with VmwllO in transient 
transfection assays (Section 1C 1.3) led to investigations of the sequence requirements of 
E gene promoters. The tk and gD promoters have been investigated extensively.
Initial experiments investigating the nature of the tk  promoter involved 
microinjection of plasmids containing the tk gene with mutated promoter sequences into 
Xenopus laevis oocytes (McKnight et al., 1981). Further investigations involved a more 
detailed analysis using 'linker-scanning' mutations (McKnight and Kingsbury, 1982). 
This defined the promoter region as extending approximately 110 nucleotides upstream 
of the mRNA start site. It was found that a TATA box was necessary for 'accurate' 
initiation of transcription and that the presence of upstream elements consisting of a 
CCAAT motif and two GC boxes enhanced transcription. These upstream regulatory 
elements were found to bind the cellular transcription factors CCAAT binding protein 
(CBP) and Sp-1, which also binds GC motifs in EE promoters (Jones et a l., 1985; Jones 
and Tijan, 1985; Graves et al., 1986). Analyses of these mutations in the viral context 
failed to uncover additional sequences necessary for transactivation by viral proteins 
(Coen etal., 1986). V  6f rA
The role played by Vmwl75 in the transactivation of the tk promoter was also 
investigated. In the viral context, it was found that deletion of the GC boxes greatly 
reduced transcription of the tk gene in the absence of Vmwl75, but that in the presence 
of Vmwl75 transcriptional reduction was minimal (Imbalzano et al., 1991). This 
indicated that Vmwl75 can functionally substitute for Sp-1 activity. Transcription 
levels in the absence of the CCAAT box did not differ depending upon whether or not 
Vm wl75 was present. This group also found that, whilst only the TATA box was 
necessary for efficient Vmwl75-induced tk gene transcription, Vm wl75 could still 
induce expression when the TATA box was disrupted. Interestingly, in the absence of 
the GC boxes and CCAAT motif, tk was still expressed as an E gene in the presence of 
V m wl75. This raises the interesting question as to what defines an early promoter 
since none of the defined regulatory sequences seem to do so. Whilst it is possible that 
the context of the promoter in the viral genome contributes to its temporal regulation, it 
was found that replacement of gC promoter sequences with tk promoter sequences did 
not result in this L gene being expressed as an E gene (Homa et al., 1988).
The sequence requirements for transactivation of the gD promoter were 
investigated by transfecting gD reporter constructs into cells in tissue culture followed 
by superinfection with HSV-1 (Everett, 1983). These experiments defined the minimal 
promoter region as lying within 83bp upstream of the mRNA start site. Linkage of the 
SV40 enhancer region upstream of various gD promoter mutants showed that there were
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no differences required in promoter sequence for cellular-mediated transactivation 
compared with viral-mediated transactivation (Everett, 1984a). As with the tk promoter, 
sequence requirements were found to be a TATA box and a CCAAT motif (inverted). 
The upstream GC-rich sequences were also important, the distal most one of which 
binds the cellular transcription factor YY1 (Seto et al., 1991; Chen et al., 1992a; Mills 
etal., 1994).
(ii) Transacting factors - Vmwl75 mechanism of action
When it was observed that Vmwl75 binds to DNA (Freeman and Powell, 1982; Faber 
and Wilcox, 1986), consensus sequences were identified and the ability of Vmwl75 to 
bind to various promoter sequences was investigated. It was found that the gD 
promoter contained three Vmwl75 binding sites, two upstream of the CAP site and one 
downstream (Faber and Wilcox, 1986; Tedder and Pizer, 1988; Tedder et al., 1989). In 
an in vitro transcription assay, Tedder etal. (1989) showed that deletion of the Vmwl75 
binding sites in the gD promoter led to reduced levels of Vmwl75-stimulated 
transcription. However, removal of all three Vmwl75 binding sites from the gD 
promoter in the viral context had no effect on gD expression during HSV-1 infection in 
cell culture (Smiley et al., 1992). Similarly, the tk promoter was found to contain 
Vmwl75 binding sites although a virus carrying a mutant IE3 gene encoding a 
Vmwl75 protein which was unable to bind to these sites in vitro did not show reduced 
levels of tk expression during infection (Kristie and Roizman, 1986a; Imbalzano et al., 
1990). The importance of these Vmwl75 binding sites and their precise function and 
relevance to Vmwl75-mediated transactivation in the viral context remains unclear. 
However, these experiments showed that the TATA box is required for efficient 
transactivation of these promoters, indicating that Vmwl75 may mediate transactivation 
by interacting with a cellular transcription factor such as TFIID.
More is known of the interactions of Vmwl75 with cellular transcription factors 
in the repression of the IE3 promoter (Section 1C 1.2). Further hints that Vmwl75 may 
interact with components of the basal transcription machinery came with the work of 
Abmayr et al. on the related IE protein of Pseudorabies virus (PRV). This group 
initially showed that the PRV IE protein was responsible for the non-specific increase in 
transcription seen in infection from RNA polymerase II genes in an in vitro system 
using infected nuclear extracts (Abmayr et al., 1985). They then went on to show that 
in their in vitro assay, transcription levels were increased by the addition of non- 
promoter containing DNA which titrated non-specific DNA binding proteins, or by the 
preincubation of template DNA either with an unfractionated nuclear extract or with 
purified TFIID. They concluded that the IE protein acts by increasing the rate or extent 
of formation of a preinitiation complex rather than by acting at the initiation or 
elongation steps of transcription (Abmayr et al., 1988). It has also been shown in an in
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vitro assembly system that the PRV EE protein stimulates TFIID binding to promoter 
sequences, resulting in effective competition with nucleosomes during chromatin 
folding (Workman et al., 1988). DeLuca's group have shown that Vmwl75 mediates its 
repression of the IE3 promoter by repressing Sp-1 activated transcription, as a result of 
the formation of a tripartite complex with TBP and TFIID (Gu et al., 1993; 1995; Smith 
etal., 1993; see also Section 1C1.2).
1C1.5 Activation of L gene expression
Early investigations of the requirements of late gene promoters involved studies of the 
promoters of the ’true late' (y2) genes US11 and gC. In the context of the replicating 
viral genome, it was found that gC sequences spanning the mRNA start site and TATA 
box were sufficient for late promoter activity (Homa et al., 1986). In transient 
transfection assays, Johnson and Everett (1986a; 1986b) showed that an active origin of 
DNA replication was required for efficient transactivation of the US11 promoter in the 
plasmid context, and Shapira et al. (1987) showed that this was also necessary for 
transactivation of the gC promoter. The conclusion from these experiments was that a 
TATA box/cap site region was sufficient for L gene transcription in a replication 
competent template. In support of this model, deletion of the gD upstream regulatory 
sequences and linkage of the remainder of the promoter to a functional origin of 
replication conferred late kinetics on the gD gene (Johnson and Everett, 1986a). The 
situation may be different for 'leaky-late' (y l) genes as binding sites for the cellular 
transcription factor YY1 have been identified in the promoters of yl genes UL19, UL37 
and gB. In the case of UL19, deletion of this binding site in the promoter leads to a 
reduced level of transcription of the UL19 gene (Seto etal., 1991; Chen et al., 1992a; 
Mills etal., 1994).
A number of groups have provided experimental evidence which implies that the 
type of TATA box in the promoter contributes to the characteristics of late gene 
expression (Homa eta l., 1988; Flanagan eta l., 1991). This has been supported in the 
viral context in an experiment in which the tk gene was expressed as a late gene when 
its TATA box was replaced with the gC promoter region (Levine et al., 1991). 
However, conflicting results arose in an experiment carried out by Imbalzano and 
DeLuca (1992) which showed that substitution of the tk TATA box with that of the gC 
promoter failed to alter the temporal expression of the tk gene.
Sequences at or near the mRNA start site may contribute to L promoter activity 
and even play a role in the requirement of a replication origin for L gene expression 
(Blair et al., 1987; Mavromara-Nazos and Roizman, 1989; Kibler et al., 1991; Steffy 
and Weir, 1991). It may be that cellular factors bind these sequences, contributing to 
gene expression or repressing expression, with the latter effect removed by replication 
of the viral genome. However, such cellular factors have not yet been identified. As a
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consensus sequence is absent, the requirement would be for promiscuous DNA binding 
proteins. As with E gene promoters, it is likely that Vmwl75-mediated transactivation 
of L genes occurs through Vmwl75 interacting with components of the basal 
transcription machinery.
1C2 HSV infection and cellular gene expression
Whilst the majority of cellular genes are shut-off during HSV infection, a subset are 
expressed (Patel et al., 1986; Kemp and Latchman, 1988; Section 1B2.5). A number of 
groups showed that when viral genes were inserted into the cellular genome, they were 
transactivated by HSV-1 superinfection. This led to the conclusion that there were 
specific sequences in viral gene promoters that distiguished them from cellular 
promoters (Sandri-Goldin et al., 1983; Dennis and Smiley, 1984; Silver and Roizman, 
1985). However, Everett (1985) showed that infection with HSV-1 could stimulate 
non-viral promoters (e-globin and P-globin) which were stably integrated in the cellular 
genome and that this effect was mediated by Vmwl75 and Vmwl 10. As these cellular 
promoters are not activated on HSV infection in their normal locations, it was 
concluded that chromatin structure must play a role in the expression of cellular genes. 
For example, it is possible that the integrated cellular genes were present at sites of open 
nucleosomal structure and as such were accessible by the viral transactivators. The 
down-regulation of cellular gene expression during infection may also be a result of 
Vmw63-mediated repression of transcript splicing (Hardy and Sandri-Goldin, 1994).
Experiments in which the p-globin gene was inserted into the viral genome 
showed that it was expressed as an E gene, whether the gene was under the control of its 
own promoter or the gD promoter (Smiley et a l., 1987). This supports conclusions 
concerning the mode of action of Vmwl75, namely that Vmwl75-mediated 
transactivation requires no virus-specific regulatory sequences. The a-globin gene is 
expressed constitutively from transfected plasmids during transient expression assays in 
the absence of viral proteins but is expressed as an E gene in the context of the viral 
genome (Smiley et al., 1991). The adenine phosphoribosyl transferase (aprt) gene, 
which lacks a functional TATA box, was not expressed in the context of the viral 
genome, which supports the requirement of interactions of Vmwl75 with the basal 
transcription machinery for its transactivation ability (Tackney et al., 1984). The 
conclusions drawn from this work were that viral transactivators act on all polymerase II 
promoters provided they are accessible and TATA-dependent.
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1C3 Gene expression during latent infection
(i) Latency associated transcripts
Transcription during latent infection of HSV-1 in neurons is restricted mainly to the 
latency associated transcripts (LATs). Transcription occurs from a promoter situated in 
the repeat sequence bounding the long unique region of the genome, and the stable 
transcripts overlap approximately a third of the EE1 gene coding sequence (Figure 1D2). 
Two major and partially co-linear polyA- RNAs of approximately 1.2kb and 2.0kb have 
been found (Rock etal., 1987; Spivak and Fraser, 1987; Stevens etal., 1987); the 1.2kb 
LAT is thought to be derived from the 2.0kb LAT by splicing in a process which 
probably involves neuron-specific factors (Spivak et al., 1991). There are also less 
abundant poly A + LATs (the minor LATs), and it has been suggested that all latent phase 
transcripts arise from a single 8.3kb transcript which is subsequently processed to give 
the abundant polyA- LATs (Dobson etal., 1989). There have also been suggestions that 
the polyA* LATs are stable introns (Devi-Rao etal., 1991; Farrell etal., 1991).
Due to their unusual structure, it is unlikely that any of the major LATs encode 
protein. However, one group detected a latency associated protein in primary neurons 
using an antiserum raised against a bacterially expressed fusion protein from a plasmid 
construct containing the 2.0kb LAT sequences (Doerig et al., 1991). The putative 80kD 
latency associated protein has not been detected in infected cells in culture or in latently 
infected mice. It is not known whether the minor polyA+ transcripts encode latency 
associated proteins.
It was initially thought that as LAT transcripts are antisense in part to the IE1 
transcript, they could regulate latency by inhibiting translation of IE 1 mRNA (Stevens 
et al., 1987). In view of the fact that Vmwl 10 mutant viruses reactivate poorly from 
latency (Clements and Stow, 1989; Lieb etal., 1989; Cai et al., 1993) and that Vmwl 10 
mutant viruses are unable to reactivate latent virus in an in vitro latency system (Russell 
et al., 1987; Harris et al., 1989) this was an attractive suggestion. However, the 
situation is more complicated; experiments with LAT mutant viruses have shown that 
LAT expression is non-essential for the establishment and maintenance of latent 
infection in mouse and rabbit models (Javier et al., 1988; Ho and Mocarski, 1989; Lieb 
et al., 1989; Sedarati et al., 1989; Steiner et al., 1989; Hill et al., 1990; Block et al., 
1990). Some mutants, but not all, showed defects in the efficiency of reactivation 
compared with wild type virus. However, Sawtell and Thompson (1992) have 
suggested that LAT expression promotes the establishment of latency in mouse 
trigeminal ganglia since a LAT deletion mutant that they constructed established latent 
infection in 80% fewer ganglia than the parent virus. This difference was not seen when 
latency was established in the lumbosacral ganglia, which implies that the establishment 
of latent infection is, to an extent, dependent upon the host cell. It is generally held that 
between 1-5% of neurons in latently infected mouse ganglia harbour LATs (Speck and
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Simmons, 1991; Rock et a l., 1992); these experiments were carried out using in situ 
hybridisation techniques following isolation of ganglia which were fixed, sectioned and 
mounted on slides. In situ hybridisation has also shown that the minor LATs are 
localised to sharply defined intranuclear foci of l-3pm in diameter in latently infected 
primary sensory neurons of mice and humans (Arthur et al., 1993). The major LATs 
were found to be distributed throughout the nucleoplasm, with the exclusion of the 
nucleolus. An investigation of the nature of the foci may uncover cellular or viral 
proteins with which the minor LATs interact which could lead to an understanding of 
their function.
(ii) Are LATs a suitable marker for latency?
When mice were infected with equal amounts of plaque forming units of wild type virus 
or ml814 via the right rear footpad, it was found that the dorsal root ganglia of in 1814 
infected mice contained many more LAT+ neurons compared with ganglia of mice 
harbouring wild type virus (Ecob-Prince et a l., 1993a). Vims in 1814 encodes a mutant 
Vmw65 protein which is incapable of transactivating IE gene expression but is 
functional in its role in virion structure (Section 1C 1.1). LAT+ neurons were also found 
in the dorsal root ganglia of ml814 mice which did not innervate the original site of 
infection. It was concluded that the large number of LAT+ neurons and the spread of 
this vims was related to the high particle numbers in the inoculum and that spread of the 
vims was a consequence of limited replication as well as the low neurovimlence of 
ml814. Ecob-Prince and co-workers also investigated the possibility that a greater 
population of LAT+ neurons led to a more extensive reactivation upon administration of 
a reactivation stimulus (Ecob-Prince et al., 1993b). Mice were infected with wild type 
vims or with m l814 via the right rear footpad and reactivation was induced by 
neurectomy of the sciatic nerve. Ganglia were removed and fixed at various times post 
neurectomy or were explanted into tissue culture. Reactivation was detected in fixed 
cells by in situ hybridisation with an IE1 mRNA probe and in tissue culture by 
removing the medium from explanted ganglia and plating dilutions on BHK cell 
monolayers under conditions which would complement the m l814 mutation. It was 
found that the frequency of reactivation did not correlate with the number of LAT+ 
neurons, as the levels of reactivation corresponded to 0.25% of neurons in ganglia 
regardless of the input vims.
The examination of a ribonucleotide reductase-deleted HSV-1 mutant in rat 
trigeminal ganglia following corneal inoculation indicated that a population of LAT" 
latent genomes may exist (Ramakrishnan et al., 1994). In situ hybridisation with a 
digoxigenin-labelled riboprobe specific for LATs detected an average of 1-2 LAT+ cells 
in 6pm ganglion sections. In contrast, in situ PCR using digoxigenin-labelled 
nucleotides with primers specific for HSV-1 gB DNA identified up to 120 genome
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positive cells per section. These results suggest that cells with detectable LATs 
represent only a small proportion of those ganglionic neurons containing HSV-1.
(iii) Do LAT+ neurons reactivate?
Ecob-Prince and Hassan (1994) have found evidence of reactivation occurring primarily 
in neurons with do not express LATs. Ganglia were isolated, explanted into tissue 
culture for various lengths of time (2-3 days), fixed, sectioned and examined using in 
situ hybridisation and immunocytochemistry. Reactivation was detected by ascertaining 
the presence of the virus specific mRNAs and antigens associated with lytic infection. 
Infrequently, IE2 and IE4/5 mRNAs were found in LAT+ neurons. On the whole, viral 
mRNA and antigens were found in neurons which did not contain LATs. It is possible 
that the abundant LATs were lost quickly following the onset of replication but there 
was little evidence of this because, as the number of reactivating neurons increased 
following explantation, the number of LAT+ neurons was not seen to decrease. It is 
therefore possible, although it has not been conclusively shown in these experiments, 
that there is a population of neurons in latently infected ganglia which harbour the latent 
HSV genome but do not express LATs.
An attempt was made to identify a population of latently infected neurons which 
do not express LATs in experiments carried out with m l853, a derivative of ml814 
with the (3-galactosidase gene inserted at the TK locus under the control of the HCMV 
enhancer (Ecob-Prince et al., 1995). The reporter gene was found to be weakly 
expressed in the dorsal root ganglia of mice infected via the rear footpad for up to five 
months post infection. In ganglia which were explanted, fixed and sectioned at the 
appropriate times, about 30% of (3-galactosidase positive neurons did not contain LATs 
as detected by in situ hybridisation. However, the detergents used to enable penetration 
of the P-galactosidase substrate also reduced the levels of LATs; in neurons with low 
levels of LATs this may have reduced levels to below those detectable by in situ 
hybridisation. Consequently, the evidence from this experiment for the existence of a 
population of latently infected LAT- neurons was weak. However, an in situ PCR based 
method for detecting viral genomes in latently infected neurons has been developed 
(Mehta et al., 1995). This method has been used to show that 4.8% of neuronal cell 
bodies contain latent viral genomes, as detected by amplification of the viral DNA 
polymerase gene, compared with 1.6% of cell bodies which were LAT positive, as 
detected by RNA hybridisation. Amplification of a single copy mouse gene, all-1, in a 
control experiment gave a positive signal in 48% of cells, indicating that up to 9.6% of 
neurons could contain latent viral genomes. However, it is possible that cells which 
appeared to be LAT- may have expressed low levels of LATs which were not detected 
in the RNA hybridisation experiment. Consequently, whilst it appears that some 
latently infected neurons may harbour viral genomes which do not express LATs, it has
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yet to be conclusively proven. The implications of the existence of such a population of 
neurons are intriguing; in particular, if the LAT expressing viral genomes do not 
reactivate, this could be applicable for gene therapy if the mechanism of activation of 
expression was understood.
(iv) Expression of other viral genes
A lack of assay techniques sufficiently sensitive to detect very low levels of viral gene 
expression has led, in the past, to the assumptions that LATs are the only transcripts 
produced during latent infection. Kramer and Coen (1995) have developed a sensitive 
and quantitative PCR assay which showed that one to seven IE3 gene transcripts per 
viral genome were present in about 20% of ganglia examined. In order to determine 
whether or not Vmwl75 was present, they looked at the levels of tk gene transcription, 
as this is dependent on the presence of Vmwl75 in lytic infection, and found a 
corresponding number of transcripts (about 500 per latent viral genome). This 
observation has interesting implications for the mechanism of reactivation from latency 
(as defined by the detection of infectious virus). It has been proposed in the past that 
reactivation is the result of a single step which produces a switch to the lytic cycle 
(Stevens et al., 1987; Sawtell and Thompson, 1992). The recent results of Kramer and 
Coen (1995) imply that the switch could be much more gradual, depending upon 
threshold levels of accumulation of certain transcripts and their proteins.
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ID VmwllO 
1D1 History
Vmwl 10 was first classified as an IE gene product by Honess and Roizman (1974). 
Using HSV-1 and HSV-2 intertypic recombinants, the EE1 gene encoding Vmwl 10 was 
initially mapped to the repeat sequences bounding the long unique region of the genome 
(Preston etal., 1978). The 5' and 3' ends of the mRNA were subsequently mapped more 
precisely and correlation between the map sites for the ends of the transcript and its 
actual size suggested that the primary transcript is spliced (Clements et al., 1979; 
Watson etal., 1979; Anderson et al., 1980; Mackem and Roizman, 1980; Rixon etal.,
1984). This was later confirmed by sequence analysis (Perry et al., 1986; McGeoch et 
al., 1988a).
The failure to isolate Vmwl 10 ts mutants meant that its properties could not be 
extensively investigated until a number of groups almost simultaneously discovered that 
it is a potent transactivator of gene expression in transient transfection assays (Everett, 
1984a; Gelman and Silverstein, 1985; O'Hare and Hayward, 1985a; Quinlan and Knipe,
1985). The isolation of Vmwl 10 deletion mutant viruses showed that Vmwl 10 is non- 
essential for lytic infection in tissue culture although virus growth is impaired at low 
multiplicities of infection (Stow and Stow, 1986; Sacks and Schaffer, 1987). However, 
there has been much interest in the potential role that Vmwl 10 plays in latent infection. 
Vmwl 10 mutant viruses are unable to induce the reactivation of latent virus in an in 
vitro latency system (Russell et al., 1987; Harris et al., 1989) and they reactivate poorly 
from latency in mouse models (Clements and Stow, 1989; Lieb et al., 1989; Cai et al., 
1993).
It has long been known that Vmwl 10 is located in the nucleus of infected cells 
(Pereira et al., 1977; Wilcox et al., 1980; Ackerman et al., 1984) and later 
immunofluorescence experiments confirmed this and showed that VmwllO was 
localised to specific domains within the nucleus (Gelman and Silverstein, 1986; Everett, 
1988a). More recently, the identification of these domains as novel nuclear structures, 
whose disruption during HSV-1 infection has been attributed to the presence of 
Vmwl 10 in the cell, has sparked an interest in the potential interactions of Vmwl 10 
with cellular proteins (Sections 1D9.2 and 1D9.3). These interactions are likely to be 
crucial to the understanding of both lytic and latent infection.
1D2 IE1 gene and transcript structure
Gene IE1 lies entirely in the long repeat region of the HSV-1 genome and encodes a 
predicted protein product of 775 amino acids. In the interior repeat, gene IE1 is 
transcribed from right to left with the transcriptional start site at position 124,256 and 
the polyadenylation signals (preceeding the 3' terminus of the primary transcript) at
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120,693 and 120,734 (Mackem and Roizman, 1982b; Perry et al., 1986; McGeoch et 
al., 1988a). There are two introns, the first between coordinates 122,484-122,621 (after 
codon 19) and the other between 123,287-124,053 (within codon 242). The predicted 
translational stop and start sites are at positions 124,108 and 120,882 respectively. The 
gene is partially overlapped in the same orientation by one of the ICP34.5 transcripts 
and in the opposite orientation in part by the latency associated transcripts (LATs) 
(Figure 1D2).
118801
Vmwl 10 ICP34.5
120672
\
\
\
129403
Vmwl75
118801
8.77kb polyA+ LAT
127167
SD 2.0kb LAT SA
119461--------------------121416
1.5kb LAT
Figure 1D2 Diagram showing the relative positions of the Vmwl 10, ICP34.5 and LAT 
transcripts. The Vmw110/LAT region is in the repeat region bounding U|_. The 
Vmwl 10 and ICP34.5 genes overlap in the same orientation but the transcripts do not. 
The 8.77kb minor LAT overlaps the Vmwl 10, ICP34.5 and part of the Vmw175 
encoding genes; it is present during productive infection, as is the stable 2kb LAT RNA, 
which is the major latency transcript. The 2kb LAT is derived from the 8.77kb LAT by 
splicing; the splice donor (SD) and splice acceptor (SA) sites are shown. The smaller 
1.5kb LAT represents a spliced variant found only in latent infection.
As very few HSV-1 transcripts are spliced, it was of interest to investigate the 
importance of the introns in the Vmwl 10 primary transcript. In transfection assays, loss 
of the first intron reduced the transactivation of a reporter construct by 60%. This figure 
was 40% with loss of the second intron and deletion of both led to abolition of 
transactivation (Everett, 1991a). Surprisingly, removal of the introns in the viral 
context had little effect on the behaviour of the virus. The growth rate, particle:pfu ratio 
and viral polypeptide expression was similar to that of the parent virus (Everett, 1991a). 
In contrast, removal of the introns from the SV40 late transcription unit resulted in little 
or no accumulation of SV40 late transcripts (Ryu and Mertz, 1989). It is possible that
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the differences between the results of the transfection assays and the properties of the 
virus mutants is due to a defect in IE 1 RNA processing in transfected cells which leads 
to low levels of Vmwl 10 production. The defect may be overcome in the presence of 
other viral proteins. Interestingly, an HSV-1 virus mutant with the IE1 gene introns 
deleted establishes and reactivates from latency in mice with the efficiency of a wild 
type virus (Natarajan etal., 1991).
The IE1 promoter, like all IE promoters, is responsive to transactivation by 
Vmw65 in a complex with cellular proteins, which recognises the consensus sequence 
TAATGARAT (Preston etal., 1978; Mackem and Roizman, 1982a) (Section lC l.l(ii)). 
Of three copies of the TAATGARAT sequence, that between -168 to -142, relative to 
the mRNA start site, is necessary for IE specific regulation (Kristie and Roizman, 1984; 
Gelman and Silverstein, 1987a; 1987b). The promoter contains the normal TATA box 
and capsite regions. At position -46 to -71, there is also a Vmwl75 binding site (Kristie 
and Roizman, 1986b; Faber and Wilcox, 1988). The binding of Vmwl75 to this site has 
been implicated in the reduction of expression of Vmwl 10 caused by the presence of 
Vmwl75 in transfection assays (Gelman and Silverstein, 1987a; 1987b; Resnick et al., 
1989; Everett and Orr, 1991c). However, the repression seen in transfection assays may 
not reflect the true situation as the IE1 gene transcript and its product accumulate 
throughout virus infection in tissue culture (Harris-Hamilton and Bachenheimer, 1985; 
Weinheimer and McKnight, 1987; Everett and Orr, 1991c) (Section 1C2).
1D3 VmwllO polypeptide structure and physical properties
The 775 amino acid IE1 gene product (Perry et al., 1986) has a predicted molecular 
weight of 78,452D but the protein migrates on SDS polyacrylamide gels with an 
apparent molecular weight of approximately 1 lOkD (Honess and Roizman, 1974). The 
protein contains an unusually high proportion of alanine, proline, glycine and arginine 
residues, which is probably a reflection of the high GC content of the gene. 
Phosphorylation of a serine-rich region between residues 554-591 may be responsible 
for the increased molecular weight of the protein seen on polyacrylamide gels 
(Ackerman et al., 1984). There are small clusters of acidic and basic residues 
throughout the protein, but mutational analysis of these and of the serine-rich region 
indicates that they are not essential for the function of the protein (Everett, 1987a; 
1988a; Section 1D5). Figure 1D3 shows the amino acid sequence of Vmw 110.
A cysteine-rich region between residues 106 and 150 has been shown, in transfection 
assays and in the context of the viral genome, to be essential for Vmwl 10 function 
(Everett, 1987a; 1988a; 1989; Section 1D5). It is now known that these sequences 
comprise a zinc binding domain, a RING finger, whose structure has been elucidated by 
nuclear magnetic resonance spectroscopy (Everett et al., 1993b; Barlow et al., 1994; 
Section 1D8.2).
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MEPRPGASTRRPEGRPQREPAPDVWVFPCDRDLPDS SDSEAETEVGGRGD 5 0 
ADHHDDDSASEADSTDTELFETGLLGPQGVDGGAVSGGSPPREEDPGSCG 100 
GAPPREDGGSDEGDVCAVCTDEIAPHLRCDTFPCMHRFCIPCMKTWMQLR 150 
NTCPLCNAKLVYLIVGVTPSGSFSTIPIVNDPQTRMEAEEAVRAGTAVDF 200 
IWTGNQRFAPRYLTLGGHTVRALS PTHPE PTTDEDDDDLDDADYVPPAPR 250 
RTPRAPPRRGAAAPPVTGGASHAAPQPAAARTAPPSAPIGPHGSSNTNTT 300 
TNS SGGGGSRQSRAAAPRGASGPSGGVGVGVGWEAEAGRPRGRTGPLVN 350 
RPAPLANNRDPIVISDSPPASPHRPPAAPMPGSAPRPGPPASAAASGPAR 400 
PRAAVAPCVRAPPPGPGPRAPAPGAEPAARPADARRVPQSHSSLAQAANQ 450 
EQSLCRARATVARGSGGPGVEGGHGPSRGAAPSGAAPLPSAASVEQEAAV 500 
RPRKRRGSGQENPSPQSTRPPLAPAGAKRAATHPPSDSGPGGRGQGGPGT 550 
PLTSSAASASSSSASSSSAPTPAGAASSAAGAASSSASASSGGAVGALGG 600 
RQEETSLGPRAASGPRGPRKCARKTRHAETSGAVPAGGLTRYLPISGVSS 650 
W A L  S P YVNKTITGDCL P IL  DMETGNI GA YWLVDQTGNMATRLRAAVPG 700  
WSRRTLLPETAGNHVMPPEYPTAPASEWNSLWMTPVGNMLFDQGTLVGAL 750 
DFRSLRSRHPWSGEQGASTRDEGKQ 775
Figure 1D3 The amino acid sequence of Vmwl 10.
Vmwl 10 has been expressed in large quantities in a baculovirus system. The 
purified protein has been shown to exist as a multimer in solution (Everett, 1991b). 
This result was confirmed by Silverstein's group who expressed sufficient quantities of 
Vmwl 10 in HeLa cells infected with a recombinant adenovirus expressing VmwllO 
(Chen et al., 1992b). This property is one of the functions of the C-terminal end of 
Vmwl 10 (Ciufo eta l., 1994; Sections 1D11 and 3B). Everett (1991b) also showed that 
VmwllO bound to single and double stranded DNA cellulose matrices, confirming 
earlier findings in which passage of crude nuclear extracts of infected cells down calf 
thymus DNA-cellulose columns resulted in retention of Vmwl 10 on the columns (Hay 
and Hay, 1980). However, it was not possible to detect a stable interaction between 
VmwllO and DNA in filter binding assays (Everett, 1991b) which suggests that 
Vmw 110 does not exert its effects through a direct interaction with DNA.
Analysis of the protein content of nuclear and cytoplasmic fractions of infected, 
radiolabelled tissue culture cells showed that VmwllO was localised primarily in the 
nucleus (Pereira et al., 1977; Wilcox et al., 1980; Ackerman et al., 1984). It was later 
shown in immunofluorescence experiments that VmwllO expressed from a plasmid 
construct localises to discrete domains in the nucleus of host cells (Gelman and■
Silverstein, 1986; Everett, 1988a). In the viral context, VmwllO is localised to the 
punctate domains at 2hr post infection but by 8hr post infection, it is present in both 
nucleus and cytoplasm and the punctate domains are no longer visible (Everett and
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Maul, 1994). These domains have since been identified as novel nuclear structures of 
unknown function called ND10, Kr bodies or PODs (Ascoli and Maul, 1991; Xie e ta l., 
1993; Dyck et al., 1994; Koken et al., 1994; Weis etal., 1994; Section 1D9.1). They 
are known to contain a number of cellular proteins, one of which is PML, a RING finger 
oncoprotein implicated in the pathogenesis of acute promyelocytic leukaemia (de The et 
al., 1991; Goddard et al., 1991; Kakizuka et al., 1991; Kastner et al., 1992; Section 
1D9.2). The disruption of ND10 during the course of infection is known to be a 
property of Vmwl 10 (Maul et al., 1993). It is evident from the analysis of mutant 
VmwllO proteins that the RING finger and C-terminal regions of Vmwl 10 are 
important for the normal interaction of Vmwl 10 with ND10 during infection with wild 
type virus (Maul and Everett, 1994; See Section 1D9.1).
1D4 Activation of gene expression in transfection assays
The use of transient transfection assays has proved to be invaluable in the study of the 
regulation of gene expression and it was in using such assays that Vmwl 10 was found 
to be a potent transactivator of gene expression (Everett, 1984a; Gelman and Silverstein, 
1985; O'Hare and Hayward, 1985a; Quinlan and Knipe, 1985). These assays involved 
transfecting a plasmid encoding Vmwl 10 into cells together with a plasmid construct in 
which the marker gene was under the control of a promoter of choice. The detection of 
increased promoter activity was carried out either by direct quantification of correctly 
initiated RNA or by the analysis of chloramphenicol acetyltransferase (CAT) enzyme 
activity, when this was expressed from the reporter gene construct.
It was found that the transactivating ability of Vmwl 10 could be divided into 
three categories: the transactivation of viral promoters, the transactivation of 
heterologous promoters and transactivation in synergy with the IE polypeptide 
Vmwl 75.
A number of groups have shown that VmwllO transactivates promoters of all 
three classes of HSV-1 genes (Everett, 1984; 1986; O'Hare and Hayward, 1985a; 
1985b; 1987; Quinlan and Knipe, 1985; Gelman and Silverstein, 1985; Mavromara- 
Nazos et al., 1986; Shapira et al., 1987; Sekulovich et al., 1988b). In the category of 
heterologous promoters, VmwllO transactivates the SV40 early promoter (O'Hare et 
al., 1985a; Everett, 1988) as well as the HIV LTR (Mosca et al., 1987). Vmwl 10 can 
also transactivate the rabbit P-globin and the human e-globin promoters (Everett, 1985). 
The only promoter tested which has been found to be unresponsive to Vmwl 10 is the 
VZV tk promoter (Inchauspe and Ostrove, 1989). Examination of the promoters which 
respond to transactivation by Vmwl 10 shows that apart from normal RNA polymerase 
II promoter motifs, there are no consensus sequences which could explain Vmwl 10 
induced activation by a direct DNA binding mechanism. This makes sense given that 
Vmwl 10 has not been found to form a complex with DNA in solution (Everett, 1991b).
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However, Blair and Wagner (1986) reported that sequences between -168 and -75 in the 
HSV-1 major capsid protein (VP5, 'leaky-late' gene) were necessary for VmwllO to 
transactivate gene expression, but this observation was not pursued. Groups which 
found Vmwl 10 to be a potent transactivator also noted that Vmwl 10 acted in synergy 
with the IE protein Vmwl75. However, in one system, the levels of transactivation 
seen were approximately 20 times greater than with either Vmwl 10 or Vmwl75 alone 
(Everett, 1984). The levels of transactivation varied widely between different 
experimental systems. It is likely that one reason for this was the amounts of plasmid 
DNA transfected. This would affect the levels of Vmwl 10 and Vmwl75 present both 
directly and indirectly as Vmwl75 represses transfected EE 1 and IE3 promoters (Section 
1C 1.2). Although there are many variations in the levels of activation seen by Vmwl 10 
both alone and in synergy with Vmwl75, there is agreement that Vmwl 10 is a potent 
and promiscous transactivator of gene expression.
1D5 Functional regions of VmwllO
The relative ease of setting up transfection assay systems has made it possible to analyse 
closely the regions of Vmwl 10 which are important for its ability to transactivate gene 
expression, both alone and in synergy with Vmwl75. It has been found that the results 
from various laboratories regarding levels of activation of gene expression were 
inconsistent, and that the details of the experimental system utilised affected the results. 
Thus the target promoter, amounts of plasmid DNA transfected, the cell type, and the 
cell growth conditions all affected the outcome of the experiments (Everett, 1988b). 
However, the results in any one transfection system were consistent, so that it was 
possible to examine the effects of mutations in Vmwl 10 provided the assay conditions 
remained constant.
Everett (1987a; 1988a) constructed a family of plasmid-borne IE1 genes 
containing 12bp insertions throughout the VmwllO coding sequence such that four 
amino acid insertion mutants of VmwllO were expressed. From these mutants, a 
family of in-frame deletion mutants were derived. The ability of the various mutant 
Vmwl 10 proteins to transactivate gene expression was tested by cotransfection with a 
reporter gene construct expressing the CAT gene under the control of the viral gD 
promoter and a construct expressing Vmwl75 if appropriate.
1D5.1 Transactivation in the presence of Vmwl75
The transactivating abilities of the various mutant Vmwl 10 proteins in the presence of 
Vmwl75 showed that there were five mutation sensitive regions. These are numbered 
from the N- to the C-terminus of the protein as 1 to 5 (Figure 1D5.1). The region most 
affected was the C-terminal end, region 5; all insertions between residues 633-723 led to 
a significant loss of activity. Insertions between residues 150-222 in the second exon of
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the gene, region 1, also substantially reduced the ability of VmwllO to transactivate 
gene expression in synergy with Vmwl75. This region encompasses the RING finger 
(Everett, 1988a). Region 2, at residue 278, and region 3, at residue 406, are 
represented by single insertion mutants. Insertions at residues 575-592 (region 4) 
showed that disruption of the serine-rich tract led to a moderate reduction in reporter 
gene expression.
These results were substantiated by experiments with the in-frame deletion 
mutants (Everett, 1987a; 1988a). The deletion mutant Vmwl 10 protein expressed from 
pllOFXE, missing residues 106-150, was the most severely impaired. Substantial 
reductions in reporter gene expression were also seen with the C-terminal deletion 
mutants expressed from constructs pi 10D12, pi 10D13, pi 10D14 and pi 10D15. The 
expressed proteins were missing residues 594-633, 633-680, 680-720 and 723-767 
respectively. Deletion mutant proteins expressed from pi 10D8 and pi 10D9, missing 
residues 475-548 and 424-549 respectively, were also significantly affected. 
Immunofluorescence experiments have shown that these latter two proteins do not enter 
the nucleus so that loss of residues in the region between 424-549 appears to define a 
nuclear localisation signal. Further mutational analysis has narrowed down the nuclear 
localisation signal to between residues 474-509.
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Figure 1D5.1 Diagram showing the five functional regions of Vmw110, as determined 
by linker insertion mutagenesis. The coordinates of the functional regions of Vmwl 10, 
regions 1,2,3,4 and 5, as determined by the abilities of various insertion and deletion 
mutant proteins to activate gene expression in transfection assays, are shown. The 
positions of a selection of the deletion mutants are shown.
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1D5.2 Transactivation in the absence of Vmwl75
Transactivation levels resulting from Vmwl 10 activity in the absence of Vmwl75 have 
been more difficult to assess in some systems as VmwllO gives only a 3-5 fold 
activation of the gD promoter compared with the 20 fold increase seen in synergy with 
Vmwl75. However, the results showed two significant differences between the activity 
of VmwllO alone compared with its activity in synergy with Vmwl75. Firstly, 
insertions in regions 3 and 5 had little effect on the activity of VmwllO alone, 
indicating that these regions may be important in the synergistic activity of Vmwl 10 
with Vmwl75. It has been suggested that these proteins physically as well as 
functionally interact (Gelman and Silverstein, 1986; Yao and Schaffer, 1994; Mullen et 
al., 1995) but this is not necessarily the case (Section ID 10). The second difference is 
that insertions in region 1 completely abolish Vmwl 10 activity. This comparison of the 
effects of the same mutations on the activation of the gD promoter in the presence and 
absence of Vmwl75 suggests that Vmwl 10 may act through two different but possibly 
related mechanisms. Analysis of experiments with the deletion mutants yielded similar 
results.
1D6 Analysis of VmwllO mutants in the viral context
The role of VmwllO during viral infection was difficult to assess before deletion 
mutants had been isolated. The first experiment which produced a significant reduction 
of VmwllO expression during infection was approached by infecting cells stably 
transformed with a plasmid expressing the antisense EE1 gene transcript (Sandri-Goldin 
et al., 1987). It was estimated that Vmwl 10 activity was reduced to less than 10% of 
wild type levels and from the results it was concluded that Vmwl 10 does not play a 
major role in the viral life cycle in tissue culture. The Vmwl 10 mutants which were 
eventually isolated (Stow and Stow, 1986; Sacks and Schaffer, 1987) showed 
interesting phenotypes which highlighted the importance of Vmwl lO during low 
multiplicity infections. „
Vmwl 10 mutant viruses were initially isolated on the basis that Vmwl 10 may be 
essential for virus growth. Stow and Stow (1986) isolated the mutant dl 1403 using 
complementing cell lines which were cotransfected with wild type HSV-1 DNA and 
plasmid DNA encoding a mutant IE1 gene with a large deletion which was known to 
affect the activity of Vmwl 10 in transfection assays. Sacks and Schaffer (1987) used a 
similar approach to isolate mutants dlX0.7 and dlX3.1. They cotransfected the DNA of 
a Vmwl75 null mutant virus into a VmwllO complementing cell line with plasmid 
DNA encoding Vmwl75 and a mutant IE1 gene.
Virus dl 1403 contains a 2kb deletion within both IE 1 genes such that the gene 
encodes a polypeptide consisting of the N-terminal 105 amino acids of the protein fused 
to 56 amino acids encoded by a new reading frame (Figure 1D6). This mutant showed
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no differences in polypeptide profile, DNA replication and encapsidation when 
compared with wild type virus at a multiplicity of infection of 5pfu/cell in BHK cells. 
However, although similar numbers of particles were produced, the d ll403 progeny 
showed a significantly higher particle/pfu ratio than wild type virus. It was found that at 
low multiplicities of infection the plaquing efficiency of dl 1403 was much less in Vero 
and HFL cells than in BHK cells (Stow and Stow, 1986). The effects of the deletion are 
therefore only seen at low multiplicities of infection (the probable in vivo situation) and 
are overcome at high multiplicities of infection.
Mutant dlX3.1 contains a 3.1 kb deletion in both EE 1 genes which removes the 
transcriptional regulatory region and most of the 5' coding sequences, whilst dlX0.7 
contains a 700bp deletion (Figure 1D6). The viruses were grown in Nero cells (Vero 
cells with G418 resistance) and it was found that they produced similar protein profiles 
to wild type virus although slightly lower levels of late gene products were seen. It was 
also observed that the levels of DNA replication were reduced in these mutants. The 
conclusions reached were that VmwllO is non-essential for viral growth in tissue 
culture, an observation which has simplified the isolation of further Vmwl 10 mutants.
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Figure 1D6 Diagram showing the postitions of deletions in Vmw110 mutant viruses 
dl1403, dlX3.1 and dlX0.7. The positions of the deletions in the IE1 gene of IRl in the 
HSV-1 genome are indicated. The details of the mutant Vmw110 proteins produced 
are discussed in the text.
A series of ten viruses with lesions in the IE1 gene were constructed in order to 
investigate more closely the regions of Vmwl 10 important for its activity in the viral 
context (Everett, 1989). The viruses were made by cotransfecting virus dl 1403 DNA 
into BHK cells with linearised plasmids encoding IE1 genes containing insertions or 
deletions known to affect the transactivating ability of VmwllO. The viruses were 
analysed for defects in single-step growth curve experiments and by analysis of viral 
polypeptide synthesis at low and high multiplicities of infection. Just as the activity of 
Vmwl 10 in transfection assays varied in different experimental systems, it was found 
that mutant virus growth also varied, depending upon the cell type used and even on the 
culture medium utilised. However, it was generally found that mutations in the 
functional regions of Vmwl 10, as defined by the transfection assays, were reflected in
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the growth properties of viruses carrying mutations in these regions. This meant that 
the viruses with mutations in region 1, encoding the RING finger, and region 5, the C- 
terminal end, were most affected. Virus FXE, missing residues 106-150 which encode 
the RING finger, grew almost as poorly as d ll403 at low multiplicities of infection. 
The same was true of the C-terminal deletion mutants, D14 and D15, missing residues 
680-720 and 723-767 respectively. The growth reduction seen in D13, with Vmwl 10 
residues 633-680 deleted, was also significant.
From the studies of Vmwl 10 deletion mutant viruses, attempts have been made to 
explain the role of Vmwl 10 in the viral life cycle. The high particle/pfu ratio of dl 1403, 
dlX0.7 and dlX3.1 has been explained by the suggestion that Vmwl 10 mutants have a 
reduced ability to initiate plaque formation at low multiplicities of infection. Also, 
mutants dlX3.1 and dlX0.7 plaque 15-50 times more efficiently on complementary cell 
lines which express Vmwl 10.
The differences between mutant plaquing efficiencies on different cell types led to 
the suggestion that a cellular function could substitute for Vmw 110. It was found that a 
cellular activity expressed maximally in Vero cells 8hr after release from growth arrest 
in the Go/Gj phase of the cell cycle enhanced plaque formation and gene expression of a 
VmwllO mutant virus (7134) (Cai and Schaffer, 1991; Ralph et al., 1994). It has 
recently been found that an activity expressed by the osteosarcoma line U20S can 
functionally substitute for Vmwl 10 activity (Yao and Schaffer, 1995).
In summary, it is likely that Vmwl 10 plays an important role in activating gene 
expression at low multiplicities of infection. This conclusion is supported by the work 
of Everett (1989), as viruses with mutations in Vmwl 10 which affected their ability to 
transactivate gene expression in transfection assays grew poorly in tissue culture. It is 
evident that in low multiplicity infections, viral gene expression is not sufficiently high 
for the virus to enter the lytic cycle.
1D7 The role played by VmwllO in latent infection
(i) In vitro latency
The potential involvement of Vmwl 10 in the establishment or reactivation of HSV-1 
from latency was indicated initially by the failure of the Vmwl 10 deletion mutant virus, 
dl 1403, to reactivate latent virus in an in vitro latency system (Russell et a l., 1987). The 
in vitro latency system was set up with HFL cells by infection with HSV-2 at the supra- 
optimal temperature of 42°C (Russell and Preston, 1986). Infectious virus was not 
detected in the medium when the cells were subsequently maintained at 37°C for a 
number of days, indicating that a latent or quiescent infection had been established. 
Superinfection with HSV-1 or HCMV stimulated reactivation of HSV-2 latent viral 
genomes. Although the failure of dl 1403 to reactivate HSV-2 in this system indicated 
that VmwllO was involved in the process, it was possible that the LATs were
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important, as the deletion in dl 1403 also affects these transcripts. However, adenovirus 
recombinants expressing Vmwl 10 were also able to reactivate latent HSV-2 in the in 
vitro latency system, indicating that disruption of the IE 1 coding sequences rather than 
the LAT coding sequences led to the failure of dl 1403 to reactivate latent viral genomes 
(Harris et al., 1989). In the in vitro latency system, it was found that the HSV-1 mutant 
virus, FXE (VmwllO A106-150), was incapable of reactivating HSV-2 genomes, 
indicating that the RING finger region which is important in transfection assays 
(Section 1D5) is important in reactivation in this system (Harris et a l., 1989). The 
VmwllO C-terminal deletion mutant virus, D14 (VmwllO A680-720), was able to 
reactivate HSV-2, indicating that the deleted residues are not important for this function 
in this system. This suggests that C-terminal residues of Vmwl 10 may not be important 
for the role of Vmwl 10 in in vitro latency, although it would be of value to examine 
more mutants in the light of the findings presented in this Thesis.
(ii) Latency in mouse models
Virus dl 1403 was used to investigate the role of VmwllO in latency in the mouse 
footpad model (Clements and Stow, 1989). The Vmwl 10 deletion reduced virulence 
and the mutant was slower to reactivate from explanted ganglia compared to wild type 
virus. Clements and Stow (1989) concluded that VmwllO is dispensable for the 
establishment and maintenance of latency and for reactivation from the latent state.
The Vmwl 10 mutant viruses dl 1403, dlX3.1 and dlX0.7 (Section 1D6) were used 
to investigate the role of Vmwl 10 in latency in the mouse ocular model (Lieb et al., 
1989). Viruses dlX3.1 and dlX0.7 were replication competent in the eye and in ganglia, 
although levels were approximately 10-100 fold lower than those of wild type virus in 
the eye and approximately 100 fold lower than wild type virus in ganglia. These figures 
were obtained by plating eye swab material and homogenated ganglia on Vero cell 
monolayers in standard plaque assays. It was found that virus did not reactivate from 
the explanted trigeminal ganglia of mice infected with dlX3.1 and dlX0.7. Further 
investigations by slot blot hybridisation and superinfection of dissociated ganglionic 
neurons with a replication incompetent virus indicated that this was not due to the 
absence of latent viral genomes. Interestingly, it was evident that although the levels of 
replicating dlX0.7 virus in ganglia were the same as those of dIX3.1 in the initial stages 
of infection, there was much less viral DNA in the ganglia of mice infected with dlX0.7 
compared with those infected with dlX3.1. These dlX0.7 genomes were resistant to 
reactivation in the superinfection assay. It was found in these assays that whilst d ll403 
was less latency competent than its parent virus, HSV-1 strain 17+, it was significantly 
more competent than dlX3.1 or dlX0.7 which were derived from the wild type KOS 
strain. It was concluded from these results that whilst Vmwl 10 is not essential for the
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establishment, maintenance or reactivation of the virus from latency, it plays a role in 
the efficiency of the process.
Schaffer's group have also examined whether or not mutations in the EE 1 gene or 
mutations in the LATs are responsible for the reduced efficiencies of Vmwl 10 mutant 
viruses in establishing latency and in reactivating from the latent state (Cai et al., 1993). 
They constructed a series of Vmwl 10 nonsense, insertion and deletion mutant viruses 
which expressed VmwllO polypeptides with C-terminal truncations and all of which 
expressed near wild type levels of the 2kb LAT. The mutant Vmwl 10 polypeptides 
exhibited graded levels of VmwllO specific transactivation in transient transfection 
assays. On testing the mutant viruses for their ability to establish and reactivate from 
latency, it was found that all of them entered and reactivated from latent infection less 
efficiently than wild type virus but to an extent which reflected the ability of the 
encoded mutant VmwllO protein to transactivate gene expression. Quantitative PCR 
analysis carried out using DNA isolated from ganglia showed that whilst the amounts of 
viral DNA in latently infected ganglia varied, there was no correlation between virus 
reactivation frequencies and the levels of viral DNA present.
In another investigation of the particular roles of VmwllO and LATs in latent 
infection, Schaffer's group inserted a copy of the IE 1 gene between the UL26 and UL27 
genes of the IE1 and LAT deletion mutant virus 7134. The 7134 virus exhibits a 
marked impairment in its ability to replicate in the mouse eye and to reactivate from 
latency. The presence of the inserted EE1 gene restored the ability of the mutant to 
replicate in the eye and to reactivate from latency to approximately half of wild type 
levels. Taken together with the results from the insertion mutants this indicates that, 
although VmwllO is not essential for establishment, maintenance or reactivation from 
latency, it plays a role in latent infection which is distinct from that of the LATs.
1D8 The RING finger
1D8.1 RING finger proteins
Vmwl 10 is a member of a growing family of proteins containing the C3HC4 or RING 
finger motif. Named after the RING-1 gene product, the first protein identified as 
containing this sequence (Freemont, 1991; 1993; Hanson et al., 1991; Lovering et a l.,
1993), the motif is represented more fully as C-X2-C-Xn.30-C-X-H-X2-C-X2-C-Xu.19- 
C-X2-C. The function of the RING-1 gene product is unknown but, on the basis of 
other RING finger proteins apparently being involved in the regulation of gene 
expression, it was initially proposed that the RING-1 gene product regulated gene 
expression by binding to DNA. Members of the family have since been found in a 
variety of organisms and appear to be involved in diverse cellular metabolic pathways. 
Some appear to be involved in the regulation of gene expression but others play a role in
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nucleic acid metabolism, cell cycle regulation and in cytoplasmic signal transduction 
pathways. Many of these proteins also have a variety of motifs, other than the RING 
finger, such as SH3 domains or coiled-coil motifs, suggestive of their involvement in 
protein :protein interactions.
The variety of functions in which RING finger proteins are involved is not 
surprising given the lack of homology between many of them outside the RING domain, 
and even within the variable parts of the RING finger itself (Barlow et a l., 1994). It is 
apparent that the domain is unlikely to be involved in DNA interactions per se as some 
RING finger proteins are components of multiprotein complexes and others are located 
in the cytoplasm.
(i) Regulation of gene expression
Examples of proteins involved in the regulation of gene expression include rpt-1, a 
protein involved in the regulation of the interleukin 2 receptor gene in resting T- 
lymphocytes (Patacara et al., 1988), and the Drosophila protein male specific lethal 2, 
which also contains a metallothionein-like cysteine cluster and is involved in the 
equalisation of X-linked gene products in male flies (Zhou et al., 1995). A number of 
RING finger proteins are involved in development and therefore, by inference, in the 
regulation of gene expression; these include COP-1, an Arabidopsis regulatory gene 
involved in seedling morphogenesis (Deng et al., 1992), neuralised, a Drosophila 
protein involved in the decision-making process that determines whether a primary cell 
will have a neuronal or epidermal fate (Price et al., 1993) and A33, a newt protein 
which is associated with lampbrush chromosomes and may influence development by 
acting at the post-transcriptional level (Bellini et al., 1993). Also included in this group 
are Vmwl 10 and the related proteins of other a-herpesviruses such as the VZV gene 61 
protein and the EHV-1 gene 63 protein.
(ii) Recombination and repair
RAG-1 is a RING finger protein involved in V(D)J recombination in maturing B 
lymphocytes (Schatz et al., 1989). The yeast proteins rad8 and RAD 18, from 
Schizosaccharomyces pombe and Saccharomyces cerevisiae respectively, are involved 
in DNA repair following damage by UV radiation (Jones et al., 1988; Doe et al., 1993).
(iii) Replication
Some viral expressed RING finger proteins may be involved in replication; the pox 
viruses Shope fibroma virus and Ectromelia virus both express proteins which localise 
to sites of viral DNA replication (Upton et al., 1994; Senkevich et al., 1995). It is 
interesting to note that the nuclear domains to which VmwllO localises early in 
infection are adjacent to or overlap viral replication compartments (Maul et al., 1996).
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(iv) Oncogene translocations
The RING finger protein PML is fused to the RARa protein as a consequence of a 
chromosomal translocation in the immature granulocytes of patients with acute 
promyelocytic leukaemia (Section 1D9.1). Like PML, the RING finger proteins rfp and 
T18 are implicated in cell transformation as a result of chromosomal translocations 
(Takahashi et al., 1988; Miki et al., 1991; Isomura et al., 1992). The rfp gene is fused 
with the ret proto-oncogene and the mouse T18 gene to the B-raf proto-oncogene.
(v) Proteinrprotein interactions
Recently, a number of RING finger proteins have been implicated in protein:protein 
interactions. The Caenorhabditis elegans protein, Sli-1, is a developmental regulatory 
protein which acts on an epidermal growth factor receptor-like tyrosine kinase (Yoon et 
al., 1995). It has been proposed that Sli-1 and its mammalian counterpart, c-cbl, a 
proto-oncogene, belong to a new class of proteins that modify receptor tyrosine kinase- 
mediated signal transduction. The human protein, HT2A, mediates the interaction 
between the HIV-1 Tat protein and its cellular cofactor Tat binding protein, enabling the 
complex to interact with the TAR element (Fridell et al., 1995). TRAF-2 is a protein 
which binds to the cytoplasmic tails of members of the tumour necrosis factor (TNF) 
receptor subfamily (Rothe et al., 1994; 1995): the RING finger domain of this protein 
has been shown to be necessary in a signal transduction pathway which leads to the 
activation of the transcription factor NF-kB. The related protein, CRAF1, interacts with 
the cytoplasmic tail of CD40, another member of the TNF receptor subfamily which is 
found in B-cell membranes (Cheng et al., 1995). Like TRAF-2 and CRAF1, PAF-1, a 
peroxisome associated protein, is cytoplasmic in its location (Tsukamoto et al., 1994). 
Further examples of the diversity of function exhibited by RING finger containing 
proteins are iap, a baculovirus protein involved in preventing apoptosis (Clem and 
Miller, 1994) and p36, a protein which forms a multiprotein complex in a cell cycle 
dependent fashion (Fisher etal., 1995).
1D8.2 Structure and functional analysis of the EHV-1 gene 63 RING finger
As the RING finger is present in such a large variety of proteins, it was of interest to 
determine the its structure. The VmwllO RING finger region is important for its 
function in transfection assays (Section 1D5) and also for the normal disruption of 
nuclear structures called ND10 (Everett and Maul, 1994; Section 1D9.2), so attempts 
were made to obtain structural information from this protein as well as from the 
equivalent RING finger proteins of two other alpha herpesviruses.
The regions encompassing the Vmwl 10 RING finger and also those of the related 
genes in VZV (gene 61) and EHV-1 (gene 63) were cloned and expressed in bacteria, 
and the expressed proteins were purified by gel filtration chromatography under non­
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denaturing conditions (Everett et al., 1993b). The purified proteins were analysed for 
their zinc content by atomic absorption spectroscopy and their concentrations were 
determined by amino acid analysis. The results showed that the VmwllO and 
equivalent VZV peptides contained 3-6 atoms of zinc per protein monomer and that the 
EHV-1 protein contained between 1.4(±0.4)-3.7(±0.4) atoms of zinc per molecule. 
Analysis of the COP-1 RING finger and that of the RING-1 gene product showed that 
these molecules coordinate approximately 1.7 and 1.8 zinc atoms respectively (Lovering 
etal., 1993; von Arnim and Deng, 1993). The purified VZV gene 61 and VmwllO 
RING finger peptides aggregated, making them unsuitable for structural analysis by 
nuclear magnetic resonance (nmr) spectroscopy.
The structural analysis revealed that the EHV-1 RING finger motif adopts a ppap 
fold around two zinc atoms (Everett et al., 1993b; Barlow et al., 1994). Cysteines 1, 2, 
4 and 5 coordinate one zinc atom, with cysteines 3, 6 and 7 and the histidine residue 
coordinating the other. The structure folds such that an a-helix lies along the surface of 
a triple-stranded anti-parallel (3 -sheet. The sequences involved in forming one of the p- 
strands are C-terminal to the final cysteine residue. A phenylalanine residue prior to the 
fourth cysteine lies at the centre of the structure; it is worth noting that all RING finger 
proteins contain a residue with a bulky, hydrophobic side-chain at this position. 
Another interesting structural feature is that cysteine 3 and the histidine residue, which 
are separated by only one amino acid, coordinate the same zinc atom. In all other 
known zinc binding proteins, the separation between residues coordinating the same 
metal ion is at least two amino acids.
Although part of the RING finger showed limited structural similarity to the 
TFIHA type of zinc finger, the purified viral RING finger domains did not bind DNA or 
RNA in gel retardation assays and they also did not bind to DNA cellulose columns 
(Everett et al., 1993b). In contrast, the RING finger domain of the RING-1 gene 
product was shown to weakly bind DNA in solution (Lovering et al., 1993), but this 
may be a reflection of the overall positive charge of this domain. Consideration of the 
EHV-1 RING finger structure suggested that exposed a-helical polar residues may be 
important for its functions. To test this possibility, equivalent residues in the predicted 
Vmwl 10 a-helix were mutated and it was shown that some point mutations, as well as a 
number of double and triple point mutations, abolished Vmwl 10 function in transient 
transfection assays (Barlow eta l., 1994). This region of the VmwllO RING finger 
domain has also been shown to be important in the context of the virus (Everett et al., 
1995c).
The structure of the PML RING finger has also been determined by nmr analysis 
(Borden et al., 1995). The overall structure is similar to that of the EHV-1 RING 
finger; the positions of the central p-strands and the residues coordinating zinc atoms, as 
well as the packing of hydrophobic residues, are identical. However, there are some
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differences in the structure which is not surprising as outside of the zinc coordinating 
residues the overall homology of the domains is less than 15%. The main structural 
difference is that in place of the EHV-1 a-helix, there is a [3-strand. This is suggestive 
of the RING finger structure acting as a scaffold for protein domains involved in very 
different functions.
The structural differences between the PML and Vmwl 10 RING finger proteins 
were highlighted in domain-swap experiments (Everett et al., 1995b). Replacing the 
Vmwl 10 RING finger with that of PML resulted in a virus which grew no better than 
the RING finger deletion mutant virus FXE. Complete replacement of the IE1 gene 
with the PML gene also produced a virus with a Vmwl 10-null phenotype, indicating 
that PML is not a functional counterpart of Vmwl 10. However, it is now known that 
the Vmwl 10-PML RING finger domain-swap did not encompass the entire PML RING 
finger domain as sequences C-terminal of the final cysteine residue which are known to 
form a P-strand were missing.
Another series of experiments were carried out in which the VmwllO RING 
finger domain was replaced with the entire EHV-1 gene 63 RING finger (Everett et al., 
1995b). The hybrid protein did not transactivate gene expression in transient 
transfection assays. However, the growth properties of an HSV-1 virus expressing the 
entire EHV-1 gene 63 protein in place of Vmwl 10 were intermediate to those of the 
wild type virus and virus FXE. These experiments show that the RING finger domain is 
not a simple moveable element and support the conjecture that the RING finger 
structure is a scaffold around which a variety of sequences involved in different 
functions can fold. However, a larger domain swap has been successful (Moriuchi et 
al., 1994). VZV gene 61 residues 1-105 fused to Vmwl 10 residues 246-775 and the 
reciprocal domain-swap protein (Vmwl 10 residues 1-245 and VZV gene 63 residues 
106-467) partially maintained the transactivating functions of both proteins in transient 
transfection assays. It could be that the RING finger domain needs to be in the context 
of a larger portion of the parent protein to be active.
1D9 The nuclear localisation of VmwllO 
1D9.1 ND10
(i) Identification
The nucleus is the site of a wide variety of cellular processes, including DNA 
replication, RNA transcription and processing, and ribosome biogenesis (Hancock and 
Boulikas, 1982; Newport and Forbes, 1987). DNA replication occurs at specific sites 
(Gerace and Burke, 1988; Hozak et al., 1994) and ribosome biogenesis occurs within 
the nucleolus (Finley etal., 1989). Factors involved in RNA processing, hnRNPs and 
snRNPs, are organised in 20-50 speckled domains within the nucleus (Spector et al.,
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1983; Fakan et al., 1984; Hamm et al., 1988; Fu and Manniatis, 1990). Autoimmune 
sera often stain nuclear components such as kinetochores, telomeres and coiled bodies 
(Moroi et al., 1981; Eamshaw etal., 1984; Gottschling and Zakian, 1986; Cech, 1988; 
Morin, 1989; Andrade et al., 1991). A number of nuclear domains including 
perichromatin fibrils and interchromatin granules have also been identified (Fakan etal., 
1984; Puvion etal., 1984; Visa etal., 1993).
On screening over 1,700 human autoimmune sera in immunofluorescence studies, 
a novel nuclear domain of 0.2-0.3(im diameter was identified by a small proportion of 
the sera (Ascoli and Maul, 1991). The sera, as well as two monoclonal antibodies 
which were isolated, stained approximately 10 nuclear dots per cell, hence the name 
nuclear dot 10 (ND10). Double label immunofluorescence experiments showed that 
ND10 were separate from chromosomes, kinetochores and centromeres (in spite of their 
frequent paired appearance), and were not sites of abundant RNA synthesis and mRNA 
processing (Ascoli and Maul, 1991; Kastner etal., 1992; Xie et al., 1993; Dyck etal., 
1994; Koken et al., 1994; Weis et al., 1994). Their relatively large size indicated that 
ND10 are probably multiprotein complex structures and to date they are known to 
contain at least five proteins, three of which have been cloned.
(ii) Protein constituents
Ascoli and Maul (1991) investigated methods of enriching cell extracts for ND10 in a 
series of in situ biochemical fractionation experiments combined with 
immunofluorescence assays. These experiments revealed that ND10 were highly 
hydrophobic and were stably attached to a nuclear matrix component. The in situ 
procedure was scaled up and residual proteins separated by polyacrylamide gel 
electrophoresis, Western blotted and probed with sera that detected ND10 in 
immunofluorescence experiments. Proteins such as the centromere proteins CENP-A, 
-B and -C were detectable, indicating that proteolysis was minimal. The anti-NDIO 
autoimmune sera recognised a band of approximately 55kD, and isoelectric focusing 
and size separation followed by immunoblotting with one of the monoclonal antibodies 
showed that there were three charge isomers of the 55kD protein.
A second ND10 protein, SplOO, was identified earlier than the 55kD protein but 
was not recognised as localising to ND10 until double label immunofluorescence 
experiments were carried out with the anti-55kD antisera and SplOO antisera (Stuurman 
et al., 1992). The SplOO autoantigen was initially identified as a DNase and RNase 
insensitive, readily extractable nuclear protein with a molecular weight of 
approximately lOOkD, as determined by polyacrylamide gel electrophoresis (Szostecki 
et a l, 1987). The gene encoding SplOO was cloned following the screening of a Xgtl 1 
cDNA expression library (Szostecki et al., 1990). Xie et al. (1993) screened 892 
autoimmune sera and used one which detected ND10 in immunofluorescence
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experiments (as shown by double labelling experiments with Ascoli and Maul's anti- 
55kD antiserum) to screen a A,gtl 1 cDNA expression library. They also identified a 
clone encoding the SplOO protein although this group observed that the protein migrated 
with an apparent molecular weight of 72kD on polyacrylamide gels. In contradiction to 
Ascoli and Maul's in situ biochemical fractionation experiments, Xie et al. (1993) 
reported that ND10 were associated with DNA. They suggested that in Ascoli and 
Maul's experiment DNase treatment may have been incomplete. However, this 
observation has not been supported by other groups and it is generally held that ND10 
are attached to a component of the nuclear matrix. The gene encoding the SplOO 
protein encodes a protein of a predicted molecular weight of 53kD. Analysis of a 
number of library clones indicated that the primary transcript was alternatively spliced. 
The anomalous molecular weights seen in polyacrylamide gel electrophoresis probably 
reflect the different gel systems used and it is also possible that SplOO is modified. It 
has been suggested that residues 360-409 of the 480 residue protein are weakly 
homologous to some transcription factors (Szostecki et al., 1990) and Xie et al. (1993) 
showed experimentally that fusion of SplOO residues 333-407 to the lexA DNA binding 
domain resulted in transcriptional activation of a reporter gene construct in 
Saccharomyces cerevisiae. It was concluded from these experiments that SplOO is a 
transcription factor. However, these results should be interpreted with caution as the 
homology with transcription factors is very weak and transcriptional activation 
experiments are better approached using whole proteins in transfection assays rather 
than just isolated domains.
A third component of ND10 was identified as PML (Section 1D9.2) after the 
isolation and characterisation of the monoclonal antibody 5E10 (Stuurman etal., 1992). 
This group showed that the antigen recognised by 5E10, as well as being in the same 
domains as the 55kD protein and SplOO, was associated with the nuclear matrix (in 
agreement with Ascoli and Maul, 1991). It was found by Western blot analysis that 
5E10 recognised four protein bands which were of 149kD, 126kD, 95kD and 63kD, 
with the 126kD band being most prominent. Dyck et al. (1994) showed, using a rabbit 
antiserum raised against a bacterially expressed PML-GST fusion protein, that PML 
localised to nuclear dots which they called PML oncogenic domains (PODs). Double
label immunofluorescence experiments led to PODs being excluded as previously
.recognised nuclear structures. Western blot analysis of bacterially expressed PML 
showed that 5E10 recognised an epitope in the PML protein. Analysis using anti-55kD 
antisera and SplOO antisera confirmed that PML colocalised to ND10 (or PODs). It was 
■ not possible to demonstrate an interaction between PML and SplOO in an in vitro 
translation assay in which PML and PML-RARa formed heterodimers, indicating that 
another protein may bind both PML and SplOO and confirming further the multiprotein 
nature of ND10 (Koken et al., 1994).
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Dyck et al. (1994) also carried out immunofluorescence experiments with a 
monoclonal antibody derived from sera originally raised against EBV infected cells 
(Epstein, 1984) and showed that the antibody cross-reacted with ND10 with a 65kD 
protein being the target. This protein has yet to be further characterised.
More recently, another ND10 protein has been cloned (Korioth et al., 1995). A 
monoclonal antibody was isolated which detected nuclear dots in immunofluorescence 
assays, following immunisation of mice with crude nuclei from human osteosarcoma 
cells and the generation of hybridomas. In combination with immunofluorescence 
assays, in situ cell fractionation showed that this antigen was also associated with the 
nuclear matrix. Western blotting of electrophoresed proteins from crude nuclear 
fractions led to the detection of a 55kD protein using the antibody. NEPHGE (near 
equilibrium pH gradient electrophoresis) analysis showed that the protein is acidic and 
has no charge isomers, making it distinct from the 55kD antigen previously identified 
(Ascoli and Maul, 1991). The gene encoding the protein was isolated by screening a 
A,gt 11 cDNA expression library and sequence analysis showed that the clone encoded a 
52kD protein which was consequently named nuclear dot protein 52 (NDP52). The 
protein contains a predicted coiled-coil motif which is followed by a leucine zipper 
motif. At the C-terminal end, there are seven cysteine residues spaced such that there is 
sequence homology with the LIM domain which has the consensus sequence CX2CX16. 
23HX2CX2CX2CX 16_2iCXi.3(C,H,D). These domains, which coordinate zinc, have 
been found in proteins that appear to be involved in the control of gene expression and 
differentiation (Freyd et al., 1990). However, one of the cysteine residues and the 
histidine residue is not present indicating that NDP52 must coordinate zinc in a different 
manner to LIM domains, or possibly not at all. Therefore, as with SplOO, caution 
should be exercised in ascribing a transcriptional activation function to NDP52.
Whilst more ND10 proteins are being discovered and their genes cloned, the 
function of these domains remains obscure. That they are potentially important for 
normal cell function has been shown in cells expressing the PML-RARa fusion protein; 
treatment with RA causes the reassembly of disrupted ND10 and concomitant 
regression of the associated leukaemia (Section 1D9.2). It has been shown that 
interferon treatment increases the number of ND10 as shown by immunofluorescence 
detecting SplOO and NDP52 (Guldner et al., 1992; Korioth e ta l ., 1995). This arises as 
a result of increased mRNA levels as determined by Northern blot analysis. In addition, 
interferon treatment of Cos-7 cells, which do not contain NDP52 in ND10, caused 
NDP52 to be localised to nuclear dots in approximately 10% of cells (Korioth et al., 
1995). ND10 were also dramatically increased in number during heat stress (Ascoli and 
Maul, 1991, unpublished data). Histological analysis has shown that ND10 are 
upregulated in the hepatocytes of patients with inflammatory liver disease such as 
chronic hepatitis or primary biliary cirrhosis and in proliferating epithelia as well as in
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epithelial tumours (Terris et al., 1995). Whether or not the upregulation of ND10 in 
these latter instances is a cause or effect of the associated diseases and cellular processes 
is not known.
(iii) The effects of viral infection
Perhaps more of an idea as to the function of ND10 has come with studying the effects 
of viral infection on the known protein components. It has been shown that by 5hr post 
infection with HSV-1, ND10 staining, as detected by an anti-55kD protein antibody, 
disappears (Maul et al., 1993). This has been shown to be a direct result of VmwllO 
expression (Section 1D9.3). The PML protein is also redistributed during HSV-1 
infection (Maul and Everett, 1994). Early experiments suggested that ND10 did not 
coincide with viral replication compartments, as indicated in immunofluorescence 
experiments using an antibody directed against the major viral DNA binding protein, 
ICP8 ; it was found that loss of the anti-55kD protein staining occurred 2hr before ICP8 
aggregation in replication compartments (Maul et al., 1993). More recently, however, it 
has been shown by in situ DNA hybridisation and immunofluorescence analysis that 
viral DNA is preferentially localised to sites which are adjacent to or overlap ND10 by 
3hr post infection. As ND10 were disrupted at later times in infection with wild type 
virus, infection with a Vmwl 10 deletion mutant vims was carried out. It was found that 
5hr post infection with dll403, the SplOO and ICP8 staining patterns were also closely 
adjacent or overlapping, indicating that replication compartments are closely associated 
with ND10 (Maul etal., 1996).
HCMV infection also causes disruption of ND10 and this has been shown, as with 
HSV-1, to be an immediate-early protein function (Kelly et al., 1995). Experiments 
carried out to observe the effect of adenovirus infection on ND10 showed that PML was 
apparently redistributed into a meshwork of fibrous structures which also contain the 
gene product of the adenovirus E4-ORF3 gene (Carvalho et al., 1995). The E4-ORF3 
gene product is a non-essential viral protein thought to be involved in the regulation of 
alternative splicing of viral mRNAs and also in the regulation of viral DNA synthesis 
(Carvalho et al., 1995 and references therein). Transfection assays have shown that the 
adenovirus El A protein localises to ND10 and that the (D)LXCXE sequence, which is 
necessary for binding pRb and the related p i07 oncoproteins, is required for this 
localisation. The SV40 large T antigen has been shown to locate in close proximity to 
ND10 in similar assays. Consistent with these findings are observations made by G. 
Maul which show that the adenovirus and SV40 DNA genomes, like the HSV-1 DNA 
genome, are associated with ND10 early in infection (personal communication).
Whilst infection with different viruses results in different effects on ND10 protein 
relocalisation, it is evident that disruption of the normal pattern is a common 
consequence of nuclear DNA virus infection. In view of the fact that ND10 are
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increased upon treatment with interferon (Guldner et al., 1992), it is possible that their 
disruption during virus infection circumvents a cellular defence mechanism. As 
VmwllO and the adenovirus E4-ORF3 protein are involved in the reorganisation of 
ND10, yet neither are essential viral proteins, it is possible that disruption of ND10 is 
only essential in low multiplicity infections when viral gene expression is too low to 
overcome cellular defence mechanisms. It is likely that the cloning of more ND10 
proteins and discovery of their functions in the cell will give a clearer understanding of 
the role of ND10.
1D9.2 PML
PML is a RING finger protein which is of interest in the role that Vmwl 10 plays in the 
HSV-1 infected cell as both proteins localise to the same nuclear domains at the onset of 
infection (Section 1D9.3). However, PML initially became a focus of interest with the 
observation that its gene was involved in a chromosomal translocation (t( 15; 17)) which 
was associated with acute promyelocytic leukaemia (APL). This reciprocal 
translocation between the long arms of chromosomes 15 and 17, links the C-terminal 
portion of the retinoic acid receptor (RAR) a  to the N-terminal portion of PML, which 
includes its RING finger domain (de The et al., 1990; Borrow et al., 1990; Kakizuka et 
al., 1991; Goddard etal., 1991). The disease is characterised by the clonal expansion of 
myeloid cells that are unable to differentiate into mature granulocytes. Treatment with 
retinoic acid (RA), a vitamin D derivative that is known to influence differentiation in a 
number of experimental systems (Strickland and Mahdari, 1978; Roberts and Spom, 
1984; Thalle and Eichele, 1987), stimulates differentiation of these cells leading to a 
complete remission (Huang etal., 1988; Castaigne et al., 1990).
(ii) Gene structures
RARa belongs to a superfamily of nuclear steriod/thyroid hormone receptors. There 
are a number of retinoic acid receptors, arising from the differential use of two 
promoters and alternative splicing (Petkovich et al., 1987; Brand et al., 1988; Evans, 
1988; Green and Chambon, 1988). The proteins all have DNA binding and retinoic acid 
recognition domains, as well as a dimerisation interface. These domains are all retained 
in the fusion protein, PML-RARa, which arises as the result of the t( 15; 17) 
translocation in APL patients (de The et al., 1991). Transcriptional transactivation of 
retinoic acid responsive gene promoters occurs in the presence of RA when RAR 
proteins form heterodimers with RXR, an auxiliary nuclear protein of similar structure. 
The heterodimers bind to specific target DNA sequences in responsive promoters
reviewed by Green, 1993). RXR can also heterodimerise with a number of other
(i) APL
Chapter 1 Introduction
nuclear receptor proteins such as the thyroid hormone receptor and the vitamin D 
receptor. RARa does not bind efficiently to DNA as a homodimer (Leid et a l., 1992).
Analysis of the translocation breakpoint on chromosome 17 led to the cloning and 
characterisation of the PML gene and protein (Goddard et al., 1991; Kakizuka et al., 
1991). The gene encodes at least three isoforms arising from alternatively spliced 
transcripts; the largest of these is 633 residues and the isoforms have residues 27-46 or 
419-466 missing. The distinctive features of the protein which are retained in PML- 
RARa fusion proteins are a cysteine-rich region and a potential coiled-coil a-helical 
region. Analysis of the sequence of the cysteine-rich region revealed that it is composed 
of three elements, one of which forms a RING finger, while the other two are more 
similar to previously characterised zinc finger DNA binding domains. This latter 
observation led to the suggestion that PML may be a transcription factor. Interestingly, 
although later immunofluorescence experiments showed that PML localises to the 
nucleus (Section lD9.1(iv)), the protein does not contain a recognised nuclear 
localisation signal.
Translocation breakpoints in APL patients cluster in two regions of the gene, 
either side of an alternatively spliced exon. This is reflected in the sizes of PML-RARa 
fusion proteins in the immature myeloid cells of APL patients (Kastner et al., 1992; 
Pandolfi et al., 1992). Transcripts also arise from the reciprocal translocation, encoding 
RARa-PML products but these are not always translated (Alcalay et al., 1992; Kastner 
etal., 1992). It has therefore been concluded that that the PML-RARa fusion protein 
rather than the RARa-PML fusion protein is responsible for the block in differentiation 
of myeloid cells in APL. It has also been suggested that disruption of the RARa gene is 
responsible for the pathogenesis of APL rather than disruption of the PML locus. This 
is based on the ability of RA to induce remission in APL patients, as well as the 
observation that APL has been associated with a t( 11; 17) translocation involving the 
RARa receptor and a Kriippel-like zinc finger encoding gene (Chen et al., 1993). 
However, it has more recently been shown that PML may be a growth supressor; 
transfection of APL-derived cells in tissue culture with a construct expressing PML 
resulted in supression of anchorage independent growth in soft agar and reduced 
tumorigenicity of the cells in nude mice (Mu et al., 1994). PML was also found to 
supress the transformation of rat embryo fibroblasts by the cooperative oncogenes neu 
and Ha-raj. Cotransfection of PML and PML-RARa expression plasmids resulted in a 
significant reduction of the suppressor function of PML in these experiments, indicating 
that the fusion protein can act as a dominant negative inhibitor of PML function 
'Kastner et al., 1992; Mu et al., 1994). This means that disruption of both RA Ra and 
ML may contribute to APL pathogenesis.
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(iii) Functional studies
Transient transfection assays have shown that the transactivating properties of PML- 
RARa fusion proteins differ from those of RARa. Transfection assays carried out in 
HepG2 cells showed that, in the presence of RA, RA Ra is a more efficient 
transactivator of the retinoic acid response element (RARE) (3 than a PML-RARa 
fusion protein, as indicated by the level of luciferase reporter gene expression (de The et 
al., 1991). It was also shown that cotransfection of PML-RARa and RARa led to 
reduced luciferase expression in the presence of RA, indicating that PML-RARa 
interferes with the normal function of RARa. Experiments carried out in Cos-1 and 
HeLa cells showed that, in the presence of RA, PML-RARa could transactivate gene 
expression from RAREs as efficiently, or less or more efficiently than RA Ra depending 
on the nature of the target RARE (Perez et al., 1993). As with the transient transfection 
assays carried out with Vmwl 10 and Vmwl75 (Section 1D5), it was evident that the 
levels of gene expression induced could vary widely in different experimental systems 
and caution was needed in interpreting the results. Generally, it was found that PML- 
RARa repressed the basal activity of RAREs in the absence of RA, an activity which is 
not a property of RARa.
Chambon's group showed that PML-RARa forms homodimers via the coiled-coil 
region in the PML protein in vitro (Perez et al., 1993). This region of PML is also the 
interface through which PML-RARa heterodimerises with PML (Kastner et al., 1992). 
The PML-RARa protein interacts with RXR via RARa sequences and contacts DNA in 
a similar manner to RAR-RXR heterodimers, with one RARa DNA binding domain 
and one RXR DNA binding domain in contact with DNA. Immunofluorescence studies 
showed that the PML-RARa protein localised mainly to the cytoplasm and that it 
sequestered RXR (Perez et a l , 1993; Weis et a l., 1994). This observation has 
implications for the disruption of more than one hormonal stimulatory pathway, as RXR 
interacts with other hormone responsive nuclear receptors (reviewed by Green, 1993).
(iv) Nuclear localisation
The earliest immunofluorescence experiments with PML were carried out with 
transfected cells; PML was seen to localise to domains within the nucleus unless the 
RING finger was disrupted, in which case PML staining was diffuse within the nucleus 
'Kastner et al., 1992). The PML-RARa fusion protein was found in both the nucleus 
ind cytoplasm but was located in the PML domains in the presence of RA. Kastner et 
il  suggested that PML might be colocalising with ribonucleoprotein particles, based on 
its homology with Ro/SSA, the 52kD RING finger component of ribonucleoprotein 
particles which localises in a speckled pattern in the nucleus (Ben-Chetrit et al., 1988). 
It has since been found, however, that PML localises to distinct nuclear structures called 
ND10, Kr bodies or PODs which contain a number of cellular proteins (Ascoli and
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Maul, 1991; Kastner eta l., 1992; Xie etal., 1993; Dyck et al., 1994; Koken et al., 1994; 
Weis et al., 1994) (Section 1D9.2). Two groups have since shown that in APL derived 
cell lines, treatment with RA causes the cytoplasmic PML-RARa fusion protein to be 
located to ND10 in the nucleus, while RXR returns to its normal distribution (Koken et 
al., 1994; Weis et al., 1994). Weis et al. (1994) have also shown that in APL cells, one 
of the ND10 antigens, SplOO, is located in abnormal protein complexes with the PML- 
RARa fusion protein and that treatment with RA relocated this protein to the nucleus
also.
(v) How does APL develop?
In spite of much investigation into APL, the role played by the PML-RARa fusion 
protein is far from being completely understood, and even less so is the mechanism by 
which RA induces differentiation of diseased myeloid cells. However, it is likely that 
the reassembly of ND10 may play a role in the remission seen in APL patients treated 
with RA (Weis et al., 1994). A number of different mechanisms could account for the 
block in differentiation of APL cells. Firstly, the ND10 antigens that are mislocated 
may be prevented from acting in the normal way, or their activity may be redirected. 
There is evidence for the former scenario regarding PML; the binding of PML to PML- 
RARa disrupts the supressive activity that PML has on cell growth (Kastner et al., 
1992; Mu et al., 1994). Secondly, sequestration of RXR in the cytoplasm of APL cells 
is likely to have a number of knock-on effects. In connection with this, it has been 
shown that vitamin D 3 can induce differentiation of APL cells (reviewed by DeLuca, 
1988; Reichel and Norman, 1989). Chambon's group have shown that large amounts of 
PML-RARa in transfected cells inhibits the transcriptional activation mediated by 
vitamin D3 (Perez et al., 1993). Thirdly, PML could act on its own, as it has been 
demonstrated that it represses some RAREs (Kastner et al., 1992). The location of the 
ML-RARa protein to ND10 in the presence of RA could remove this activity. 
Possibly, the key to understanding the pathogenesis of APL will come with a clearer 
knowledge of the function of ND10 in the cell.
1D9.3 VmwllO and ND10
(i) Infected cells
An investigation of IE1 deletion mutant viruses determined that Vm wllO was 
responsible for the apparent disappearance of ND10 by 5hr post infection in all cell 
types tested; ND10 remain undisturbed until later in infection in cells infected with the 
Vmwl 10 deletion mutant virus dll403 (Maul et al., 1993). ND10 are still present at 6hr 
post infection with dl 1403 and by 16hr post infection ND10 proteins form hollow 
spheres and nuclear tracks of unknown significance (Maul and Everett, 1994). 
Immunofluorescence experiments also showed that Vmwl 10 localised to N D 10 early in
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infection (before 4hr), prior to ND10 disappearance. That Vmwl 10 was sufficient for 
this process was shown in an experiment with an adenovirus recombinant where the EE1 
gene was placed under the control of the adenovirus major late promoter. It is known 
that ND10 proteins are redistributed and not degraded from Western blot analyses of 
infected cell extracts (Maul et al., 1993). This is supported by immunofluorescence 
experiments which have shown that PML and other ND10 antigens are relocated in part 
to the nuclear membrane (Everett and Maul, 1994; Maul and Everett, 1994). During 
wild type HSV-1 infection, VmwllO becomes increasingly diffusely spread through 
both the nucleus and cytoplasm following its transient localisation to ND10. It is 
possible that other ND10 proteins are similarly re-distributed into both nucleus and 
cytoplasm (Maul and Everett, 1994).
It has been shown that the regions of Vmwl 10 responsible for the redistribution of 
ND10 proteins involve the RING finger and C-terminal residues (Everett and Maul, 
1994; Maul and Everett, 1994). Experiments with the RING finger deletion mutant 
viruses FXE (A106-150) and D22 (A 162-188) showed that the mutant Vmwl 10 proteins 
localised to ND10 for a longer period than wild type Vmwl 10 protein; late in infection 
there is a general disruption of nuclear architecture and the RING finger deficient 
Vmwl 10 proteins were sometimes seen in long fibrous structures, which may be related 
to the PML tracks seen in dl 1403 infected cells. By 16hr post infection with D22, 
VmwllO was found in precise spherical structures suggestive of membranous origin.
I Under the electron microscope membranous whorls were seen, containing cytoplasmic 
material such as rough endoplasmic reticulum and it was suggested that they arose as a■
result of major invagination of the nuclear envelope. Direct evidence that these 
;i structures contain VmwllO or ND10 antigens was not obtained but confocal 
microscopy of sections through the nucleus showed that ND10 antigens were present at 
the nuclear membrane.
Experiments with the C-terminal deletion mutant viruses D13 (A633-680) and 
D14 (A680-720) showed that, at early times in infection, the mutant Vmwl 10 proteins 
were diffusely spread through the nucleus, supporting the results of transfection assays 
(Everett, 1988a; Chen et a l, 1991). The D13 and D14 deletions cause only moderate 
reductions in Vmwl 10 function in transfection assays except in synergistic activation 
with Vmwl75 (Section 1D5), and deletion mutant virus D14 is able to reactivate latent 
virus in an in vitro latency system (Harris et al., 1989). The apparent non-essential 
nature of the C-terminal region in transfection assays may be explained by the eventual 
loss of ND10 in cells infected with the D13 and D14 viruses. It is evident that the 
RING finger domain of Vmwl 10 is necessary for ND10 disruption but that residues at
the C-terminal end are required for the initial interaction of Vmwl 10 with ND10.■
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1  (ii) Transfected cells
Expression of Vmwl 10 in transfected cells resulted in weaker PML staining with 5E10 
antibody and in some instances PML staining disappeared altogether (Everett and Maul, 
1994). This indicated that PML was redistributed or that a conformational change 
occurred which resulted in occlusion of the 5E10 epitope. It was evident also from 
these assays that C-terminal residues of Vmwl 10 are necessary for the localisation of 
VmwllO to ND10 and that the RING finger is needed for their disruption. 
Interestingly, confocal lasar scanning microscopy showed that Vmwl 10 missing the C- 
terminal 180 residues was strongly associated with the nuclear membrane. Experiments 
were also carried out to investigate the nature of the C-terminal domain of Vmwl 10 by 
generating fusion proteins with (3-galactosidase. Transfection with a plasmid construct 
expressing the C-terminal 300 residues of Vmwl 10 fused to P-galactosidase showed 
that this protein was distributed in a micropunctate pattern within the cell, but it was 
difficult to see whether or not colocalisation with PML occurred, as indicated by the use 
of monoclonal antibody 5E10. A related fusion protein with the C-terminal 228 
residues of Vmwl 10 was diffusely distributed throughout the cell and, in a significant 
number of cells expressing this fusion protein, PML was also found in the cytoplasm. 
This indicates that by itself, the C-terminal end of Vmwl 10 can have a dramatic effect 
on PML and ND10 structures. PML was also seen in the cytoplasm of cells transfected 
with a plasmid expressing a mutant VmwllO protein lacking the nuclear localisation 
signal (A424-549). The significance of these observations is unknown but Vmwl 10 and 
PML may both be involved in nuclear and cytoplasmic functions, given that Vmwl 10 is 
found in the cytoplasm as infection proceeds.
The results of Hayward's group are, to an extent, contrary to those of Everett and 
Maul (Everett and Maul, 1994; Maul and Everett, 1994; Mullen et al., 1995). In 
agreement with other groups, they found Vmwl 10 proteins truncated at residues 519 
and 712 gave predominantly diffuse nuclear staining in immunofluorescence 
experiments but truncations at residues 312 and 364 gave mixed cytoplasmic and 
nuclear staining which was more punctate in character. They found that shorter N- 
terminal versions of Vmwl 10 were unstable and so, to further define the N-terminal 
sequences of Vmwl 10 responsible for the punctate property, fusions with Vm wl75 
were made. In their immunofluorescence assays, Hayward's group found that the 
diffuse staining pattern of Vmwl75 was altered to a punctate nuclear staining in cells 
transfected with a construct expressing VmwllO residues 1-244 fused to Vmwl75 
residues 84-1298. They suggested that the punctate staining of Vmwl 10 is a property 
of the N-terminal domain but that C-terminal residues contribute. However, Everett and 
Maul (1994) have expressed Vmwl 10 residues 1-262 stably in transfection assays and 
immunofluorescence experiments have shown that this protein is diffusely spread 
throughout the cytoplasm. It is likely, therefore, that fusion of Vmwl 10 and Vmwl75
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sequences gives rise to proteins which exhibit characteristics that are not representative 
of the individual proteins.
1D10 Do VmwllO and Vmwl75 interact physically?
The question as to whether or not Vmwl 10 and Vmwl75 interact physically is pertinent 
given that these proteins activate gene expression synergistically. The experimental 
approaches taken to investigate their potential interaction have included 
immunofluorescence assays as well as more direct molecular biological approaches. 
The results of immunofluorescence assays have often differed between different groups 
and have, in some cases, yielded contradictory results. This is reminiscent of the 
transient transfection assay systems (Section 1D5) and may only be a reflection of the 
various experimental conditions used, indicating that the results from any one group 
should be interpreted with care.
Gelman and Silverstein (1986) showed that Vmwl 10 was located in the nucleus in 
punctate domains in transfected cells and that Vmwl75 was diffusely spread throughout 
the nucleus. Transfection with constructs expressing VmwllO and a ts Vmwl75 
protein at the permissive temperature showed that both Vmwl 10 and f.sVmwl75 were 
located throughout the nucleoplasm. At the non-permissive temperature both proteins 
were located in nuclear granules. The conclusion drawn from this was that Vmwl75 is 
necessary for the diffuse distribution of Vmwl 10 within the nucleus, but that it has no 
effect on the nuclear localisation of Vmwl 10. In contrast, Knipe and Smith (1986) 
observed that in cells infected with a different Vmw 175 ts mutant at the non-permissive 
temperature, Vmwl 10 and Vmw 175 were located in the cytoplasm. As Vmwl 10 can 
localise to the nucleus in the absence of Vmw 175 (Gelman and Silverstein, 1986), it 
was concluded that Vmw 175 had a negative effect on the nuclear localisation of 
Vmwl 10. Knipe and Smith (1986) also observed that in the presence of teVmwl75, the 
uclear localisation of ICP8 was affected. It was concluded from this either that 
rmwl75 interacts with VmwllO and also with ICP8 (for which there is very little 
evidence) or that Vmw 175 interacts with a transport protein that is involved in the 
nuclear localisation of both Vmwl 10 and ICP8 . The evidence for a direct interaction 
between Vmwl 10 and Vmw 175 in these experiments is weak; even though double label 
immunofluorescence experiments were not carried out, it can be seen that when 
Vmwl 10 and Vmw 175 are present in the cytoplasm, Vmwl 10 is present in perinuclear 
granules whereas Vmw 175 is in diffusely spread punctate granules.
In direct contrast to the observations of Knipe and Smith (1986), Hayward's group 
have shown in transfection assays that VmwllO can relocate a cytoplasmic form of 
Vmwl75 to punctate granules in the nucleus (whether or not these were N D 10 was not 
investigated) (Mullen et al., 1995). Additionally, a mutant Vmwl 10 protein located in 
punctate domains in the cytoplasm was shown to locate Vmw 175 to the same domains,
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although some remained diffusely distributed in the nucleus. From these experiments it 
was concluded that VmwllO is the dominant protein affecting the localisation of 
Vmw 175. Interestingly, it was also noted that Vmwl 10 and Vmw 175 colocalised to 
punctate domains in the nucleus of Vero cells and not in 293 cells. Thus, the results of 
these experiments may be cell type dependent. However, Knipe and Smith's 
experiments were also carried out in Vero cells so the different results cannot be 
explained by differences in the cell types used in this case. It is, however, possible that 
these proteins behave differently depending on whether or not they are in the viral 
context. In addition, results obtained from transfection assays can be unrealistic in that 
the amounts of viral protein present in cells can be far higher than in infected cells.
Schaffer's group has also examined the localisation of Vmwl 10 in the cell, with 
particular reference to the effects of Vmw 175 and Vmw63 on its distribution. In 
contrast to the results of Hayward's group, which inferred that Vmwl 10 was the more 
dominant of the two proteins in affecting the cellular localisation patterns, Schaffer's 
group suggested that Vmw 175 was the more dominant of the two (Zhu et al., 1994). 
They attributed the presence of Vmwl 10 in the cytoplasm by 5hr post infection with a 
Vmw 175 null mutant as a result of the absence of the nuclear localising activity of 
Vmw 175. However, the presence of Vmwl 10 in the cytoplasm of infected cells by 
! approximately 5hr post infection is observed in infections with wild type virus (the 
exact time-course is cell type dependent) (Everett and Maul, 1994). Vmw63 appeared 
j to have a negative effect on the nuclear localisation of Vmwl 10 as the latter was found 
| localised more strongly to the nucleus in infection with a Vmw63 mutant virus than in 
wild type infection. These effects could be indirect and do not necessarily mean that 
Vmwl 10 is interacting with Vmw 175 or Vmw63. To an extent, these results were also 
seen in transfection assays, particularly when large amounts of DNA (5-10|ig per 60mm 
cell culture dish) were used in the assays. Based partly on these results, and also on the 
observations of the ability of Vmwl 10 to transactivate gene expression in transient 
transfection assays, it was concluded that VmwllO and Vmwl75 may interact 
physically.
Schaffer's group have attempted a more rigorous investigation of the potential 
physical interaction between VmwllO and Vmw 175 using molecular biological 
techniques (Yao and Schaffer, 1994). In Far Western blotting experiments carried out 
on infected cell extracts using [35S]methionine-labelled in vitro translated Vmwl 10 or 
[35S]methionine-labelled in vitro translated Vmw 175 as probes, they showed that 
VmwllO interacted with Vmwl75 and with itself. VmwllO residues 1-244, 1-394, 
395-616 and 395-775 were expressed as GST fusion proteins and it was found that 
residues 395-775 interacted with [35S]methionine-labelled in vitro translated Vmw 175. 
All of the GST-VmwllO fusion proteins bound [35S]methionine-labelled in vitro 
translated Vmwl 10. This latter observation throws doubt regarding the specificity of
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binding in the experiments with the GST fusion proteins. That Vmwl 10 exists as a 
dimer or higher order multimer has been established (Everett, 1991b; Chen et al., 1992), 
but it is unlikely that all of the Vmwl 10 domains expressed as fusion proteins in these 
experiments would contain dimerisation interfaces. Additionally, in order to avoid the 
danger of non-specific protein:protein interactions arising, it would have been of greater 
value to have carried out the assay in the presence of other proteins. In this context, it 
has not yet been shown that Vmwl75 is immuneprecipitated with VmwllO and vice 
versa. Whilst this does not necessarily mean that these proteins do not interact, as the 
evidence from immunofluorescence studies is also not conclusive, caution should be 
taken in ascribing that these two proteins bind specifically to each other. It is equally 
possible that the synergistic transactivation properties of Vmwl 10 and Vmw 175 arise as 
a result of VmwllO displacing a cellular protein from ND10 which interacts with 
Vmw 175 in such a way as to enhance its transactivating potential.
1D11 Mapping the VmwllO multimerisation domain
Various groups have attempted to map a domain within Vmwl 10 through which self 
interactions occur to form dimers or higher order multimers. The multimeric nature of 
Vmwl 10 was shown initially by the sedimentation rate of purified Vmwl 10 on glycerol 
gradients compared to that of known standards (Everett et al., 1991b). VmwllO 
isolated from mammalian cells infected with an adenovirus recombinant was also 
shown to exist as a multimer in solution based on its elution profile from a Sephacryl- 
S400 column (Chen et al., 1992b). This group also found that some mutant forms of 
Vmwl 10 could negatively dominate the transactivating ability of Vmwl 10 in transient 
transfection assays. They proposed that this was likely to be due to the formation of 
hetero-multimers containing both mutant and wild type VmwllO, with the mutant 
protein inhibiting the normal activity of the wild type protein. On this basis they
9 mapped a multimerisation domain to the N-terminal end of Vmwl 10.' However, such 
'indirect assays cannot be taken as strong evidence for a multimerisation domain within 
this part of Vmwl 10.
The existence of dominant negative mutant Vmwl 10 proteins was also observed 
by Weber and Wigdahl (1992). Rather than suggesting that this was a result of 
VmwllO multimerisation, they proposed that VmwllO may mediate its promiscuous 
transactivation property by interacting with some very general component of the host 
cell transcription machinery, so competing with the mutant protein. It is also possible 
that the mutant VmwllO protein occludes the VmwllO binding sites in the cell. 
Interestingly, it has been shown that a dominant negative mutant Vmwl 10 protein is 
expressed in infected cells when the second intron, which contains an in frame stop 
codon, is not excised (Everett et al., 1993a). The 262 residue product contains residues 
1-241 of Vmwl 10 plus additional intron coded residues. It is possible that expression
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of this product is dependent upon cellular factors and that production of large amounts 
of the 262 residue protein could lead to a generalised suppression of viral gene 
expression and aid the establishment of latent infection.
Hayward's group have identified a multimerisation domain in the C-terminal end 
of VmwllO (Ciufo et al., 1994). They constructed a plasmid which expressed a 
Vmwl75 epitope tagged C-terminal domain of VmwllO (Vmwl75 residues 1- 
383/Vmwl 10 residues 313-775) and found that the hybrid protein was located diffusely 
in the nucleus, but in the presence of wild type VmwllO it localised to punctate 
granules. That Vmwl 10 contains a multimerisation domain cannot be concluded on the 
strength of this experiment alone as hybrid proteins may have properties which do not 
reflect those of the individual proteins (Section 1D9). However, Hayward's group have 
shown the formation of stable mixed-subunit oligomers by coimmune precipitation of 
different sized, in vitro translated VmwllO polypeptides which were haemagglutinin 
epitope tagged. It was found that the oligomers formed only when the subunits were 
cotranslated and not when they were simply mixed together, which indicates the 
involvement of a high affinity subunit interaction mechanism with a low dissociation 
rate. The presence of oligomers of higher order than dimers was ascertained in 
glutaraldehyde cross-linking experiments. Using the coimmune precipitation assay, the 
N-terminal boundary of the multimerisation domain was mapped to between residues 
555-617 and theC -terminal boundary to between residues 712-767. Experiments in this 
Thesis have also mapped a multimerisation domain to the C-terminal end of Vmwl 10 
(Section IB). Although the evidence for the presence of a multimerisation domain in 
the C-terminal end of Vmwl 10 is stronger than that for a domain in the N-terminal end, 
the presence of a N-terminal multimerisation domain cannot be excluded. It is possible 
that there is more than one multimerisation interface on the surface of the intact and 
correctly folded protein.
1D12 Aims of the work presented in this Thesis
The main aim of the work presented in this Thesis was to identify and characterise 
■cellular proteins which interact with the HSV-1 IE protein Vmwl 10. At the start of the 
project there was evidence that VmwllO is implicated in latency (Section 1D7), a 
process which almost certainly involves some kind of virusicell interaction, and 
immunofluorescence experiments had shown that some C-terminal mutant VmwllO 
proteins were unable to interact with ND10 in the nucleus. These observations 
indicated that Vmwl 10 may interact with one or more cellular proteins. It was therefore 
| an appropriate time in the history of VmwllO investigations to attempt to uncover its 
mode of action in the viral life cycle by looking at cellular proteins with which it 
interacts.
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Initial experimental work involved the expression of C-terminal residues of 
VmwllO as GST fusion proteins from GEX plasmids, and their use in 'pull-down' 
assays with whole cell extracts, which would minimise the observance of non-specific 
interactions. It was proposed that any cellular protein which strongly and specifically 
interacted with Vmwl 10 residues would be purified, subjected to amino acid analysis 
and the encoding cDNA cloned by a PCR method.
An additional aim of the project was to show biochemically the multimeric nature 
of the C-terminal domain of Vmwl 10. The relevant Vmwl 10 sequences were removed 
from the GEX plasmids, expressed in a T7 system and purified by ion exchange 
chromatography. These investigations served as a means of partially separating 
sequences involved in interacting with a cellular protein of 135kD from those involved 
in multimerisation.
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2A Materials
2A1 Plasmids
The following plasmids were provided by the acknowledged authors: 
p ill:  (Everett, 1987a) This encodes the entire VmwllO protein and was derived from 
plasmid pJR3 through an intermediate pi 10del7 (Perry eta l., 1986). 
pllOA8: (Everett, 1987a) This encodes the entire Vmwl 10 protein with an 8bp HindHI 
linker inserted at the Aval site at position 4699 (residue 647).
pllOE2: (Everett, 1987a) This encodes the entire Vmwl 10 protein with a 12bp EcoRI 
linker inserted at the Haem site at position 4930 (residue 723).
pllOE35: (Everett, 1987a) As pllOE2 but with the linker inserted at position 4849 
(residue 696).
pllORS: (Everett, 1987a) As pllOE2 but with the linker inserted at the Rsal site at 
position 4801 (residue 680).
pllOE52: (Everett, 1987a) As pi 10E2 but with the linker inserted at the Haelll site at 
position 4543 (residue 594).
pllOE58: (Everett, 1987a) As pi 10E2 but with the linker inserted at the Haelll site at 
position 4660 (residue 633).
pllOD12: (Everett, 1988a) This encodes the VmwllO protein with residues 594-633 
deleted.
pll0D14: (Everett, 1988a) This encodes the VmwllO protein with residues 680-720 
deleted.
pllOFXE: (Everett, 1988a) This encodes the Vmwl 10 protein with residues 106-150, 
spanning the zinc binding domain, deleted.
pllOE52X: (R. Everett, unpublished) This encodes a VmwllO protein truncated at 
residue 594.
The pGEX series of plasmids were designed for inducible expression in bacteria of 
fusion proteins containing a polypeptide of interest linked to glutathione-S-transferase. 
pGEX2TN3: (M.Hughes; Meredith et al., 1994) This was derived from the commercial 
vector pGEX2T (Pharmacia) by inserting a DNA fragment containing NcoI-EcoRI- 
HindHI sites between the BamHI and EcoRI sites downstream of the GST coding 
sequence, thus removing the original BamHI, Smal and EcoRI sites (Figure 2Al(i)).
The pi 10 series of plasmids were derived from p i l l .  They contain the IE 1 gene region 
including the IE1 promoter, intron and 3' processing signals in a pUC9 background 
[Perry etal., 1986; Everett, 1987a; 1988a).
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Figure 2Al(i)
Ncol
EcoRI
Hindm
GST
laciq PGEX2TN3 
4968 bp
on
PstI 1916
pGEX2T
P R G S P G I H R D  STOP 
CCGCGTGGATCCCCGGGAATTCATCGTGACTGACTG 
I________ I I________ I
BamHI — * EcoRI
Linkers
5 ’ 3’
GATCGACCATGGCTAGAATTCGGAAGCTT
CTGGTACCGATCTTAAGCCTTCGAATTAA 
I I I________ I----- I------------ 1
Ncol EcoRI HindHI
pGEX2TN3
P R G S T M A R I R K L N S S  STOP 
CCGCGTGGATCGACCATGGCTAGAATTCGGAAGCTTAATTCATCGTGACTGA 
I________ I I________ I I------------ 1
Ncol EcoRI Hindm
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Figure 2Al(ii)
GST
tac ,(SmaI)/(EcoRI) 879GST
E58lacM Sail 1286pGEXE58
5813 bp
(HpaI)/(SmaI) 1734
on EcoRI 1744
GST-E58 junction
633 E58
G S P I R A V G A  
GGATCCCCAATTCGGGCCGTCGGTGCC 
I I
BamHI (SmaI)/(EcoRI)
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Figure 2Al(iii)
GST
Ncol 878tac EcoRI 885
GST
lacI9 pGEXE52
Sail 1403
5950 bp
(HpaI)/(SmaI) 1851
(on
EcoRI 1861
PstI 2898
GST-E52 junction
594 E52
G S T M A R I R A V G A L  
GGATCGACCATGGCTAGAATTCGGGCCGTCGGTGCCCTG 
I________ I___ I________ I
Ncol EcoRI
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Hindm
SphI
PstI
Sail
Xbal
BamHI
Smal
Kpnl
SacI
EcoRI
N col2593
SphI/(PvuII) 2299
BamHI
2682
EcoRV
2814
T7 termination
T7 promoter
/  p585T7a
3200 bp Ampr |
Pvul 628 
PstI 754
p585T7a
5, M A E F  3, 
CCATGGCTGAATTC 
|GGTACC|GA)CTTAAG|
Ncol EcoRI
p585T7b2
M A R N 
5’ CCATGGCTAGAATTCG 
p G T A C C ^A'Ij’C T T A A qC
Ncol EcoRI
Figure 2A1 Structure of plasmids pGEX2TN3, pGEXE58, pGEXE52, p585T7a and 
p585T7b2. In all cases, restriction sites relevant to the construction or further use of 
the plasmids are shown; (i) Plasmid pGEX2TN3 was constructed from the commercial 
vector pGEX2T (Pharmacia) by digestion with BamHI and EcoRI and insertion of the 
linker sequences shown, (ii) Plasmid pGEXE58 was constructed as described in the 
text, such that translational initiation occurs at the GST ATG downstream of the Ptac 
promoter, and the termination signal is encoded by Vmw110 sequences. The 
sequence at the GST-E58 junction is shown. The Sall-Hpal segment is composed of 
IE1 sequences including the Vmw110 termination codon and 3’ flanking sequences,
(iii) Plasmid pGEXE52 was constructed as described in the text. The GST-E52
67
Chapter 2 Materials and Methods
junction sequence is shown, (iv) This shows the structure of the cloning vector 
p585T7a and the sequence difference which introduces a frameshift in the MCR of 
P585T7b2.
pGEXE58; (M.Hughes; Meredith et al., 1994) This encodes GST sequences fused to 
residues 633-775 of Vmwl 10 (Figure 2Al(ii)). The termination signal is encoded by 
VmwllO sequence. The plasmid was made in a number of stages: the Sall-Hpal 
fragment of pT7FXE (R. Everett, unpublished data), encoding Vmwl 10 residues 768- 
775 and the Vmwl 10 stop codon and poly A signal, was inserted between the Sail and 
Smal sites of the commercial vector pUC19 to give pUCl 10. A Sall-EcoRI fragment 
was isolated from pUCllO (3' end restriction sites (HpaI)/(SmaI)-KpnI-SacI-EcoRI) 
and ligated with the Smal-EcoRI fragment of pGEX2T and the EcoRI(end-filled)-SalI 
fragment of p i 10E58 to give pGEXE58.
pGEXE52: (M.Hughes; Meredith et al., 1994) This plasmid encodes GST sequences 
fused to residues 594-775 of VmwllO (Figure 2Al(iii)). As with pGEXE58, the 
termination signal is encoded by Vmwl 10 sequence. The plasmid was made in a three 
fragment ligation with the EcoRI-PstI fragment of pGEX2TN3, the Pstl-Sall fragment 
of pGEXE58 and the EcoRI-Sall fragment of pi 10E52.
p585T7a: (Tyler, 1994) (Figure 2Al(iv)) This is a cloning vector used for expression of 
peptide sequences from a T7 promoter. It was originally derived from pET8c (Studier 
et al., 1990) via p585.4. The pBR322 Sphl-PvuII vector sequences were removed from 
p585.4 and the pUC19 EcoRI-Hindlll MCR was inserted, with the aid of adaptors, 
between the Ncol and HindHI sites downstream of the 010 promoter. 
p585T7b2: (Tyler, 1994) (Figure 2Al(iv)) This was made in the same way as p585T7a 
except that different adaptor sequences were used to alter the reading frame of the 
MCR.
2A2 Enzymes
Restriction enzymes were obtained from Boehringer Mannheim or New England 
Biolabs. DNasel, RNase A and lysozyme were purchased from Sigma and T4 
polynucleotide kinase, T4 DNA ligase, calf intestinal phosphatase, E.coli DNA 
polymerase I Klenow fragment and proteinase K from Boehringer Mannheim. PCR 
was carried out using cloned Pyrococcus furiosus DNA polymerase obtained from 
Stratagene or Thermus aquaticus DNA polymerase obtained from Boehringer 
Mannheim. Reverse Transcriptase Moloney-Murine Leukaemia Virus was also 
obtained from Boehringer Mannheim.
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2A3 Synthetic oligonucleotides
Oligonucleotides were synthesised on site using a Biosearch model 8600 DNA 
synthesiser or a Cruachem PS250 automated synthesiser by Dr. J. McLauchlan, Mr. F. 
Van Deursen, Miss S. Fitzpatrick, Mr. J. McGeehan or Mr. R. Reid.
2A4 Bacteriophage X library
The bacteriophage X expression library screened in the studies described in this Thesis 
was obtained from Professor P. Chambon of the Institut de Chimie Biologique, 
Strasbourg. It was derived by random priming of HeLa cell polyA+ RNA and the 
products were cloned into the X ZAPII vector (Stratagene) using EcoRI oligonucleotide
linkers.
2A5 Bacteria (E.coli strains)
The E.coli strain D H 5a (F/endAl hsdR17 (rk"mk+) supE44 thil recAl gyrA (Nalr) 
relAl A(lacZYA-argF)U169 (<&80dlacA(lacZ)M 15) was used for maintenance and 
propagation of plasmid DNA. Strain BL21(DE3)pLysS (F“ ompT rg m 'e ) (Studier et 
al, 1990) was used for expression of proteins using pT7 vectors: the integrated 
lysogenic X bacteriophage DE3 has an IPTG inducible promoter from which T7 RNA 
polymerase is expressed and the plasmid pLysS encodes T7 lysozyme and also a gene 
conferring chloramphenicol resistance. Protein expression from pGEX plasmids 
utilised strain BL21. Strain TGI (supE hsdA5 thi A(lac-proAB) F'(traD36 proAB+ 
lacIQ lacZAM15) was used for blue-white screening of some cloned PCR products. The 
E.coli strain provided by the Invitrogen TA Cloning Kit was INVaF' (endAl recAl 
hsdR17(r^m+k) supE44 X~ thi-1 gyrA rel al d>801acZaAml5A(lacZYA-argF) deoR+ 
F'). The bacteriophage X library (Section 2A4) was plated out and amplified in the 
train XL-1 Blue MRF (A(mcrA)l83 A(mcrCB-hsdSMR-mrr) 173 endAl supE44 thi-1 
ecA gyr96 relAl lac X-): the F  episome encodes pili which allows infection by 
■filamentous bacteriophage and the /^FZA M 15 mutation which enables blue/white 
selection of recombinant colonies/plaques on LB agar plates supplemented with IPTG 
and X-gal. It also carries a tetracycline resistance gene.
M ' ,,V7 :,V X . .
2A6 Bacterial culture media
The DH5a strain was grown in L-broth (lOg NaCl, lOg Bactopeptone, 5g yeast extract 
in 11 water, pH 7.5) and all other strains in 2YT broth (5g NaCl, 16g Bactotryptone, lOg 
yeast extract in 11 water). Agar plates were made with 1.5% (w/v) agar in L-broth. Top 
agar contained lOg Bactotryptone, 8g NaCl and 8 g agar in 11 water. Where necessary, 
media and LB agar plates were supplemented with antibiotics: lOOjig/ml ampicillin for 
bacteria harbouring pUC and pBR322 derived plasmids (including pT7 and pGEX
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series), 25|J,g/ml chloramphenicol for strains harbouring the pLysS plasmid and 
15pg/ml tetracycline for the E.coli XL-1 Blue MRF strain.
2A7 Cells and tissue culture media
All cell culture media were obtained from Gibco.
BHK-21 C l3 cells, a fibroblastic line derived from baby hamster kidney cells 
(MacPherson and Stoker, 1962), were grown in Glasgow Modified Eagle's Medium 
(GMEM) supplemented with 10% newborn calf serum, 10% tryptose phosphate broth, 
100 units/ml penicillin and lOOjig/ml streptomycin.
WS HeLa cells (obtained from Dr. W. Schaffner, Zurich), an epithelial cell line, 
were grown in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 2.5% 
foetal calf serum, 2.5% newborn calf serum and antibiotics as above.
HFL cells (obtained from Flow Laboratories) are a fibroblastic line derived from human 
foetal lung tissue and were grown in DMEM supplemented with 10% foetal calf serum 
supplemented with antibiotics as above.
U-2 OS cells (obtained from American Type Culture Collection), a human 
osteogenic sarcoma line, were grown in McCoy's 5a medium supplemented with 15% 
foetal calf serum and antibiotics as above.
ND7 cells were obtained from Dr. S.M. Brown by permission of Professor D. 
Latchman (Department of Molecular Pathology, University College London): they are a 
neuronal line derived from fusion of neuroblastoma cells with primary rat sensory 
neurons (Wood et al, 1990). They were grown in Leibovitz medium supplemented with 
10% foetal calf serum, 0.35% glucose, 7.5% sodium bicarbonate and antibiotics as 
bove. The cells were differentiated by seeding in 50% DMEM, 50% Ham's nutrient 
ix F I2, 250ng/ml bovine insulin, 5p.g/ml human transferrin, 30nM sodium selenite 
and antibiotics as above for 3-4 days.
2A8 Antisera and monoclonal antibodies
The anti-VmwllO mouse monoclonal antibodies 11060, 10810 and 10503 were 
obtained from Dr. A. Cross. MAb 11060 recognises an epitope between amino acids 
^20-105, 10810 an epitope between residues 594-633, and 10503 and epitope between 
residues 633-775 (Everett etal, 1993a).
The monoclonal antibodies, MAb 1150 and MAb 5E10, recognising 55kD and 
126kD ND10 antigens respectively, were obtained from Professor G. Maul (Wistar 
Institute, Philadelphia).
Protein A horse radish peroxidase (HRP) conjugate, anti-mouse IgG whole 
molecule peroxidase conjugate, TRITC conjugated goat anti-rabbit and FITC 
conjugated goat anti-mouse immunoglobulin were supplied by Sigma.
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2A9 Radiochemicals
All radiochemicals were purchased from Amersham at the following specific activities: 
a 32P dATP 3,000Ci/mmol (10pCi/|il)
y32P ATP 5000Ci/mmol (1 OpCi/pl)
35S L-methionine ~800Ci/mmol (15|iCi/|il)
2A10 Solutions
10X agarose gel loading
10X CAPS:
Coomassie stain:
50X Denhardt's solution: 
20X dNTPs: 
Electroblotting Buffer: 
Extract Buffer:
ImM
Formamide dyes:
Gel soak I:
Gel soak II:
buffer: 1 X TBE, 1% SDS, 50% glycerol,
1 mg/ml bromophenol blue
lOOmM CAPS, pH to 11 with NaOH
0.2% Coomassie Brilliant Blue in methanol:water:acetic
acid in a 50:50:7 ratio
1% polyvinylpyrrolidone, 1% BSA, 1% ficol 
1 mM of each of dATP, dCTP, dGTP, dTTP 
IX CAPS, 10% methanol
50mM HEPES (pH 7.5), lOOmM NaCl, 0.4% CHAPS, 
PMSF, 0. ImM DTT
lOmM EDTA, 1 mg/ml xylene cyanol FF, 1 mg/ml
bromophenol blue in formamide
1.5M NaCl, 0.5M NaOH
1.5M NaCl, 0.5M Tris.Cl, ImM EDTA, pH 7.2
Glycine SDS PAGE buffers:
(i) 3X gel loading buffer: 29% SGB, 6% SDS, 2M 2-ME, 29% glycerol,
1 mg/ml bromophenol blue
(ii) RGB (resolving gel buffer): 1.5M Tris.HCl, 0.4% SDS, pH 8.9
(iii) SGB (stacking gel buffer): 0.5M Tris.HCl, 0.4% SDS, pH 6.7
(iv) Tank buffer: 0.05M Tris, 0.05M glycine, 0.1 % SDS
Guanidine Thiocyanate solution: 4M guanidine thiocyanate, 0.02M N-lauryl-sarcosinate
2X HBS:
10X hybridisation buffer: 
5X kinase buffer:
5X ligase buffer:
(sodium salt), 0.024M Na citrate, 0.7% 2-ME 
280mM NaCl, 50mM HEPES, 1.5mM Na2HP04, pH to 
7.12 with NaOH
1.5M KC1, 0.1M Tris.HCl (pH 8.3), lOmM EDTA 
350mM Tris.HCl (pH7.5), 50mM mgCl2, 25mM DTT 
250mM Tris.HCl (pH 7.6), 50mM MgCl2, 5mM DTT, 
5mM ATP, 25% PEG 8000
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0.5M NaCl wash buffer:
PBS (A):
PBS-complete:
Protein gel destain: 
Protein gel fix:
RNase reaction mix:
1 OX seq buffer:
20X SSC:
STET:
5 OX TAE:
TEN 100 buffer:
20X TBE:
TBS:
TE:
TE(P): 
owbin (blotting buffer):
0.5M NaCl, 50mM Tris.HCl (pH 8 ), ImM EDTA, 0.5% 
NP40, ImM PMSF, 0.5fig/ml leupeptin, 40|ig/ml 
bestatin
170mM NaCl, 3.4mM KC1, lOmM Na2HP04, 1.8mM 
KH2P04, pH 7.2
PBS(A) plus CaCl2.2H20  and MgCl2.6H20  at lg/1 
5% methanol, 7% acetic acid in water 
12.5% acetic acid, 3% ethanol in water 
100pg/ml salmon sperm DNA, 20|ig/ml RNase A in 
TEN 100 buffer
lOOmM Tris.HCl, lOOmM MgCl2,pH 8.5 
3M NaCl, 0.3M trisodium citrate 
8% sucrose, 5% triton X-100, 50mM EDTA (pH 8.0), 
50mM Tris.HCl (pH 8.0)
0.2M Tris, 0.05M EDTA (pH 8.0), pH to 8.0 with acetic 
acid
lOOmM Nacl in TE (pH 7.5)
2.5M Tris, 800mM boric acid, 54mM EDTA
0.02M Tris, 0.5M NaCl, pH 7.5 with HC1
lOmM Tris.HCl, ImM EDTA, pH 8.0
ImM Tris.HCl (pH 7.5), 0.05mM EDTA
25mM Tris.HCl, 192mM glycine, 20% methanol, pH 8.3
ricine SDS PAGE buffers: 
i) 3X gel loading buffer:
(ii) Gel buffer:
(iii) Lower tank buffer:
(iv) Upper tank buffer:
150mM Tris.HCl, 12% SDS, 36% glycerol, 
6 % BME, 1 mg/ml bromophenol blue, pH 6.8 
3.0M Tris.HCl, 0.3% SDS, pH 8.45 
200mM Tris.HCl, pH 8.9 
0.1M Tris, 0.1M Tricine, 0.1 % SDS
TTBS:
Versene:
TBS plus 0.05% TWEEN-20
0.6mM EDTA in PBS(A), 0.002% phenol red
2A11 Chemicals and reagents
All chemicals and reagents were purchased from BDH Chemicals UK or from Sigma 
Chemical Co. unless otherwise stated in this Section or in the Methods Section: 
Beecham Research: Ampicillin
Bio-Rad: TEMED, ammonium persulphate, Coomassie brilliant blue,
gelatin, tricine
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Boehringer Mannheim: protease inhibitors, RNase Inhibitor
Melford Labs Ltd.: 
Pharmacia:
Prolabo:
Dupont:
Fisons:
Fluka:
En3hance
Ammonium hydroxide
Formamide, formaldehyde, guanidine hydrochloride 
Caesium chloride 
7-deaza-dGTP, dNTPs, ddNTPs
Boric acid, butanol, chloroform, ethanol, glacial acetic acid, 
glycerol, hydrochloric acid, isopropanol, methanol
I
2B Methods
2B1. Nucleic acid manipulation and cloning procedures 
2B1.1 Large scale plasmid DNA preparation
E.coli harbouring the plasmid were streaked (from an older agar plate) or spread 
(newly transformed bacteria - Section 2B 1.6 ) on an agar plate containing appropriate 
antibiotics (see Section 2A6) and incubated overnight at 37°C. Colonies were 
inoculated into 300ml L-broth with antibiotics as appropriate (Section 2A6) and shaken 
for 16-18hr at 37°C.
Plasmid DNA was prepared by the ‘maxi-boiling’ technique as described by 
Holmes and Quigley (1981) and supercoiled plasmid DNA was purified on caesium 
chloride gradients. Bacterial cultures were centrifuged at 5krpm for 5min at 4°C 
(Sorvall GS3 rotor), the pellets were resuspended in 20ml STET and 2.5ml fresh 
lOmg/ml lysozyme solution in STET were added. The mixture was brought to the boil 
over a bunsen flame and placed in a boiling water bath for 50sec. Cell debris were 
pelleted by centrifugation at 18krpm for 45min at 4°C (Sorvall SS34 rotor). DNA was 
precipitated from the supernatant by the addition of 0.9 volumes of isopropanol and 
pelleted by centrifugation at 3krpm for 5min at RT (Beckman GPR centrifuge). The 
pellet was resuspended in 5ml TE (to give a volume Xml) and X+0.7g CsCl and 0.2ml 
lOmg/ml ethidium bromide added. The CsCl was dissolved over a 10-15min period on 
ice and the samples were centrifuged at 3krpm for lOmin at RT to pellet debris. The 
supernatant was transferred to a crimp-seal centrifuge tube (Dupont 03945) using a 
syringe and centrifuged at 40 krpm (Sorvall TV865 vertical rotor) for 16hr at 15°C. The 
plasmid DNA band was removed using a syringe, taking care to avoid contamination 
with the upper chromosomal DNA band. The EtBr was removed from the plasmid 
solution by 2-3 extractions with TE-saturated butan-l-ol and the plasmid solution was 
transferred to dialysis tubing. Dialysis against TE was carried out for 2-3hr to remove 
CsCl. Following this, the solution was treated with 100 |ig/ml RNase A at 65°C for lhr 
Ind then with 100|ig/ml proteinase K and 0.1%SDS at 37°C for lhr. The plasmid DNA
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was purified by extraction firstly with TE-saturated phenol and then chloroform and 
pelleted following an ethanol precipitation by centrifugation at 3krpm for 15min at RT. 
The pellet was resuspended in 400pl 0.3M NaAc and ethanol precipitated again. The 
final pellet was washed in 75% ethanol, resuspended in TE and stored at 4°C. The 
plasmid concentration was determined by measuring the absorbance at 260nm, 
assuming lA 260=5 0 jig/ml.
2B1.2 Miniprep plasmid DNA preparation
Plasmid DNA was prepared on a small scale as follows: single colonies of transformed 
bacteria were picked and inoculated into 3ml aliquots of L-broth and the cultures grown 
overnight at 37°C in a shaking incubator. Aliquots (1.5ml) of the cultures were 
centrifuged for 2 0 sec in a microfuge and the pelleted cells were resuspended in 2 0 0 fil 
STET. Lysozyme (5pl fresh lOmg/ml solution in STET) was added to each tube which 
was then vortexed and placed in a boiling water bath for 50sec. Cell debris were 
pelleted by centrifugation for lOmin and the supernatant was removed and made up to 
200 j l x 1 with STET. Plasmid DNA was precipitated by the addition of 180|il isopropanol 
(0.9 volumes) and pelleted by centrifugation for 5min. The pellets were washed with 
75% ethanol, lyophilised, resuspended in 20 j l l 1 water and stored at -20°C.
2B1.3 Restriction enzyme digestion of DNA
Restriction enzyme digestion of DNA was carried out at 37°C (or the temperature 
specified by the supplier) in 20|il volumes using 1 unit of enzyme per 0.5|ig DNA per 
hour in the buffer supplied with the enzyme. The buffer system used most often was 
the Boehringer Mannheim A, B, M, L, H system and less fequently the New England 
Biolabs NEBuffer 1, 2, 3, 4 system. Usually, 0.5pg DNA was digested for diagnostic 
analysis and 2-10|J.g for isolation of specific restriction fragments. Samples (5jil) of 
plasmid DNA prepared by the miniprep method (see Section 2.2) were digested in the 
presence of RNase A at 50pg/ml.
2B1.4 Electrophoretic separation and purification of DNA fragments
I ' (i) non-denaturing agarose gels 
DNA fragments produced by restriction enzyme digestion or PCR were resolved by 
non-denaturing agarose gel electrophoresis. Horizontal slab gels approximately 0.5cm 
thick were utilised and samples were loaded following addition of the relevant amount 
>f agarose gel loading buffer. For separation of fragments over 150bp, 0.5-1.5% 
igarose gels made up in 1XTBE or 1XTAE (for resolution of DNA for use in PCR) 
'ere used and run at 12V/cm in the appropriate buffer. For separation of small PCR 
>roducts, 2-4% NuSieve GTG Agarose gels (FMC Bioproducts) made up in 1XTAE 
'ere used and run at 12V/cm in 1XTAE. Appropriate size standard markers were
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always run on the gels: Hpall digested pBR322 gave fragments in the range 27-622bp, 
while X DNA digested with HindHI gave fragments of 0.55-23.lkb. Following 
electrophoresis, DNA was visualised under short-wave UV light (long-wave for 
preparative gels) after staining the gel in a l|ig/ml EtBr solution followed by a thorough 
rinse in water. Photography was carried out using The Imager (Appligene) or a 
polaroid camera.
(ii) DNA purification from agarose gels
Agarose blocks containing appropriate DNA fragments were excised from gels under 
long-wave UV transillumination and the DNA recovered using a commercial kit, 
GENECLEANII (BIO 101 Inc., La Jolla, CA). The kit contains a silica matrix which 
binds DNA in the presence of high concentrations of sodium iodide (Vogelstein and 
Gillespie, 1979). IX TBE agarose blocks were mixed with 4.5 volumes Nal solution 
and 0.5 volumes TBE modifier and incubated at 55°C until the gel slice had dissolved. 
The silica matrix was then added (5pJ for up to 5jLLg DNA) and the mixture vortexed and 
left at RT for 5-10min. Following a 5-10sec centrifugation, the silica matrix pellet was 
washed 3 times in 200fil ‘NEW’ wash and the DNA eluted into 20|ll1 water by mixing 
the washed pellet with water and incubating at 55°C for 5min. The matrix was again 
pelleted and the 20fil supernatant containing the DNA removed and stored at -20°C. 
The GENECLEANII kit was also used in situations where electrophoresis was not 
required, particularly for separating DNA from nucleotides and PCR primers. In these 
cases, 3 volumes Nal were used and the TBE modifier omitted.
PCR products were run on TAE gels and excised bands mixed with 200-500jil 
water and placed in a boiling waterbath for 5min to melt the agarose: the DNA was then 
available for use in further PCR experiments.
(iii) Denaturing polyacrylamide gels
Vertical denaturing polyacrylamide (acrylamide:bisacrylamide 19:1) gels, containing 
8M urea and IX TBE, were used to resolve the products of DNA sequencing reactions 
and to purify synthetic oligonucleotides. Polymerisation was instigated by adding 
0.00lvol TEMED and O.Olvol 10% APS. DNA sequencing gels (0.35mm thick and 
35cm long) contained 8 % acrylamide. The samples were boiled with formamide dyes 
rior to loading, and electrophoresis was in 1XTBE running buffer at 40W for 2-5hr. 
12 % acrylamide gels (1.5mm thick X 25cm long) were used for purifying 
ligonucleotides: the samples, again boiled with formamide dyes, were electrophoresed 
1250V for 4-5hr in IX TBE running buffer.
2B1.5 End repair and DNA ligation
It was often necessary to modify the ends of DNA fragments to enable efficient ligation. 
This was carried out as detailed below and, after each step, enzymes were heat 
inactivated by incubation of the reaction mixes in a 70°C water bath for lOmin. DNA
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was purified by extraction with TE-saturated phenol, followed by extraction with 
chloroform and an ethanol precipitation. The DNA pellets were washed in 75% ethanol 
and resuspended in water before use in ligation reactions or storage at -20°C.
(i) Filling-in of 5' overhangs
Restriction fragments generated by enzymes which produce 5' extensions were made 
blunt-ended as follows. DNA in IX M buffer containing 50jiM of all four dNTPs was 
incubated with 2 units of Klenow fragment for 20-30min at 37°C. The reaction could 
be performed either immediately following digestion with the appropriate restriction 
enzymes or following purification of the fragment by agarose gel electrophoresis. If a 
single blunt end was required, end filling was carried out after digestion with the first 
enzyme and prior to digestion with the second.
(ii) Removal of 3' overhangs
The removal of 3' extensions produced after restriction enzyme digestion was carried 
out by the addition of 8 units of T4 DNA polymerase followed by incubation for 20-30 
min at 37°C.
(iii) Phosphate removal from 5' ends
Removal of the 5' phosphates of vector fragments with complementary ends produced 
by digestion with a single restriction enzyme was done by incubation with 1 unit of calf 
intestinal alkaline phosphatase in the appropriate buffer for 30min at 37°C. The 
j reaction was carried out after heat inactivation of the restriction enzymes or following 
purification of digested DNA by phenol and chloroform extractions and ethanol 
precipitation.
(iv) Phosphate addition to 5 ' ends
J It was necessary to add phosphate to the 5’ ends of PCR products produced by Pfu 
polymerase to facilitate blunt-end ligation reactions with a plasmid vector. The 
reactions were carried out in 20|il of IX kinase buffer containing ImM ATP with 
lOunits T4 polynucleotide kinase for 30min at 37°C.
9 (v) Ligation reactions 
‘Gene-cleaned’ vector and insert fragments prepared by restriction enzyme digestion 
I  (Section 2B 1.3 and 2 B 1.4 (ii)) with ends suitably repaired were ligated in a 1:5-10 ratio 
ij in 20jlx1 reaction volumes of IX ligase buffer with 2units T4 DNA ligase overnight at 
RT. The efficiency of blunt-ended ligations was increased by incubating overnight at 
■ 13-15°C. The DNA was purified by a phenol and chloroform extraction and subsequent 
ethanol precipitation prior to transformation into competent E.coli (Section 2B1.6). 
PCR products produced with Taq polymerase were cloned into a commercial vector, 
?CR™H, provided in the Invitrogen TA Cloning Kit (version 2.2): Taq polymerase 
eaves 3' A overhangs which are complemented by 5' T overhangs in the pCR™II 
sector. The ligation reactions were carried out overnight at 14°C in lOjil volumes using 
:resh PCR products and the ligase buffer and enzyme provided in the kit. ljil samples
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of the ligation reactions were transformed into competent E.coli provided in the kit 
(strain INV ocF).
2B1.6 Preparation and transformation of competent E.coli cells for plasmid 
growth and maintenance
Plasmids were grown and maintained in the E.coli strain D H5a. A 1ml overnight 
culture grown up in L-broth from a single colony was inoculated into 100ml L-broth 
and grown for about 3hr at 37°C in a shaking incubator until the OD450 was 
approximately 0.3. The culture was then cooled on ice and the cells pelleted by 
centrifugation at 5 krpm for lOmin at 4°C. The cells were resuspended in 25ml cold 
0.1M MgCl2, repelleted by centrifugation at 5krpm for lOmin at 4°C and resuspended in 
5ml cold 0.1M CaCl2. After a 45min incubation on ice the cells were pelleted as 
previously and resuspended in 5ml cold 0.1M MOPS, 50mM CaCl2 and 20% glycerol 
and incubated on ice for 20min. lOOfil and 500|il aliquots were flash frozen and stored 
at -70°C.
About lOng plasmid DNA (or a quarter of a ligation reaction) were transformed 
into a lOOpl aliquot of competent DH5a bacteria which were thawed on ice. The DNA 
was added to the cells and the mixture incubated on ice for 20-30min prior to heat 
shock in a 42°C water bath for 45-50 sec followed by a 2min incubation on ice. 0.5ml 
2YT broth or 0.5ml SOC broth supplemented with 20mM MgC^, 20mM MgS04 and 
20mM glucose was added to the cells which were shaken for 30-60min at 37°C before 
plating onto LB agar plates containing the appropriate antibiotics. The plates were 
incubated overnight at 37°C.
2B1.7 Preparation and transformation of competent E.coli cells for protein 
expression
Plasmids incorporating the GST (pGEX series) or T7 (pT7 series) expression systems 
‘ were transfected into the appropriate E.coli host immediately before use. For pGEX 
plasmids strain BL21 was used, while pT7 plasmids were transfected into 
BL21(DE3)pLysS. Bacteria were streaked onto LB or LB/chloramphenicol agar as 
appropriate, and 3-5 fresh colonies were inoculated into 10ml 2YT and grown in a 
.^shaking incubator at 37°C for 2 -3hr until the OD450 reached about 0.3. The cells were 
pelleted by centrifugation at 3krpm for 5min at 4°C, resuspended in 0.5ml cold 0.1M 
MgCl2 and repelleted by centrifugation under the same conditions for 2min. The pellet 
was resuspended in 0 .5 ml cold 0 .1M CaCl2 and incubated on ice for at least 30min prior 
to use. About lOng of the relevant plasmid was transformed into a lOOjil aliquot of the 
competent cells as described in Section 2B1.6 .
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2B1.8 Purification of synthetic oligonucleotides
Synthetic oligonucleotides were produced by the phosphoramidite method (Section 
2A3) using 200|il synthesis columns. To remove the oligonucleotide from the column, 
5ml disposable syringes were attached to both ends of the column with one containing 
1.5ml ammonium hydroxide (0.88 specific gravity). The solution was pushed through 
the column in 200pJ aliquots with a 20min incubation between each fresh addition. 
After incubation with the final aliquot, the 1.5ml solution was pushed backwards and 
forwards through the column 4-5 times to mix the aliquots thoroughly. The 
oligonucleotide solution was incubated in a tightly sealed tube for 5hr at 55°C to 
remove protecting groups. Following lyophilisation, the oligonucleotide was dissolved 
in 200pl water and boiled in an equal volume of formamide plus 10-15|il formamide 
dyes prior to electrophoresis on a 12% denaturing polyacrylamide gel (Section 
2B1.4(iii)). Oligonucleotides were purified by passive elution from gel slices excised 
from the gel following visualisation of the DNA by UV transillumination: bands were 
visible as dark shadows against a fluorescing TLC plate. Gel slices were crushed and 
the DNA eluted overnight at 37°C in a shaking incubator. The liquid phase, containing 
the DNA, was separated from the gel fragments by filtering the mixture through 
siliconised glass wool. The DNA was purified by an ethanol precipitation and pelleted 
by centrifugation for lOmin (microfuge). The pellet was resuspended in lOOfil water, 
ethanol precipitated again and the final DNA pellet was washed in 75% ethanol, 
lyophilised and resuspended in water. The DNA concentration was determined by 
measuring the absorbance at 260nm, assuming that for short oligonucleotides (<30 
nucleotides) lA260=2 0 jig/ml.
2B1.9 Amplification of ^ZAPII library DNA
A sample of DNA from a ^ZAPII cDNA library (Section 2A4) was prepared for use as 
a template in PCR experiments by amplification from the stock (titre 1.9X109pfu/ml: 
see Section 2B5.1). Approximately 8.5X107pfu of the ^ZAPII library stock was mixed 
with 0.3ml of an overnight culture of E.coli cells (strain XL-1 Blue, Section 2A5) and 
the mixture shaken for 20min at 37°C to allow the bacteriophage to adsorb to the 
bacteria. Following addition of 12ml of 2YT broth, incubation was continued for a 
further 4hr until bacterial lysis occurred, then chloroform was added to a concentration 
of 1% and incubation continued for another 15min to ensure complete lysis. Cell debris 
were pelleted by centrifugation at 4krpm for lOmin at RT. Bacteriophage were pelleted 
from the supernatant by centrifugation at 40krpm for lhr at 4°C (in Sorvall Oak Ridge 
Polycarbonate tubes, Sorvall T1270 rotor) and resuspended in 400jil TE. The DNA was 
then purified by 2 phenol extractions (mixing for 15min) and a chloroform extraction 
(mixing for 5min) followed by an ethanol precipitation. The DNA was pelleted by 
centrifugation for lOmin at RT (microfuge), washed in 75% ethanol, lyophilised and
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dissolved in 100p.l water. The quality of the DNA was determined by digestion of a 2pl 
sample with EcoRI (Section 2B1.3) followed by electrophoresis on a non-denaturing 
agarose gel (Section 2B1.4(i)). The concentration was determined by measuring the 
absorbance at 260nm, assuming that lA 26o=50|ig/ml.
2B1.10 Preparation of RNA from tissue culture cells
All aqueous solutions used in RNA work were treated overnight with DEPC added to a 
final concentration of 0.01% to inactivate RNases. The DEPC was inactivated by 
autoclaving.
RNA was prepared from roller bottles of confluent WS HeLa cells (see Section 
2B2 for growth and maintenance of tissue culture cells) by the 'single-step' method of 
Chomczynski and Sacchi (1987). The medium was removed from the roller bottle and 
12ml guanidine thiocyanate solution added and spread over the cell sheet by rolling the 
bottle on its side for lOmin. After standing the bottle upright for a further lOmin, the 
cell lysate was removed into a sterile Sorvall polycarbonate tube to which was added 
1.2ml 2M NaAc (pH 4.0). The mixture was thoroughly vortexed and 8ml water 
saturated phenol added followed by 2.4ml chloroform/isoamylalcohol (49:1), with 
thorough vortexing after each addition, and placed on ice for at least 15min. 
Centrifugation of this mixture at lOkrpm for 30min at 4°C (Sorvall SS34 rotor) yielded 
an upper aqueous phase containing RNA and a lower organic phase containing DNA 
and cell debris. About 80% of the aqueous phase was removed and an equal volume of 
isopropanol was added to precipitate the RNA (overnight at -20°C). The RNA was 
pelleted by centrifugation at lOkrpm for 30min at 4°C and the pellet dissolved in 300JJ.1 
guanidine thiocyanate solution and reprecipitated over a period of at least lhr at -20°C 
after the addition of lOOpl water and 8 0 0 jll1 ethanol. The RNA was again pelleted, 
washed twice in 75% ethanol and resuspended in 500jil water and stored at -70°C (for 
long term storage (>2-3 weeks), the RNA was kept as an ethanol precipitate at -20°C). 
The concentration was determined by measuring the absorbance at 260nm, assuming 
1 OD26o =40(ig/ml.
For some experiments it was necessary to use poly A+ RNA and this was separated 
from the total RNA mix isolated in the above protocol using the PolyATract mRNA 
Isolation System (Promega). The system uses a biotinylated dT oligo primer which 
hybridises to the 3' polyA region of mRNAs. The hybrids are then 'captured' in an 
interaction with streptavidin which is coupled to paramagnetic particles, using a 
magnetic separation stand. Total RNA (0.1-lmg) in a final volume of 500p.l water was 
heated at 65°C for lOmin in a water bath. The solution was then placed at room 
temperature and 3 j l l 1 of the biotinylated-oligo(dT) probe added with 13p.l of 20X SSC 
and the mixture allowed to cool to RT. Meanwhile, an aliquot of streptavidin- 
paramagnetic particles were resuspended in their storage buffer and captured on the side
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of the tube by placing the tube in the magnetic stand. The storage buffer was removed 
and the particles were resuspended in 0.3ml 0.5X SSC, recaptured and washed twice 
more in a similar manner. The cooled RNA mix was added to the washed magnetic 
particles and the mixture was incubated at RT for lOmin. The tube was then placed on 
the magnetic stand to capture the particles. The particles were washed 3 times in 0.3ml 
0.1X SSC and the polyA+ RNA eluted by incubating the beads twice in water, 0.1ml 
the first time and 0.15 the second to give a total volume of 0.25ml. Due to the small 
quantities of polyA+ RNA present, the concentration was estimated by assuming that 
1% of total RNA is polyA+ RNA and 50% of this was recovered. Thus approximately 
5pg polyA+ RNA was recovered from lmg of total RNA.
2B1.11 Reverse transcription of RNA
RNA was reverse transcribed to make a cDNA template for use in PCR experiments. 
PolyA+ RNA (2fig) or 25-30|Hg total RNA were reverse transcribed at 42°C for lhr in a 
20jil reaction volume containing 5-10pmol primer (poly(dT), random hexamers, or 
reverse PCR primer), 20nmol each of dATP, dCTP, dGTP and dTTP, 25units RNase 
inhibitor and 40units M-MuLV reverse transcriptase. The mix was stored at -20°C and 
typically 0.5)ll1 was used in a 2 0 jll1 PCR amplification.
2B1.12 5' RNA extension assay
5' RNA extension assays were carried out to try to order redundant primers designed 
from 135kD peptide sequence information on the mRNA. This would subsequently 
reduce the number of primer combinations in the PCR amplifications. The method 
involved hybridising reverse PCR primers to RNA and extending in a mix including 
ct32PdATP. PCR primers (25ng) were hybridised to 25p.g RNA in a total volume of 
15pl containing hybridisation buffer at 65°C for 90min. To each hybridisation mix the 
following reagents were added: 0.9fil 1M Tris.HCl (pH 8.3), 0.9jil 0.5M MgCl2, 0.25pl 
1M DTT, 6.75(il 1 mg/ml actinomycin D (Cosmogen), lpl a 32PdATP, 3.3|il each of 
0.5mM solutions dCTP, dGTPand dGTP, lOpl water and 5units M-MuLV reverse 
transcriptase. This latter mixture was incubated at 42°C for lhr and the reaction chased 
by the addition of 0 .5 jll1 5mM dATP with further incubation for 30min. Extension was 
stopped by addition of 105|il RNase reaction mix and incubation at 37 C for 15min. 
cDNA was purified by a phenol and chloroform extraction, ethanol precipitated and 
pelleted by centrifugation for lOmin (microfuge). The pellet was washed in 75% 
ethanol and dissolved in 5|il formamide dyes and placed in a boiling water bath for 
2min. The samples were electrophoresed on an 8% denaturing polyacrylamide gel 
(Section 2B1.4(iii)) and the gel dried and exposed to Kodak X-OMAT S film.
2B1.13 Polymerase chain reaction (PCR) amplification of DNA
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PCR amplification was carried out using redundant primers designed from 135kD 
peptide sequence information in an attempt to clone a cDNA encoding the 135kD 
protein.
(i) Amplification with Pfu DNA polymerase
This enzyme was used in early experiments until it was discovered that the 3' ends of 
primers were often missing from cloned PCR products (see 3E2). Typically, 30(0.1 
reaction volumes contained 0.1-250ng template DNA (cDNA made by reverse 
transcription from polyA+ or total RNA (Section 2B1.11) ), l-5|iM primers, 100(iM 
dNTPs, 3(0.1 10X reaction buffer (supplied with enzyme) and l-2units Pfu DNA 
polymerase. The mixtures were overlayed with light mineral oil to prevent evaporation 
during cycling. Cycling conditions were varied in an attempt to minimise non-specific 
priming events, which gave rise to single primer artifacts and other non-specific 
products, and to obtain a single product from any one reaction. Initial conditions were: 
1 cycle at 95°C for 5min (denaturing), 42°C for 5min (annealing),74°C for 5min 
(elongation), followed by 38 cycles at 95°C 50sec, 42°C lmin, 74°C 2min 40sec. 
Annealing conditions were then altered by increasing the temperature to 65°C and 
reducing the time to 20sec in stages. Further optimisation involved altering the duration 
of the denaturing and extension stages. Reaction products were purified by an ethanol 
precipitation and pelleted by centrifugation, washed in 75% ethanol and dissolved in 
water. They were treated with polynucleotide kinase (Section 2B1.5(iv)) or digested 
with the relevant restriction enzymes if the primers were designed with restriction 
enzyme sites (Section 2B1.3) and ligated into pUC9 (Section 2B1.5(v)) prior to 
transformation into competent E.coli TGI. Addition of 20|il lOOmM IPTG and 40|il 
20mg/ml X-gal to the 600JJ.1 transformed cell mix, prior to spreading on LB agar plates 
containing ampicillin (Section 2A6), enabled blue-white selection of colonies 
containing vector with inserted PCR products.
(ii) Amplification with Taq DNA polymerase
This enzyme was used for the majority of PCR amplifications. A wide variety of 
reagent concentrations were used in an attempt to minimise non-specific primer 
annealing. Generally, 10-30(ll reaction volumes were made up containing 0.1-250ng 
template DNA (cDNA made by reverse transcription from polyA+ or total RNA 
(Section 2B 1.11), or JlZAPII library DNA (Section2B 1.9) with parallel control 
reactions using bacteriophage X DNA), l-5|iM primers, 100|iM dNTPs, 0.5-3p,M 
MgCl2, 1 -3(j.l 10X reaction buffer (supplied with the enzyme) and 0.1-2.5units Taq 
DNA polymerase. Cycling conditions were varied widely: initial conditions were 
similar to those used with Pfu DNA polymerase but with an extension temperature of 
72 C. Subsequently, annealing temperatures and times as well as extension times were 
altered. For a description of other strategies which were employed in an attempt to
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clone a cDNA using a PCR method see Section 3E2. PCR products were cloned by 
ligation into the pCR™H vector (Section 2B 1.5(v)).
2B1.14 Dideoxy sequencing of DNA
Plasmid DNA was sequenced by the dideoxynucleotide chain termination method based 
on that of Sanger et al (1977). Purified plasmid DNA (about 2(ig) was denatured at RT 
for lOmin in a 20jxl reaction volume containing NaOH at a final concentration of 0.4M. 
The denatured DNA was precipitated by addition of 6jil 3M Na acetate, 14}il water and 
1 20jll1 ethanol and incubated in a dry-ice ethanol bath for lOmin, pelleted by 
centrifugation for lOmin and dissolved in 8|il water.
The appropriate primer in (5pmol in lfil volume) was added to the DNA with ljxl 
10X seq buffer and annealing carried out for 20min at 37°C. E.coli DNA polymerase I 
Klenow fragment (2units in IX seq buffer) was added to the annealed DNA and 2|il 
aliquots of this mix were dispensed into 4 wells of a round bottomed 96-well microtitre 
plate (Nunclon) for the four chain termination reactions. Four chain termination mixes 
were made up, each containing a sequencing mix with one ddNTP + dNTPs (see table 
below for details) and 0.57p.M dATP and 5p.Ci a 32PdATP in a final volume of 14fil. 
Aliquots of (2|il) these mixes were added to the relevant wells, the microtitre plate was 
spun briefly to mix the contents of the wells, then the plate was incubated at 37°C for 
15min. Following this, any newly synthesised strands which had not been terminated 
by incorporation of a dideoxy nucleotide were extended into high molecular weight 
products by adding 2p.I chase mix (4X cold dNTPs each at 0.25mM) and incubating at 
37°C for 30min. The reactions were stopped by adding 2jil formamide dyes and the 
tray placed in a boiling water bath for 2min prior to electrophoresis of the samples in 
adjacent lanes on a denaturing polyacrylamide gel (Section 2B1.4(iii)). Gels were 
vacuum dried and exposed to Kodak X-OMAT S film.
Sequencing solutions:
dA-0 dT-0 dC-0 dG-0
5mM dTTP 20 (|il) 10il) 20 Oil) 20 Oil)
5mM dCTP 20 20 1 20
5mM 7-deaza dGTP 20 20 20 1
10X seq buffer 50 50 50 50
water 540 370 370 370
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Sequencing mixes:
dN-0 mixes ddNTP water
T seq 500 (jlxI) 500 (600p.M ddTTP) 0
C seq 500 105 (140p,M ddCTP) 395
Gseq 500 155 (200fiM  ddGTP) 345
A seq 500 250 (140(iM  ddATP) 370
DNA prepared by the miniprep plasmid method (Section 2B1.2) was also sequenced 
using this method: 7.5-15|il miniprep DNA were denatured in a 20(il reaction volume as 
described above and the reactions continued as normal.
2B1.15 Southern blotting (transfer of DNA to nitrocellulose) and probing of PCR 
products by DNA-DNA hybridisation
Products of PCR reactions made with redundant primers were occasionally probed with 
redundant primers not included in the reactions or with plasmid DNAs from other 
sources, as detailed in the relevant sections.
(i) Transfer of DNA to nitrocellulose
Products from PCR reactions were separated on agarose gels in IX TBE. The gels were 
incubated in Gel Soak I for 45min followed by Gel Soak II for 45min, both with 
shaking at RT. The DNA was transferred overnight onto Hybond-N+ filters (presoaked 
in 2X SSC before use) by placing gels on a wick of Whatman 3mm paper (soaked in 
10X SSC and descending into a 10X SSC reservoir), then adding sequentially Hybond- 
N+ filters, two pre-soaked sheets of Whatman 3mm paper and a stack of absorbent 
paper towelling to the top of gels. Care was taken to eliminate air bubbles between 
layers and a light weight was added to the top of the stack to aid buffer transfer. After 
transfer, the filter was briefly rinsed in 2X SSC and the DNA was fixed on the filter and 
denatured by incubating the filter, DNA side up, on Whatman 3mm paper soaked in 
0.4M NaOH for 20min. The filter was again rinsed in 2X SSC and kept moist.
(ii) DNA-DNA hybridisation
Hybond-N+ filters were pre-hybridised in a mix containing 5X SSC, 5X Denhardt s 
solution, 0.5% SDS and 20|ig/ml salmon sperm DNA for 3-4hr at 45-65°C. Probe DNA 
(107-108 cpm, see below) was added to the mix and incubation continued overnight at 
the relevant temperature. The filter was washed twice in 2X SSC, 0.1% SDS for lOmin 
at RT and then three times for 30min at the prehybridisation temperature. The filter was 
ir dried and exposed to Kodak X-OMAT S film, 
iii) Probes
ligonucleotide probes (50pmol) were radiolabelled in a 10-20fil reaction volume with 
OjiCi y32pATP using polynucleotide kinase (Section 2B1.5(iv)). The probe was
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purified by a phenol and chloroform extraction and ethanol precipitation. The pellet 
was dissolved in 20|il water and added to the prehybridisation mix.
Plasmid DNA or restriction fragment probes were prepared using the Megaprime 
system (Amersham). About 25ng of DNA was mixed with 5pl Megaprime primer in a 
final volume of 20jil and placed in a boiling water bath for 5min. The mixture was 
cooled and 10pl Megaprime buffer, 50|iCi a-32P dCTP and 4-5units Klenow fragment 
were added, bringing the reaction volume to 50|il, and the mix was incubated at 37°C 
for 20min. The reaction was stopped by the addition of 5|il 0.2M EDTA. 
Bromophenol blue was added to colour the mix which was then loaded on a Sephadex 
G-50 'nick' column (Pharmacia) that had been equilibrated with IX TE containing 0.1% 
SDS. Fractions (about 0.25ml) were collected from the column and those containing 
the highest counts in the initial peak were pooled and stored as probe. The probe was 
denatured by adding 1 /20th the volume of 5M NaOH, incubating the mixture at RT for 
lOmin and neutralising by adding l/20th the volume of 5M HC1.
2B2. Tissue culture
2B2.1 Growth of cells
Mammalian derived cells were passaged in sterile, disposable 175cm2 plastic flasks in 
the appropriate media (Section 2A.7) and were grown at 37°C in a humidified incubator 
under 5% CO2 . Confluent monolayers were harvested by washing the monolayer twice 
in 25ml trypsin:versene (1:4) (supplied by the Institute of Virology Media Services) and 
resuspending the cells in 10ml medium. Trypsinisation was unnecessary for ND7 cells 
which could be removed from flasks by gentle tapping. For continual passage, BHK 
and WS HeLa cells were split in a 1:10 ratio every 3-4 days, HFL cells in a 1:10 ratio 
every 7-10 days, U-2 OS cells in a 1:5 ratio every 4-5 days and ND7 cells in a 1:20 ratio
1
 every 3-4 days.
2B2.2 35S-methionine radiolabelling and extract preparation
Confluent monolayers of cells grown on 140mm diameter tissue culture plates were 
labelled with 35S-methionine and soluble protein cell extracts prepared for use in 
standard GST 'pull-down' assays. Plates were seeded at 1.5X107 cells per plate in 30ml 
medium and incubated at 37°C overnight. The medium was removed and the cell sheet 
was washed twice in 15ml prewarmed (37°C) PBS-complete and then incubated with 
15ml PBS complete containing 1500fiCi 33S-methionine for 2hr at 37 C. Following 
this, the cells were washed twice in cold PBS-complete and harvested in 10ml PBS- 
complete by scraping them from the plate. The cells were pelleted by centrifugation at 
Ikrprn for 5mins at 4°C and resuspended in 1ml PBS-complete prior to repelleting 
followed by resuspension in 1ml of a buffer containing 50mM HEPES (pH 7.5), 50mM
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NaCl and 0.1% NP40. The cells were lysed by sonication for 30-60sec in a soni-bath 
and debris pelleted by centrifugation at 3krpm for lOmin at 4°C. The soluble protein 
extract was stored at -70°C.
Radiolabelled WS HeLa cell nuclear and cytoplasmic extracts were made by the 
method of Dignam et al. (1983). Labelled cells from two 140mm plates were harvested 
as above and resuspended in a final volume of 2ml. An aliquot of this sample (0.5ml) 
was treated as above on a relative scale to make a whole cell protein extract. Cells in 
the remaining 1.5ml were pelleted and resuspended in 0.75ml of the HEPES containing 
buffer and NP40 was added to 0.5% prior to incubation of the mix on ice for 5min. Cell 
nuclei were spun down at 2krpm for 5min at 4°C and the supernatant retained as the 
radiolabelled cytoplasmic extract. The pellet was resuspened in 0.75ml HEPES buffer 
and sonicated prior to centrifugation at 3krpm for lOmin at 4°C. The supernatant was 
retained as the nuclear fraction.
Radiolabelling of differentiated ND7 cells was performed overnight as these cells had a 
lower rate of incorporation of the 35S-methionine compared with the other cell types 
used. Undifferentiated cells were seeded on 140mm plates in differentiation medium 
(Section 2A7) at 1.5X106 cells per plate and allowed to differentitae over 3-5 days. 
When 80% of the cells had assumed a neuron-like morphology, the medium was 
removed and the cells washed twice with Low Methionine Medium (Eagle's medium 
containing 20% of the normal concentration of methionine, supplied by the Institute of 
Virology Media Services). The cells were labelled for 16hr with 1500fiCi 35S- 
methionine in Low Methionine Medium, then washed and harvested as above. 
Undifferentiated cells seeded at the same density were also labelled overnight to 
provide a suitable control.
2B2.3 Extract preparation from roller bottles of WS HeLa cells
It was necessary to prepare large amounts of soluble protein extracts from WS HeLa 
cells in order to purify enough 135kD protein for microsequence analysis in large scale 
GST 'pull-down' experiments. The cells were grown in batches of about 10 roller 
bottles containing 100ml medium until the cells were about 95% confluent. The 
medium was removed and the monolayer was washed twice in cold 25ml PBS-complete 
and harvested by scraping in 50ml PBS-complete. The cells were pelleted by 
centrifugation at lkrpm for lOmin at 4°C and resuspended in PBS-complete (5ml per 
roller bottle) and pooled with cells from other roller bottles. The cells were pelleted 
again, under the same conditions, and resuspended in a buffer containing 50mM Hepes, 
50mM NaCl and 0.1% NP40 (2.5ml per roller bottle). The mixture was sonicated on ice 
using lOsec bursts with a soniprobe until the mixture cleared indicating that the cells 
had lysed. Debris was pelleted by centrifugation at 3krpm for 20min at 4 C and the 
soluble protein extract was adjusted to 0.5M NaCl and stored at -70 C.
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2B2.4 Calcium phosphate mediated transfection for immunofluorescence 
experiments
Cells were seeded on 13mm glass coverslips in 24-well Nunc Linbro plates at 0.5X105 
cells per well in 1ml of medium and incubated overnight at 37°C prior to transfection. 
Plasmid DNA (5jng) was made up to a volume of 70 |il in 0. IX TE and 10pl 2M CaCl2 
was added while whirlimixing. This mixture was added to 80pl 2X HBS, again while 
whirlimixing, and the mix incubated at RT for 30min before addition to cells (64p.1 per 
well). After mixing by gently swirling the plate, the cells were incubated overnight at 
37°C. The medium was removed and the cells were washed in 1ml fresh medium and 
incubated at 37°C for 16-24hr in a fresh 1ml aliquot of medium.
2B2.5 Immunofluorescence
Transfected cell monolayers (see above) were washed once with PBS(A) and fixed for 
lOmin at RT with 2% sucrose, 5% formaldehyde in PBS(A). This solution was 
removed and the cells were washed 3 times with PBS(A) and permeabilised for 10 min 
at RT with 0.5% NP40, 10% sucrose in PBS(A). The cells were again washed 3 times 
with PBS(A) supplemented with 1% calf serum (CS). Aliquots (2 0 jli1) of the relevant 
primary antibody diluted in PBS(A)+1% CS were then added to each coverslip for 45- 
60min. Again the cells were washed 3 times in PBS(A)+1% CS and incubation with a 
secondary antibody carried out if necessary. The mouse monoclonal antibody 11060 
was used at a dilution of 1/2000 and rabbit antisera raised against 135kD peptides at 
dilutions of between 1/50-1/5000. The monolayer of cells was then incubated with 20pl 
FITC labelled goat anti-mouse IgG at a 1/100 dilution and/or TRITC labelled goat anti- 
rabbit IgG (1/30 dilution) (Sigma Immunochemicals) for 30min at RT in the dark. 
After 3 washes with PBS(A)+1% CS, the cells were air dried and mounted on glass 
slides with lOjil Citifluor, a glycerol/PBS solution (UKC Chemical Laboratories). Cells 
were examined using a Nikon MICROPHOT-SA fluorescence microscope with 
appropriate filters and photographed using Kodak ASA400 black and white film.
2B3 GST ’pull-down’ assays and purification of the 135kD protein
2B3.1 GST fusion protein expression and preparation of bacterial extracts
A single fresh E.coli colony (strain BL21) transformed with the relevant pGEX plasmid 
(Section 2B1.7) was inoculated into 3ml L-broth and grown up overnight at 37 C with 
shaking. A sample (1ml) of this culture was added to 100ml 2YT broth with ampicillin 
it 100p.g/ml and the culture was grown at 37°C with shaking for 3-4hr until the OD450 
reached 0.6. Protein expression was induced by adding IPTG to 0.1 mM and incubating 
inder the same conditions for a further 2hr. Bacteria were harvested by centrifugation 
« 5krpm (Sorvall GS3 rotor) for 5min at 4 °C and the cell pellet was resuspended in 2ml
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PBS (A) prior to sonication in 20sec bursts with a soni-probe. Once the cells had lysed, 
Triton X-100 was added to 1% concentration and the lysate was incubated on ice for 
5min prior to centrifugation at 9.5krpm (Sorvall SS34 rotor) for 5min at 4°C. The 
soluble protein extract supernatant was stored at -20°C.
2B3.2 SDS polyacrylamide gel electrophoresis (SDS PAGE) of proteins
Proteins were resolved by electrophoresis through SDS polyacrylamide minigels 
(Laemmli, 1970) using the Bio-Rad miniprotean II apparatus. Tricine and glycine gel 
systems were used interchangeably. Gel mixes were made up as follows:
Tricine gels: 
Solution
49.5% acrylamide 
(3% cross-linker) 
gel buffer 
water
10% resolving gel 
1.5ml
2.5ml
7.5ml
12.5% resolving gel stacking gel 
1.87ml 250pl
2.5m l
7 .1 2 5 m l
7 7 5 jll1
2 .1 5 m l
100(il 10% APS and lOjul TEMED w ere added to each  reso lv in g  g e l m ix  and 2 5 jll1 10% 
APS and 5 jli1 TEMED w ere added to stack in g  gel m ixes.
Glycine gels:
Solution
30% acrylamide
(2.5% cross-linker)
RGB
SGB
water
7.5% resolving gel 10% resolving gel stacking gel
2.5ml
2.5ml
5ml
3.33ml
2.5ml
4.17ml
0.4ml
0.6ml
1.4ml
80 j l l 1 10% APS and 8 j l i 1 TEMED were added to each resolving gel mix and 20pl 10% 
APS and 3|il TEMED to stacking gel mixes.
Resolving gel mixes were made, poured into glass plate sandwiches in the gel former 
apparatus, overlayed with butanol and allowed to set. The butanol was washed away 
ith water and the stacking gel mixture was overlaid and a comb inserted. Protein 
amples were mixed with the relevant SDS gel loading buffer and placed in a boiling 
ater bath for 2min prior to loading. Tricine gels were run at 200V and glycine gels at 
00V until the tracking dye reached the bottom. The gels were stained with Coomassie 
lue for 5min and destained in Protein Gel Destain. Gels with radiolabelled protein 
amples were fixed for lOmin in Protein Gel Fix, incubated in En3hance for lOmin, 
riefly washed with water and vacuum dried prior to exposure to Kodak X-OMAT S 
lm.
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2B3.3 Western blot analysis of proteins
2B3.3(i) Electroblotting to nitrocellulose
Proteins resolved on SDS PAGE minigels were transfered to nitrocellulose by the 
method of Towbin et al. (1979) in a Bio-Rad mini transblot cell. A blotting sandwich 
was set up such that the gel was in contact with a sheet of nitrocellulose (Schleicher and 
Schuell Inc.) and both were sandwiched between Whatman 3mm paper of the 
appropriate size. This was in turn sandwiched between sponges provided by Bio-Rad 
and blotting carried out at 0.25mA for 3hr.
2B3.3(ii) Immunodetection
Nitrocellulose membranes were blocked by incubation at 37°C with gentle shaking for 
60min in 100ml 3% gelatin in TBS with one change of buffer after 30min. They were 
then washed 2X 5min at RT in TTBS before incubation overnight at RT on a shaker 
with the first antibody diluted appropriately in 20ml 1% gelatin in TTBS. Following 
this, blots were washed five times for 5min in TTBS at RT and protein A horse radish 
peroxidase or anti-mouse IgG whole molecule peroxidase conjugate added in a 1/1000 
dilution in 20ml 1% gelatin in TTBS. After a 90min incubation at RT, again with 
shaking, blots were washed three times for 5min in TTBS and proteins were detected 
using the Amersham enhanced chemiluminescence (ECL) system. The two reagents 
were mixed in equal volumes and a total of 3ml poured on to the filter which was then 
agitated for lmin. The filters were wrapped in cling film and exposed to Kodak X- 
OMAT S film for 5-30sec.
2B3.4 Standard GST ’pull-down' assay
The conditions for this assay were determined experimentally (see Section 3A4). The 
initial step of purification of fusion proteins by interaction with glutathione agarose 
beads was based on the method of Smith and Johnson (1988). Glutathione agarose 
beads (Sigma) were prepared for use in experiments by pre-swelling in 10X volume 
PBS(A) for 1 hr at RT and washing 3 times in excess PBS(A), spinning 20-30sec 
(microfuge) between washes to pellet the beads. After the final wash, the beads were 
resuspended in an equal volume of PBS(A) and stored as a 50% slurry for up to one 
month at 4°C.
The protocol determined for investigating cellular proteins which interact with 
segments of Vmwl 10 fused to GST was as follows. A 50% bead slurry (50pl) was 
added to 300jj,l bacterial extract and mixed end over end for 1 hr at 4°C. The beads were 
recovered by a 20-30sec spin and washed 3 times in 1ml cold PBS(A) and stored on ice 
as a 50% slurry until use. Aliquots (10pl) were analysed by SDS gel electrophoresis 
(Section 2B3.2) with size standard markers to determine the quality of the bound GST 
fusion protein. An appropriate volume of the bead slurry was mixed end over end at 
4°C for lhr with 300pl 35S-methionine radiolabelled cell extract (Section 2B2.2) in
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buffer containing 0.5M NaCl. The beads were recovered by brief centrifugation, 
washed three times for 5min in 1ml cold 0.5M NaCl wash buffer and retained as a 50% 
slurry.
For experiments utilising VmwllO-GST fusion proteins, the cell extracts were 
routinely pre-treated by this procedure with glutathione agarose beads carrying the GST 
protein expressed by pGEX2TN3 vector plasmid. This step depleted the radiolabelled 
extract of proteins which bound non-specifically to the beads or GST.
Bound proteins were eluted from 20[il aliquots of the beads by the addition of 
20|lU 50mM reduced glutathione and incubating on the bench for 15min with gentle 
agitation every 5min. The elution step was repeated with a second volume of reduced 
glutathione. The eluates were mixed with SDS gel loading buffer, boiled for 2min and 
loaded on 10% glycine gels with 1|ll1 1/10 dilution radiolabelled cell extract which acted 
as a marker track. Electrophoresis was carried out as described in Section 2B3.2.
2B3.5 Purification of the 135kD protein
2B3.5(i) Large scale 'pull-down' experiment
This procedure was determined experimentally (see Section 3C4) but is based on the 
conditions of the standard 'pull-down' assay described above.
Glutathione agarose beads (4ml 50% slurry) were mixed with 5ml 2TN3 and GEXE52 
extracts and incubated with end over end mixing at 4°C for lhr. The beads were 
recovered by centrifugation at 3krpm for 5min at 4°C and were washed 3 times in 10ml 
PBS(A) and stored on ice as a 50% slurry. Samples (10pl) of each were taken for 
analysis by SDS PAGE as in Section 2B3.4. The 2TN3 beads were mixed with a WS 
Hela cell extract made from 25 roller bottles of cells (Section 2B2.3) which gave a final 
volume of approximately 60ml (this was split into 30ml volumes for convenience). 
Following end over end mixing at 4°C for 3hr, the 2TN3 beads were removed from the 
extract and an aliquot was washed 3 times in 0.5M NaCl wash buffer. Proteins were 
eluted from the beads in an equal volume of 50mM reduced glutathione and the eluate 
stored at -70°C. The 'pre-cleared' WS Hela cell extract was then mixed in the same 
manner with 4ml GEXE52 beads for approximately 42hr to ensure maximal binding of 
the 135kD protein to Vmwl 10 sequences. (A control experiment was carried out in 
parallel on a smaller scale in which 1ml 50% slurry GEXE52 beads were mixed with 
the cell resuspension buffer for the same period of time). The beads were recovered by 
centrifugation at 3krpm for lOmin at 4°C and washed once in 10ml and twice in 5ml 
0-5M NaCl Wash Buffer. After the final wash, the GEXE52 beads were collected by 
centrifugation and all liquid removed. Proteins were eluted in 2 identical steps by 
adding 2ml 50mM reduced glutathione and incubating at RT for 30min with gentle 
agitation of the mixture every lOmin. The eluates were pooled to give a total volume of 
4ml and this was reduced to 200|il by centrifuging 1ml volumes at 5krpm in Centncon
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50 centrifugation units (Amicon). This reduced volume eluate was then mixed with 
2 0 0 jlx1 3X SDS gel loading buffer and boiled for lOmin. Samples (300pl) were loaded 
on two 2.5cm wells of a 10% glycine gel with 20jxl of a GEXE52 eluate from a standard 
'pull-down' assay using radiolabelled extract and electrophoresed (Section 2B3.2). 
Relevant control samples were also loaded onto the gel.
(ii) Transfer of proteins to Problott™ membrane
Electrophoretically separated proteins were transferred to a Problott™ membrane 
(Applied Biosystems) in a manner similar to Western blot transfer of proteins to 
nitrocellulose (Section 2B3.3). The gel was first soaked for 5min in Electroblotting 
Buffer (Section 2A10) and a membrane of corresponding size briefly rinsed in methanol 
and in Electroblotting Buffer. The transblotting ’sandwich’ set up as described above 
(Section 2B3.3(i)). Transfer was carried out for 6 hr at 0.25mA in Electroblotting 
buffer, ensuring that the buffer was kept cool by inserting an ice block in the transblot 
cell. Following transfer, the membrane was rinsed in water, then briefly in methanol, 
before staining for lmin with 0.2% Ponceau S in 1% acetic acid. The membrane was 
destained for 10-15min in water until the bands could be seen. The membrane was then 
thoroughly air dried and photocopied before an overnight exposure to Kodak X-OMAT 
S film. A stained band which co-migrated with the radiolabelled 135kD protein was 
identified and submitted for microsequence analysis.
2B4 Expression of fragments of VmwllO in bacteria using the T7 
system, and their purification and analysis
2B4.1 Expression and crude purification of T7E52 and T7E58
A single fresh E.coli colony (strain BL21(DE3)pLysS) transformed with either pT7E52 
or pT7E58 (Section 2B1.7) was inoculated into 10ml L-broth and grown shaking 
overnight at 37°C. The culture was added to 11 2YT broth with ampicillin at lOOjig/ml 
and the culture grown at 37°C with shaking for 3-4hr until the OD450 reached 0.6. 
Protein expression was induced by adding IPTG to 0.1 mM and incubating for a further 
2hr. The bacteria were harvested by centrifugation at 5krpm (Sorvall GS3 rotor) for 
5min at 4°C, the cell pellet was resuspended in 10ml cold Extract Buffer and stored 
frozen at -20°C overnight. After thawing, 10}il 20mg/ml DNasel, 25jil 2M MgCH and 
30|xl lOmg/ml lysozyme were added to the mixture and the cells were lysed using 2 0 sec 
bursts with a soniprobe. Subsequently 250pl 5M NaCl and 50pl 10% polymin P were 
added to the lysate which was incubated on ice for 30min. Cell debris and precipitated 
nucleic acids were pelleted by centrifugation at 9.5krpm for 5min at 4 C. Saturated 
ammonium sulphate was added to the supernatant to 40% volume and the mixture 
stirred on ice for 30min. Precipitated proteins were pelleted by centrifugation at 
9-5krpm for lOmin at 4°C and the pellet was resuspended in 2ml 50mM HEPES (pH
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7.5), 50mM NaCl, 0.01% CHAPS, lmM PMSF, 0.1 mM DTT. The extract was filtered 
through a 0.45^im millipore filter and stored at -20°C.
2B4.2 FPLC purification of T7E52 and T7E58
T7E52 and T7E58 were purified by two ion exchange chromatography steps and a gel 
filtration step. Columns were pre-equilibrated with the relevant buffer which had been 
filtered through a 22pm filter and de-gassed, until the UV absorbance of the eluted 
buffer reached a steady state.
(i) ion exchange chromatography
Crude samples of extracts containing the T7E52 protein were loaded onto a 20ml 
Mono-Q anion exchange column which had been pre-equilibrated in Column Buffer: 
50mM HEPES (pH 7.5), 50mM NaCl, 0.01% CHAPS, lmM PMSF, 0.0lmM DTT. 
After loading, the column was washed with Column Buffer (10ml) and proteins were 
eluted on a linear 0.05-1.0M NaCl gradient in column buffer (20ml). Flow-through 
fractions containing T7E52 (as indicated by SDS PAGE analysis-Section 2B3.2) were 
pooled and loaded on a 20ml Mono-S cation exchange column which had also been pre- 
equilibrated in Column Buffer. The column was washed with column buffer (10ml) 
and a 0.05-1.0M NaCl gradient in Column Buffer (20ml) applied. Fractions (1ml) were 
collected and analysed by SDS gel electrophoresis. The procedure was similar for 
purification of the T7E58 protein except the initial crude extract was loaded on the 
Mono-S column and pooled flow-through fractions on the Mono-Q column.
( ii) gel filtration
Purified protein samples from the ion exchange chromatography columns were loaded 
in 300-500pl volumes on a Superdex 75 column which had been pre-equilibrated in a 
buffer containing 50mM HEPES (pH 7.5), 1M NaCl, 0.01% CHAPS, lmM PMSF and 
0.0lmM DTT. Fractions (1ml) of the eluate were collected and samples were analysed 
by SDS PAGE (Section 2B3.2) prior to storage at -20°C.
2B4.3 Glutaraldehyde cross-linking analysis
G lu ta r a ld e h y d e  c o v a le n t ly  c r o s s - l in k s  a m in o  g ro u p s o f  ly s in e  r e s id u e s  o f  p r o te in s  in  
c lo s e  p r o x im ity  an d  c a n  th e r e fo r e  b e  u s e d  to  d e te r m in e  th e m u lt im e r ic  n a tu re  o f  
p rotein s. T h e  c o n c e n tr a t io n s  o f  p u r if ie d  T7E52 an d  T7E58 p ro te in s  w e r e  e s t im a te d  
from  SDS PAGE a n a ly s is  in c o m p a r is o n  w ith  k n o w n  a m o u n ts  o f  m a rk er  p r o te in s  
(S e c t io n  2B3.2) an d  20 |j.l v o lu m e s  c o n ta in in g  ljitg or  5|ig p rotein  w e r e  in c u b a te d  fo r  
30 m in  at 20°C w ith  g lu ta r a ld e h y d e  c o n c e n tr a t io n s  ra n g in g  fro m  0.001% to  0.01% . 
G ly c in e  w a s  a d d e d  to  a c o n c e n tr a tio n  o f  50mM to s to p  the rea ctio n  by c o m p e t it iv e ly  
in h ib itin g  p ro te in rp ro te in  c r o s s - l in k in g  an d  th e sa m p le s  w ere  a n a ly se d  b y SDS PAGE 
Usin g  12.5% p o ly a c r y la m id e  tr ic in e  g e ls  (S e c t io n  2B3.2). The p ro d u cts  w e r e  d e te c te d
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either by Western blotting using MAb 10503 at 1/5000 dilution (Section 2B3.3(ii)) or 
they were visualised directly by Coomassie blue staining of the gel.
2B4.4 Glycerol gradient centrifugation and dot blot analysis
About 20-30|LLg purified T7E52 and T7E58 proteins were loaded on 10-30% glycerol 
gradients poured in 5ml centrifuge tubes in a buffer containing 1M NaCl, 50mM 
HEPES (pH 7.5) with 20p.g each of the size standards bovine serum albumin (BSA) and 
carbonic anhydrase (CA). Gradients were centrifuged at 40krpm for 46-48hr at 4°C 
(Sorvall AH650 rotor), then 200p.l fractions were collected from the top of the tube. 
Aliquots (20|il) of fractions were analysed by SDS PAGE (Section 2B3.2) to determine 
the comparative sedimentation rates of the proteins. The peak positions of proteins 
T7E52 and T7E58 were further verified by dot blot analysis: 5 0 jll1 samples of gradient 
fractions were adsorbed onto nitrocellulose using a BRL Hybri-Dot manifold apparatus, 
then the filters were blocked twice for 30min in 100ml 3% gelatin in TBS at 37°C with 
gentle shaking. Antibody incubations were carried out as described for Western blot 
analysis (Section 2B3.3). The primary antibody was MAb 10503 used at 1/5000 
dilution and the secondary antibody was anti-mouse IgG whole molecule peroxidase 
conjugate used at 1/1000 dilution. Proteins were detected by ECL.
2B5 Library screening
A bacteriophage X ZAPH HeLa cDNA expression library (Section 2A4) was screened 
with 135kD rabbit antipeptide antisera (Section 3D3) and with a 53mer oligonucleotide 
(Section 3E3) designed from peptide sequence information in an attempt to isolate a 
cDNA clone encoding the 135kD protein sequence. The E.coli bacterial strain used for 
these experiments was XL-1 Blue (Section 2A5).
2B5.1 Titration of library
The library titre was determined as follows: 2-3 fresh XL-1 blue colonies grown on LB 
agar plates with tetracycline at 50|ig/ml were inoculated into 50ml 2YT broth 
supplemented with 0.2% maltose and grown overnight with shaking at 37 C. The 
maltose induces expression of the maltose operon which contains the lamb gene 
encoding the bacteriophage X receptor which is presented on the bacterial cell wall. 
The cells were then pelleted at 4krpm for lOmin at RT and resuspended in 20ml sterile 
0.01M M gS04 at RT before storage at 4°C for up to 3 days. The OD6oo of the cell 
suspension was read and the bacteria were diluted to OD6oo=2* Dilutions of library 
bacteriophage were prepared in 2YT broth and lOOp.1 dilutions mixed with 100p.l 
bacterial suspension in a shaking incubator at 37 C for 20min to adsorb the 
bacteriophage to the cells. Top Agar (3ml, prewarmed to 37°C) was added and the
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mixture which was poured onto dry 90mm LB agar plates and allowed to set. Plates 
were incubated overnight at 37°C and the plaques on the bacterial lawn were counted.
2B5.2 Antibody screening
The bacteriophage X library was plated out on 140mm plates at 7X104 pfu per plate by 
scaling up the procedure above: bacteriophage in 470|il 2YT broth were mixed with 
230fil bacteria and, following adsorption, 7ml 47°C Top Agar were added and the mix 
was poured onto the plates. Plates were incubated at 42°C for 3-4hr until plaques 
became visible. Circular nitrocellulose discs (137mm diameter) were marked with a 
ball point pen, soaked in lOmM IPTG, air dried and placed on the agar, taking care not 
to trap air between the disc and the agar. The plates were then marked with lines 
corresponding to those on the disc (to enable the plate and disc to be lined up later for 
picking plaques) and incubated at 37°C to allow protein expression and transfer to the 
membrane. The plates were then cooled at 4°C for 30-45min prior to lifting the discs 
which were washed briefly in TBS. Blocking was carried out at 37°C in a shaking 
incubator in one of three ways (in an attempt to improve the results): (i) 2X 30min in 
100ml 3% gelatin in TBS, or (ii) 2X 30min in 5% dried milk, 0.1% NP40 in PBS(A) or,
(iii) in the same buffer as in (ii) with 0.01% sodium azide for 30min and overnight. 
Following this, discs were washed twice for 5min at RT in TTBS and incubated 
overnight at RT with the r664/2 rabbit antiserum (see Section 3D3) diluted to 1/1000 in 
30ml l%gelatin in TTBS. After five 5min washes in TTBS, the discs were incubated 
for 90min with protein A horse radish peroxidase at a 1/1000 dilution in 30ml 1% 
gelatin in TTBS. They were then washed in TTBS three times for 5min and proteins 
detected by the ECL method (Section 2B3.3(ii)) using 5ml total volume of the mixed 
reagents.
Plaques thought to contain bacteriophage expressing peptides recognised by the 
antisera were picked into 1ml 2YT which was vortexed thoroughly and stored at 4 C. 
Serial dilutions were made and the samples were titrated for a second round of 
screening on 90mm plates. The protocol outlined above was followed on an 
appropriately smaller scale to isolate single plaques thought to express 135kD derived 
polypeptides.
2B5.3 DNA-DNA hybridisation screening
(i) radiolabeling of probe
The 53mer oligonucleotide was 5' end labelled in a reaction containing 20nmol DNA, 
lOOjuCi y32P ATP with T4 polynucleotide kinase in the appropriate buffer. Following 
heat inactivation of the enzyme by incubation at 70°C for lOmin, the reaction mix was 
loaded on a Sephadex G-50 'nick' column (Section2B1.15(iii)) to separate labelled
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oligonucleotide from unincorporated y32P ATP. The probe fractions were pooled and 
approximately lOnmol was used for each 140mm diameter disc.
(ii) Transfer of library DNA to nitrocellulose filters
As for the antibody screening procedure, the bacteriophage X library was plated out on 
140mm plates at 7X104 pfu per plate. Plates were incubated at 37°C for about 4hr until 
plaques appeared and then at 4°C overnight. The 137mm diameter nitrocellulose discs 
were marked with ballpoint pen, placed on the agar for lOmin, and removed and air 
dried for lOmin. A duplicate disc was also lifted from each plate. The discs were 
placed, DNA side up, on Whatman 3mm paper soaked in 0.2M NaOH, 1.5M NaCl for 
2min, then they were transferred to 3mm paper soaked in 0.4M Tris.HCl (pH 7.6), 2X 
SSC for 2min and finally to 3mm paper soaked in 2X SSC. Following baking in a 
vacuum oven at 80°C for 90min, prehybridisation was carried out at the appropriate 
temperature for 4hr in 5X SSC, 5X Denhardt's solution, 0.5% SDS and 20(ig/ml salmon 
sperm DNA before addition of the probe. The incubation was continued at the same 
temperature overnight, then the discs were washed for lOmin at RT and at the 
hybridisation temperature for 2hr in 2X SSC, containing 0.1% SDS. The filters were 
sealed in plastic bags and exposed overnight to Kodak X-OMAT S film with an 
intensifying screen. Duplicate filter autoradiographs were compared and plaques to 
which the probe had hybridised were picked as in Section 2B5.2 and plated out on 
90mm plates for re-screening.
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3A Expression of C-terminal residues of VmwllO as GST fusion proteins and 
investigations of their abilities to interact with cellular proteins in GST 'pull-down'
assays
3A1 Introduction
The aim of this project was to identify and characterise cellular proteins which interact 
with the HSV-1 immediate-early protein Vmwl 10. Two observations prior to the start of 
this work indicated that Vmwl 10 may interact with cellular proteins via residues in its C- 
terminal end. Firstly, immunofluorescence experiments with a deletion mutant virus, 
D14, which is missing VmwllO residues 680-720, showed that the VmwllO protein 
expressed by this virus no longer localised to ND10 domains at early times of infection 
but was diffusely spread throughout the nucleus (Everett and Maul, 1994). Secondly, in 
transfection assay systems, insertion and deletion mutations in the C-terminal 120 
residues significantly decreased the ability of Vmwl 10 to transactivate gene expression, 
particularly in synergy with Vmwl75 (Everett, 1987a, 1988a; see Section 1D5.1). A run 
of serine residues immediately prior to the C-terminal 180 residues of Vmwl 10 indicates 
that this is possibly a domain boundary. My initial experiments involved bacterial 
expression and purification of the putative C-terminal domain of VmwllO prior to 
investigating interactions between it and host cell proteins.
There are a variety of methods which aim to detect specific proteimprotein 
interactions, and one of the most widely used involves the construction of fusion proteins 
between the protein of interest and Schistosoma japonicum glutathione S-transferase. The 
expressed GST fusion proteins can be purified from bacterial lysates by adsorption to 
glutathione agarose beads (Smith and Johnson, 1988). The beads serve as an affinity 
matrix, allowing proteins to bind to the immobilised target fusion protein. Bound 
proteins can be partially purified by a simple centrifugation step, hence the name 'pull­
down' assay.
Purified GST fusion proteins have been used in a variety of assays either to 
investigate known proteimprotein interactions or, as described in this Thesis, to identify 
novel interactions. An example of the former case includes the expression of GST 
fusions with SV40 large T antigen residues; these were used to define more clearly the 
regions of SV40 large T antigen with which the DNA binding proteins TEF-1 and TBP 
interact (Gruda et al., 1993). In another example, 'pull-down' assays using a GST-SW15 
fusion protein and partially purified yeast cell extracts supplemented with a radiolabelled 
DNA probe were carried out; this led to the identification of a previously cloned protein, 
GRF10, which interacts with SW15 to form a DNA binding complex (Brazas and 
Stillman, 1993).
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In the investigations carried out in this project, GST fusion proteins immobilised on 
glutathione agarose beads were used in a ’pull-down' assay of the type outlined in Figure 
3A1 in an attempt to identify novel interactions between Vmwl 10 residues and cellular 
proteins: beads-bound fusion proteins were mixed with radiolabelled cellular protein 
extracts, then the complexes were isolated by centrifugation and washed in a suitable 
buffer. Cellular proteins which had bound to the fusion proteins were analysed by 
polyacrylamide gel electrophoresis. The use of whole cell extracts in the experiments 
ensured, as far as possible, that any interactions detected between Vmwl 10 residues and 
cellular proteins were not artifacts which arose as a result of over-representation of 
particular cellular proteins. This method of identifying specific proteimprotein 
interactions has been employed previously: use of a GST-pRb fusion protein showed that 
the RBI gene product interacts with at least seven cellular proteins (Kaelin et al., 1991). 
A 60kD protein, RBP60, was later identified as an essential component of the pRb-E2F 
DNA binding complex in gel retardation assays (Ray et al., 1992). Although a specific 
link between the proteins identified by these groups has not yet been established, the 
different methods utilised provide an example of a way in which an interaction seen in 
one experimental system can (perhaps) be verified in another. This is important because 
it lessens the possibility of an observed interaction being an artifact of the experimental 
system employed.
The experiments in this Section describe the optimisation of the 'pull-down' assay 
conditions and subsequent use of the assay in defining more precisely Vmwl 10 residues 
involved in interacting with a 135kD cellular protein. The assay was also used to 
investigate the half-life and cellular location of the 135kD protein. Finally, a 
collaborative experiment with other members of the group showed that the 135kD protein 
pulled down in GST assays is likely to be the same as that co-immune precipitated with 
intact, purified Vmwl 10.
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Figure 3A1 Outline of the GST 'pull-down' experimental strategy, (i) A bacterial extract 
containing a GST fusion protein was mixed with glutathione agarose beads and (ii) 
beads-fusion protein complexes were isolated by centrifugation and washed prior to 
mixing with radiolabelled cell protein extracts, (iii) Complexes on the beads were 
collected by centrifugation, then washed before bound proteins were eluted from the 
beads by competition with reduced glutathione, (iv) Eluted proteins were analysed by 
SDS PAGE. C12 indicates the space group used to link glutathione to the beads.
3A2 Construction of plasmids expressing GST fusion proteins
Plasmid pGEX2TN3 (Section 2A1) was used for expression of GST sequences. Plasmids 
pGEXE52 and pGEXE58 (Section 2A1) were used for expression of Vmwl 10 residues 
594-775 and 633-775 as GST fusion proteins. All other pGEX plasmids were derived 
from pGEXE52. Throughout this Thesis, protein nomenclature is such that a protein has 
the same name as the plasmid from which it was expressed, for example, pGEXE52 
expressed GEXE52 and pT7E52 expressed T7E52.
Plasmids pGEXR5 and pGEXE35, expressing Vmwl 10 residues 681-775 and 696- 
775 (Figure 3A2(i)), were made in ligation reactions with three fragments isolated from 
the relevant digest mixes: these were the Sall-PstI and Pstl-EcoRI fragments of pGEXE52 
and the EcoRI-Sall fragment of p ll0R 5  or p 11OE35 (Figure 3A2(i)B). As with 
pGEXE52, the fusion protein termination signal was encoded by VmwllO sequences 
downstream of the Sail site.
Plasmids pGEXE52D14, pGEXE52A8, pGEXE52E35 and pGEXE52E2 all 
expressed proteins based on GEXE52 sequences but protein E52D14 was missing 
VmwllO residues 680-720 and the others contained 12bp EcoRI linker insertions at 
Vmwl 10 codons 647, 696 and 723 respectively (Figure 3A2). These were all made in 
ligation reactions involving four fragments: these were the Sall-PstI, Pstl-EcoRI and 
EcoRI-Bgll fragments of pGEXE52 and the Bgll-Sall fragment of pi 10D14, pi 10A8, 
pi 10E35, or pi 10E2 respectively (Figure 3A2). The termination signal in each case was 
that encoded by Vmw 110 sequences downstream of the Sail site.
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Predicted fusion 
protein size /kD
594 E52 775 46.3
633 E58 775 a i  n4Z .U
680 775 37.6
696 E35 775 35.8
594 E52D14
— 775 42.4
E52A8 594 775 /1£  Q
E52E35 594 ^647 775
4 0 . 0
46.8
Af\ 8E52E2 594
^696
775
^723
4 0 . o
E52SalI 594 768 53.2
E52PmlI 594 713 39.7
E52RsaI 594 680 40.1
E52AvaI 594 646 33.1
Figure 3A2 (i) Plasmid pGEXE52 (Figure 2A1(iii)) is shown, with all the restriction sites 
relevent to the cloning of plasmids pGEXR5, pGEXE35, pGEXE52D14, pGEXE52A8, 
PGEXE52E35, pGEXE52E2, pGEXE52Sall, pGEXE52Pmll, pGEXE52Rsal and 
pGEXE52Aval (see text). For pGEXE58 see Figure 2A1(ii). The structures of the latter 
plasmids are shown as linear representations; the EcoRI site in each case representative 
of that at position 1861 in pGEXE52. The junction sequences of pGEXE52 and pGEXR5 
are shown. The termination signals for translation are encoded by Vmwl 10 sequences 
prior to the 3' most EcoRI site except in the cases of pGEXE52Rsal and pGEXE52Aval 
where they are encoded by vector sequences, (ii) A schematic diagram of the Vmwl 10 
residues expressed as GST fusion proteins is shown with their predicted molecular 
weights. The predicted molecular weight of the product of pGEXE52Rsal is inconsistent 
with that of the true product (Section 3A3); this is most likely to be due to the presence or 
absence of a single base in the construct which allows the use of an earlier stop codon.
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The GEXE52 truncation mutants pGEXE52RsaI and pGEXE52AvaI, expressing 
Vmwl 10 residues 594-680 and 584-646 respectively, were made as follows: pGEXE52 
was digested with EcoRI and the overhangs produced filled in using Klenow fragment 
and dNTPs. The DNA was then digested with Ncol and the NcoI-(EcoRI) vector 
fragment was isolated. Plasmid pGEXE52 was also digested with Aval followed by end- 
filling of the overhangs and digestion with Ncol: the 180bp NcoI-(Aval) fragment was 
isolated. The 283bp Ncol-Rsal fragment was also isolated from a digestion of pGEXE52 
with these two enzymes. In two ligation reactions, the pGEXE52 NcoI-(EcoRI) fragment 
was ligated with the NcoI-(Aval) and Ncol-Rsal fragments to give pGEXE52AvaI and 
pGEXE52RsaI respectively (Figure 3A2(i)). The termination codons utilised in these 
plasmids were those encoded by the pGEX parent plasmid, pGEX2TN3.
The truncation mutant, pGEXE52SalI, was made by cutting pGEXE52 with Sail, 
isolating the linear fragment, end-filling the 5' overhangs and religating the 'flush' ends. 
This introduced a frameshift mutation into the Vmwl 10 sequences with the resultant 
protein expressed being larger than GEXE52. The termination signal, however, was 
encoded by VmwllO sequence downstream of the position of the mutated Sail site. 
Plasmid pGEXE52PmlI was made in a similar way except that Xbal linkers were inserted 
at the unique Pmll site in codon 713: pGEXE52 was digested with Pmll, which gives 
'flush' ends, and the linear fragment was isolated. An 18bp self complementary linker, 
AATTAATCTAGATTAATT. encoding termination codons in all three reading frames 
(underlined) as well as an Xbal site (in bold), was added to a ligation reaction with the 
linear fragment.
3A3 Expression of GST fusion proteins
The plasmid constructs described in Section 3A2 were transformed into the E.coli strain 
BL21 (Section 2B1.7). Cultures were grown, then fusion protein expression was induced 
from the Ptac promoter by the addition of IPTG and protein extracts were prepared as 
described in Section 2B3.1. Extracts containing GST protein were prepared from E.coli 
BL21 transformed with pGEX2TN3 for use in control experiments.
Expression of the fusion proteins was ascertained by SDS-PAGE analysis of 
bacterial protein extracts. The gels were stained with Coomassie blue and GST fusion 
proteins of the predicted sizes were observed amongst a background of bacterial proteins 
(results not shown). To confirm expression of the expected proteins, samples of bacterial 
extracts were Western blotted onto nitrocellulose following resolution of proteins by 
SDS-PAGE, and GST-VmwllO fusion proteins were detected using the mouse 
monoclonal antibodies 10503 or 10810: the former recognises an epitope between 
residues 696-775 of Vmwl 10 and the latter an epitope between residues 594-633. The 
results showed that all of the constructs expressed proteins of the sizes expected relative
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to the GEXE52 fusion protein and that the GST protein ('c' tracks) was not detected by 
either antibody (Figure 3A3(i)).
<§* <$ <p <$P <$*■
B <§' <§*<§* <& < $'
Figure 3A3(i) Western blot analysis of bacterial extracts containing GST fusion proteins. 
From 100ml cultures induced with IPTG, 2ml of bacterial protein extracts were prepared 
and 5jil samples were subjected to SDS PAGE and the proteins Western blotted onto 
nitrocellulose. In panels A and B the major band in each track is the GST fusion protein 
indicated by the label above each track. The 'c1 tracks show the bacterial extract 
containing GST sequences alone. The monoclonal antibody 10503 was used to detect 
the proteins in A and 10810 those in B. Both antibodies were used at a dilution of 
1/5000. Bands representing dimerised fusion proteins are marked ■ .
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It was evident from the blots that the level of fusion protein expression from any 
one plasmid construct could vary: for example, compare the GEXE52AvaI with 
GEXE52. This was reflected in the amounts of protein which bound to the glutathione 
agarose beads (see below). Some of the fusion proteins showed evidence of low levels of 
degradation: for example, the GEXE52 insertion mutants. The higher level of 
degradation seen with the GEXE52SalI fusion protein was lessened with use of a freshly 
prepared extract.
VmwllO exists as a multimer in solution (Everett et al., 1991; Chen et al., 1992) 
and it has been shown indirectly that residues in the C-terminal end of the protein are 
responsible (Ciufo et al, 1994) (Sections 1D11 and 3B1). It is of interest to note that in 
many of the tracks in Figure 3A3(i), above the major fusion protein band there is a less 
intense band which probably represents fusion proteins present in a dimeric form (these 
bands are marked-)* However, it is difficult to draw conclusions from these results as to 
which residues of Vmwl 10 are necessary for multimerisation: E58 sequences appear not 
to dimerse when expressed as fusion proteins yet when expressed in isolation using the 
T7 expression system this domain forms multimers in solution (Section 3B). The GST 
enzyme of S. japonicum  belongs to a family of glutathione transferase enzymes (EC 
2.5.1.18) (Smith et al., 1986) and investigations of the physical properties of a human 
member of the family indicates that GST exists as a dimer in solution (Warholm et al., 
1983). It is possible that the dimerisation property of the GST sequences is responsible 
for the presence of these bands and that they are present only in samples which were 
incompletely denatured by boiling. It would have been of value to repeat the experiment 
but to boil the samples for five minutes rather than two or to use higher amounts of 2-ME 
in the boiling mix.
Aliquots of the bacterial extracts were mixed with glutathione agarose beads, then 
the beads were washed in PBS(A) and samples were analysed on SDS polyacrylamide 
gels (Section 2B3.4). The results (Figure 3A3(ii)) showed that the various fusion proteins 
bound to the beads to different extents: for example, compare GEXE58 with GEXR5. 
The degradation seen with some fusion proteins, particularly with GEXR5, GEXE35 and 
GEXE52D14, was minimised by the use of fresh extracts. It was necessary to be careful 
that in the 'pull-down' assays, equivalent amounts of the various beads-bound fusion 
proteins were used. Consequently, the beads-fusion protein complexes were always 
analysed by SDS PAGE prior to use in 'pull-down' assays.
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Figure 3A3(ii^ Coomassie stained polyacrylamide gels showing samples of fusion 
proteins bound to beads. Aliquots of bacterial extracts (300pl) were incubated with 10pl 
of a 50% slurry of glutathione agarose beads for 1 hr at 4'C. The beads were washed 
three times in 1ml cold PBS(A), boiled with boiling mix and samples were loaded on 
12.5% polyacrylamide gels. The bands in each track showing beads-bound fusion 
protein are indicated by the labels at the sides of each photograph, except in the cases 
of GEXR5.GEXE35 and GEXE52D14 where they are marked - • Degradation products 
are most evident in these latter tracks. The ‘c1 tracks show beads-bound GST protein in 
a control experiment. 'MW1 indicates molecular weight marker proteins whose sizes are 
shown.
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3A4 Optimisation of the GST 'pull-down' assay
The extent to which two proteins interact with each other within a cell depends upon the 
microenvironment in which the interaction occurs. Two important factors are the local 
ionic concentration and the pH. A classic example is the transient increase of intracellular 
Ca2+ seen in skeletal muscle cells of vertebrates which leads to actin and myosin 
filaments sliding over one another with subsequent contraction of the cell (Katz, 1966). 
Another is shown in the change in pH inside a macrophage endocytotic vesicle following 
binding of low density lipoprotein (LDL) to the receptor presented on the plasma 
membrane: the change in pH inside the vesicle causes the LDL to dissociate from the 
receptor which is then recycled to the plasma membrane (Brown and Goldstein, 1986). 
Optimisation of the 'pull-down' assay involved varying the ionic concentration of the 
wash buffers used in the stage prior to elution of the fusion proteins from the beads with 
reduced glutathione (Figure 3A1, step (iii)). At all other stages the ionic strength was 
low.
In an initial investigative experiment, beads-bound fusion proteins were mixed with
.
radiolabelled BHK cell extracts (Section 2B2.2) and washed three times in one of the 
buffers A, B or C (see Figure 3A4(i)). The beads were boiled with gel loading buffer and 
samples were analysed by SDS PAGE. A large number of proteins remained bound to 
the GEXE52 and control (GST) beads with the use of wash A which contained 0 .1M 
NaCl, making differences between the tracks difficult to discern. Wash B, which 
contained 0.5M NaCl, was more stringent and differences between the GEXE52 and 
control tracks were easier to see; there is one high molecular weight band of 
approximately 135kD (denoted •) in the GEXE52 track which is not present in the control 
track and also two lower molecular weight bands (denoted ° ). In this experiment, the 
latter two bands were also present in the control track of GST beads washed in wash C, 
containing LiCl. The 135kD band was also visible in the wash A E52 track but it was 
more difficult to see due to the high background.
As the high molecular weight protein consistently remained bound to the E52 beads 
in a 0.5M NaCl wash, the assay was further modified such that beads were mixed with 
radiolabelled cellular proteins in a 0.5M NaCl buffer. The presence of bands in the 
control tracks indicated that cellular proteins bound to either the glutathione agarose 
beads, the GST protein or both and so extracts were 'pre-cleared' of these proteins prior to 
incubation with GEXE52 beads by incubation with the GST beads. To be sure that the 
proteins seen in the experiments were interacting with the GST fusion proteins, 
complexes were eluted from the glutathione agarose beads by competition with reduced 
glutathione. Under these conditions (the standard GST 'pull-down assay, Section 2B3.4) 
two high molecular weight proteins bound more strongly to the GEXE52 beads and were 
still not present in the control tracks; the additional protein seen compared to that seen in 
the experiment of Figure 3A4(i) was estimated to be approximately 150kD.
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approx 
42kD *
Total
extract Wash A 
E52 c
Wash B 
E52 c
Wash C 
E52 c
Wash A 
50mM Tris pH8 
lOOmM NaCl 
ImMEDTA 
0.5% NP40
Wash B 
50mM Tris pH8 
0.5M NaCl 
lmM EDTA 
0.5% NP40
Wash C 
0.6M LiCl 
0.1M Tris pH8 
0.1% BME
Each buffer also contained protease inhibitors; 
lmM PMSF, 0.5jig/ml leupeptin, 40jig/ml bestatin
Figure 3A4fi) Investigative GST 'pull-down' assay. Aliquots (20pl) of a 50% slurry of 
control GST beads and GEXE52 beads were added to 300pl quantities of 35S- 
radiolabelled BHK cell extracts (Section 2B2.2) and incubated for 1hr at 4*C. Beads 
were then spun down and washed three times for 5min in 1ml of one of the three wash 
buffers. Boiling mix was then added and the samples loaded on a 12.5% polyacrylamide 
gel which was dried down and exposed to film following electrophoresis. A 1pl sample of 
the 35S-radiolabelled BHK cell extract was run in the far left-hand track. The tracks 
marked 'E52' show proteins bound to the GST beads and those marked c proteins 
bound to the GST beads. • denotes the high molecular weight band discussed in the
text and <> the two lower molecular weight bands.
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Figure 3A4(ii) shows the results of a typical 'pull-down' experiment carried out with 
the GEXE52 and GEXE58 fusion proteins using the standard assay conditions. The 
background in these two sets of tracks is high, indicating that these fusion proteins are 
very 'sticky'. It was found that the background in these experiments varied widely, 
although experiments carried out within the same 2-4 week period were generally found 
to show similar background proteins. The increased number of differences seen in 
experiments carried out a few months apart may be a reflection of the different batches of 
cells used to make the radiolabelled extracts. A close examination of the experiment in 
Figure 3A4(ii) shows that many of the background bands are present in the control (c) 
tracks, albeit more faintly. The major band in the control tracks is likely to be 
mammalian GST which is the same size as the helminth protein. This band was present 
only in 'pull-down' experiments where proteins were analysed on 12.5% acrylamide gels 
and was absent in those analysed on gels of a lower percentage.
'Pull-down' experiments with the GEXE52 fusion protein showed that the binding 
of the two high molecular weight proteins seen in initial experiments was completely 
reproducible. Other bands were also seen (examples marked •) and the interactions of 
these proteins with VmwllO may be significant. However, they were not pursued 
further, either because they were present inconsistently or because they were very faint 
and an alteration in the assay conditions would probably have been necessary in assisting 
further investigation.
Of the two high molecular weight bands pulled down by GEXE52, the lower of the 
two, the 135kD band, is missing in the GEXE58 track. This shows that residues 594-633 
of Vmwl 10 are essential for the interaction with this protein in this system. The details 
of 135kD interaction with VmwllO residues expressed as GST fusion proteins were 
invesigated further and are fully discussed in Section 3A6.
The sizes of radiolabelled cellular proteins pulled down by the GST fusion proteins 
in these experiments were determined by comparing them with characteristic proteins in 
the extract tracks (marked 'ex'). The sizes of these proteins were determined by 
comparing their migration positions on a gel with those of known standards: an example 
of this analysis is shown in Figure 3A4(iii).
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^ “ 135kD
Figure 3A4(ii) GST 'pull-down' assay performed under standard assay conditions. 
Positions of size standards indicated under 'MW' were ascertained as described in 
Figure 3A4(iii), following the sizing of predominant bands in the 'ex' track in which a 
sample of the 35S-radiolabelled BHK cell extract was run. In each set of tracks, 1,2 
show proteins eluted from the relevant beads (c (GST), GEXE52, GEXE58) in two 
successive steps with reduced glutathione. The 'B' tracks indicate proteins remaining on 
the beads following elution. Two proteins consistently pulled down by the GEXE52 
beads are marked as 150kD and 135kD protein bands. Bands marked ■ in the E52 
track show those which may also be significant but because of their relative low 
abundance, or the fact that they were present inconsistently, they were not analysed 
further. The strong low molecular weight band present in the 'c* tracks and to an extent 
in the E52 and E58 tracks is likely to be BHK cell GST enzyme which is approximately 
the same size as Schistosoma japonicum GST.
109
Chapter 3 Results
135kD
Figure 3A4(iih Size determination of the 135kD protein. The three panels shown are all 
of 7.5% polyacrylamide gels. The left-hand panel shows a Coomassie stained gel which 
was dried down and exposed to Kodak X-OMAT S film to give the centre panel; track 1 
shows molecular weight standards where sizes are marked and track 2 a sample of 35S- 
methionine radiolabelled WS HeLa cell proteins. Track 3 is an autoradiograph of track 2 
* the most abundant proteins were visible in both tracks which enabled a direct 
comparison of track 3 with track 1. The right-hand panel shows a standard GST 'pull­
down' assay; radiolabelled cell extract was run as a standard in track 4, proteins eluted 
from GST beads in track 5 and proteins eluted from GEXE52 beads in track 6. The 
position of the 135kD protein is marked. This protein was found to consistently co- 
migrate with a faint group of bands marked ■ which was below a characteristic band 
marked - in the WS HeLa cell extracts. A plot of logMW of the standard proteins 
against distance migrated shows the 135kD protein to migrate at approximately 130kD. 
The protein was more accurately sized by comparison with the migration position of ICP6 
(HSV-1 large subunit of ribonucleotide reductase); ICP6 has a molecular weight of 
136kD and the 135kD cellular protein migrates just below it on polyacrylamide gels.
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3 A5 An investigation of the GEXE52-135kD protein iprotein interaction in a number 
of different cell types
In the previous Section, strong and specific protein iprotein interactions were observed 
between GEXE52 and two BHK cell proteins, of molecular weights 150kD and 135kD. 
As interactions between Vmwl 10 and cellular proteins are potentially important for the 
biology of the virus (Section ID 12), the standard 'pull-down' assay was carried out using 
a number of different radiolabelled cell extracts with particular reference to looking at 
human cell lines. Three cell lines derived from tissues of the natural virus host were 
investigated: WS HeLa (a squamous epithelial line), HFL (human foetal lung, a 
fibroblastic line) and U-2 OS (an osteosarcoma line).
The results are shown in Parts A and B of Figure 3A5. A 135kD protein was pulled 
down from all cell types investgated whilst a 150kD protein was present only in the BHK 
and HFL cell extracts. The significance of the apparent presence of the 150kD protein in 
only a subset of cell types is not known. The U-2 OS cell line was investigated because it 
has been shown that a Vmwl 10 deletion mutant virus plaques as efficiently as wild-type 
virus on these cells (Yao and Schaffer, 1995). The 150kD protein was not detected in this 
cell type, and the results showed that there is not significantly more or less 135kD protein 
pulled down by GEXE52 from this cell type compared with others. It could be argued 
that the GEXE52 beads were saturated with the 135kD protein and were therefore unable 
to bind more. However, an investigative experiment during the purification of this 
protein from WS HeLa cell extracts showed that the amounts of 135kD protein pulled 
down were limited by the amount of the 135kD protein present in cell extracts rather than 
by the amount of GEXE52 protein mixed with cell extracts (Section 3C3).
The ND7 cell line was also investigated (Figure 3A5.C). This is a neuronal line 
originally obtained by the fusion of neuroblastoma cells with primary rat sensory neurons 
(Wood et a l, 1990). Experiments were carried out with this line in order to ascertain 
whether or not the 150kD and 135kD proteins were present in both undifferentiated and 
differentiated cell extracts. It was thought that the absence or presence of either of these 
two proteins in differentiated cell extracts compared with undifferentiated cell extracts 
may shed some light on the mechanism by which Vmwl 10 acts during the lytic-latent 
switch in the life cycle of HSV-1. However, the results showed that, as with the WS 
HeLa and U-2 OS cell extracts, the 150kD protein was not present in either cell extract 
and also that the 135kD protein was present in similar amounts in both types of ND7 cell 
extract.
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Figure 3 A 5 GST 'pull-down' experiments with GEXE52 and 35S-methionine radiolabelled 
extracts derived from a number of different cell types. These experiments show the 
results of standard GST 'pull-down' assays (Section 2B3.4) using the cell extract 
indicated above each experiment. The 'ex' tracks show radiolabelled whole cell protein 
samples, in A from BHK cells, B from WS HeLa and U-20S cells and in C from an 
undifferentiated ND7 cell extract. The 'c* tracks show proteins eluted from GST beads 
w'th reduced glutathione and 1,2 proteins eluted from GEXE52 beads in two successive
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steps. Panels A and C show 12.5% polyacrylamide gels and B shows a 7.5% gel. All 
cell extracts were made following a 2hr label with 35S-methionine (Section 2B2.2) except 
for differentiated ND7 cell extracts which were made following an overnight labelling of 
cells in a low methionine medium. A control extract was made from undifferentiated cells 
which were also labelled overnight. The positions of the 150kD and 135kD proteins are 
marked and it is evident that a 150kD protein is pulled down only from BHK and HFL cell 
extracts under these conditions.
It is possible that the experiments with the ND7 cell line are not a true reflection of 
the in vivo situation. Approximately 20% of the cells remained undifferentiated 
following seeding of cells in the differentiation medium (Section 2B2.1) and it is 
therefore possible that the 135kD protein pulled down from this cell extract is contributed 
by undifferentiated cells. Additionally, as differentiated cells have a low metabolic rate, 
compared with other cell types, they were labelled overnight in a low methionine medium 
which was foreign to them (Section 2B2.2). As a result, many cells showed an altered 
morphology and may have been expressing uncharacteristic proteins. A conclusive way 
of investigating the presence or absence of the 135kD protein in neuronal cells would be 
by immunostaining with a suitable anti-135kD antibody.
As the interaction of GEXE52 with the 135kD protein was widespread amongst the 
cell types tested, this cellular protein was investigated further. In an investigation of the 
Vmwl 10 residues involved in the interaction, BHK and WS HeLa cell extracts were used 
interchangeably (Section 3A6). In attempts to isolate the 135kD protein in sufficient 
quantities to obtain microsequence information, WS HeLa cell extracts were used because 
this cell line was derived from tissue of the natural host and it was also the most 
convenient human line to grow. In addition, it was found that in general the 135kD band 
was most intense in this cell type. This may have been because the protein was more 
abundant in this cell type, because the WS HeLa cell 135kD protein contained more 
methionine residues than that of other cell types, or because the interaction was stronger 
with the human protein.
3A6 An investigation of the ability of the various GST fusion proteins to bind the 
135kD protein
Having established the existence of a strong and specific interaction between GEXE52 
and a 135kD cellular protein, standard GST 'pull-down' assays were carried out with all of 
the GST fusion proteins (Section 2A2) to investigate which residues of the C-terminal 
domain of Vmwl 10 were necessary for the interaction. The results are shown in Figure 
3A6. Radiolabelled BHK cell extracts were used for the experiments in A, B and C and 
radiolabelled WS HeLa cell extracts for the experiments in D, E and F. G summarises the 
results shown in A-F.
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It is evident from the results shown in A that GEXE58 did not interact with the 
135kD protein, which indicated that residues 594-633 of Vmwl 10 were necessary for the 
interaction in this system. As expected, the smaller fusion proteins, GEXE35 and 
GEXR5, which were also missing Vmwl 10 residues 594-633, did not interact with the 
135kD protein (Panel C). GEXE52D14 was found to bind weakly but reproducibly to the 
135kD protein (Panel B). The most likely explanation for this is that the deleted residues 
contribute to an altered conformation of the domain rather than that the deleted residues, 
670-720, are required for binding.
Part D shows that the GEXE52 truncation mutant GEXE52SalI bound the 135kD 
protein as did the insertion mutant GEXE52E2 whilst GEXE52E35 did not. The strong 
bands visible just below the 135kD bands in these gels were peculiar only to this 
experiment and are another example of the variabilty in background which was seen in 
the 'pull-down' experiments. It is possible that the band represents a 135kD break-down 
product.
The result with the GEXE52E35 mutant was surprising in view of the fact that the 
truncation mutant GEXE52AvaI bound the 135kD protein (Panel E). This indicated that 
Vmwl 10 residues 594-646 were sufficient for the interaction, yet the four amino acid 
insertion in GEXE52E35 was at residue 696. It is possible that an insertion mutation can 
alter the conformation of a domain in such a way as to render it non-functional whilst 
deletions in a similar region do not adversely affect its folding. Similarly, the insertion at 
647 in GEXE52A8 (Panel E) also reduced 135kD binding. As expected from the 
GEXE52AvaI result, the truncation mutants GEXE52PmlI and GEXE52RsaI (Panel F) 
also interacted with the 135kD protein.
Panel G summarises these results. It can be concluded that Vmw 110 residues 594- 
633 are essential for the interaction with thel35kD protein and that residues 594-646 are 
sufficient.
Although the interaction with the 150kD protein was not investigated in detail, it 
was concluded from the experiments shown in Panel A that Vmwl 10 residues 633-680 
were necessary for this interaction because GEXE58 bound the 150kD protein but 
GEXR5 did not.
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Figure 3A6 GST 'pull-down1 experiments investigating Vmwl 10 residues involved in 
binding the 135kD protein. Panels A-F show 'pull-down1 experiments carried out using 
the standard assay conditions (Section 2B3.4) with the GST fusion proteins used 
indicated above each set of tracks. The 'c' tracks show control experiments with GST 
beads. Panel G summarises the results. In A, B and C, 35S-methionine radiolabelled 
BHK cell extracts were used and in D, E and F, radiolabelled WS HeLa extracts. Panels 
A-D show 12.5% polyacrylamide gels and E and F 7.5% gels. The ex tracks show 
samples of radiolabelled cellular proteins, tracks labelled 1,2, show proteins eluted from 
the relevant GEX beads with reduced glutathione in two successive steps and b tracks 
show proteins remaining on the beads following elution. The positions of the 150kD and 
135kD proteins are shown where relevant.
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3A7 An investigation of the half-life of the 135kD protein in cells
An ada.pta.tion of the standard GST pull-down' assay enabled an investigation of the 
stability of the 135kD protein in tissue culture cells. Following the standard 2 hour 
labelling procedure with 35S-methionine, WS HeLa cells were either harvested as usual or 
the label mix was replaced with normal growth medium and the cell extracts made 5 or 12 
hours later (Section 2B2.2). 'Pull-down' experiments were carried out using the GEXE52 
fusion protein. The results show that similar amounts of radiolabelled 135kD protein 
were pulled down from extracts harvested immediately or 5 or 12 hours after labelling 
(Figure 3A7).
The interpretation of these results depends on the intracellular pool size of 
methionine and the capacity of the GEXE52 beads for the 135kD protein. The conditions 
used for this experiment were those of a standard pulse-chase experiment to label viral 
polypeptides, where it is commonly observed that further incorporation of radiolabelled 
methionine into viral proteins is halted by its removal from the medium and its 
replacement by unlabelled methionine. This implies that the intracellular pool size of 
35S-methionine is small and rapidly turned over; if this was not the case, the radiolabelled 
135kD band would have been more intense at the 5hr time point than it actually is. It 
could be argued that an increased level of 135kD binding was not seen at the 5hr time 
point because the GEXE52 beads were saturated with 135kD protein at the level seen at 
the zero time point. This is unlikely to have been the case as the experiment shown in 
Figure 3C3 indicated that the GEXE52 beads used in the 'pull-down' experiments bound 
most of the 135kD protein present in cell extracts. Therefore, the persistence of 
radiolabelled 135kD protein with little or no indication of its depletion showed that a 
small proportion of the total amount of 135kD protein present in the cell was labelled 
during the pulse and that the 135kD protein was stable, having a half-life of at least 12 
hours.
The significance of this observation can only be speculated at. Proteins with a short 
half-life are often those with key regulatory roles in the cell and whose intracellular 
concentrations are regulated by changes in their rates of synthesis, for example, some of 
the proteins involved in cell cycle control (Amon et al., 1993). It is possible therefore 
that the interaction between Vmwl 10 and the 135kD protein is long lasting relative to 
tnany other proteinrprotein interactions in the cell (hours rather than minutes) and that 
Vmwl 10 exerts its effects during virus infection in a complex with this cellular protein.
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Figure 3A7 Investigation of the half life of the 135kD protein. WS HeLa cells were 
labelled for 2hr with 35S-methionine (Section 2B2.2) and harvested immediately for 
extract preparation (t=0) or the label medium was replaced with normal growth medium 
and the cells harvested after 5 or 12hr. Standard 'pull-down' assays were carried out 
using GEXE52 beads. The 'ex' track shows radiolabelled whole cell proteins from the 
t=0 extract. The 'c' tracks show proteins eluted from GST beads with reduced 
glutathione in control experiments and tracks labelled 1,2, show proteins eluted from 
GST beads in successive elution steps.
3A8 An investigation of the cellular location of the 135kD protein
In a crude investigation of the location of the 135kD protein in the cell, 'pull-down' 
experiments using the GEXE52 fusion protein were carried out with labelled nuclear and 
cytoplasmic WS HeLa cell extracts. These extracts were prepared using the method of 
Dignam etal. (1983) (Section 2B2.2).
The results show that the 135kD protein was present in both cell fractions (Figure 
3A8). A s the experiment was performed using using nuclear and cytoplasmic extracts 
from the same number of cells, it can be concluded that there is more 135kD protein in 
the cytoplasm than in the nucleus. The reason for this and its significance is unknown, 
hut the quantities of the 135kD protein present in this extract appear to be far too large to 
be explained by leakage from nuclei during extract preparation. It would, however, have 
been of value to test the extracts for characteristic nuclear and cytoplasmic proteins.
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Figure 3A8 A GST 'pull-down' experiment using radiolabelled nuclear and cytoplasmic 
cell extracts. The extracts used in this experiment were prepared by the method of 
Dignam et al. (1983) (Section 2B2.2). Standard GST 'pull-down' assays were carried out 
using the GEXE52 fusion protein. The 'ex' tracks show samples of the relevant 
radiolabelled cellular proteins, tracks labelled 1,2, show proteins eluted from GEXE52 
beads with reduced glutathione in two successive steps and 'b' tracks show proteins 
remaining on the beads after elution. The position of the 135kD protein is indicated.
3A9 The interaction of a 135kD protein with intact VmwllO
As with any experiment involving the use of isolated protein domains, it was important to 
provide evidence that the behaviour of the C-terminal domain of Vmwl 10 in the GST 
pull-down' assays was representative of its behavior in the intact protein.. It was possible 
that the interactions seen between some of the VmwllO-GST fusion proteins and the 
135kD cellular protein were a property peculiar to the fusion proteins and that Vmwl 10 
residues did not behave as they do in the intact protein. Experiments carried out by other 
members of the group showed that a 135kD protein was co-immune precipitated from 
HSV-1 infected cell extracts using the anti-VmwllO monoclonal antibody 11060 
(Meredith et al., 1994). The result was similar when purified Vmwl 10 (Everett et al., 
1991b) was added exogenously to cell extracts.
A collaborative depletion binding experiment was carried out to investigate whether 
0r not the 135kD protein pulled down by GEXE52 was the same as that co-immune 
Precipitated with exogenously added Vmwl 10. Following a pull-down experiment with 
GEXE52 beads, purified Vmwl 10 protein was added to the 135kD protein-depleted cell 
extract and immune-precipitated with MAb 11060. The amounts of 135kD protein co- 
Immune precipitated were much less than in a control experiment (compare lanes 4 and 5
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of Figure 3A9). The experiment was repeated in the reverse order with the same result 
(compare lanes 9 and 10 of Figure 3A9). These experiments indicated that the 135kD 
proteins observed in the two experimental systems were likely to be the same. This could 
be conclusively shown in a Western blot with an anti-135kD antibody but unfortunately, 
such an antibody was not available.
Confirmation of the necessity for Vmwl 10 residues 594-633 (Section 3A6) in the 
interaction with the 135kD protein was also obtained. A deletion mutant virus, D12, 
lacking these residues, was made by another member of the group and it was found that a 
135kD protein was not detectably co-immune precipitated with Vmwl 10 from virus D12- 
infected radiolabelled cell extracts. A 135kD protein was precipitated in a control 
experiment using the wild-type virus, 17+ (Meredith et al., 1995). This experiment used 
a genetic approach to support the conclusion that the 135kD proteins which bind to intact 
Vmwl 10 and its isolated C-terminal domain are likely to be the same. In view of the 
potential importance of Vmwl 10 interactions with cellular proteins in the life cycle of the 
virus, particularly with reference to the lytic-latent switch, these results provided grounds 
for further investigation of the 135kD protein.
Interestingly, the 150kD protein from BHK c e l l s  was not detected in immune 
precipitates with Vmw 110 either from infected ce l l  extracts or when V m w l  10 was added 
exogenously. This suggests either that the interaction with the 150kD protein seen in the 
GST 'pull-down' assays was artifactual or that binding conditions in the immune 
precipitation experiments were unsuitable or insufficiently sensitive for the interaction to 
be detected.
1 2 3 4 5 6 7 8 9  10
135kD
Figure 3AQ Reciprocal depletion experiment. Tracks 1-5: a radiolabelled BHK cell 
extract was made (Section 2B2.2) and precleared with GST beads. To one half of this 
extract, purified Vmwl 10 was added and immune precipitated with monoclonal antibody 
11060. A 'pull-down' experiment with GEXE52 beads was carried out with the other half, 
followed by an immune precipitation with added Vmw110 using monoclonal antibody 
11060. Track 1 shows a sample of radiolabelled BHK cell proteins. Track 2 shows
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proteins eluted from GST beads with reduced glutathione. Track 3 shows proteins 
eluted from GEXE52 beads. Track 4 shows proteins co-immune precipitated with 
exogenously added Vmwl 10 following extract 'preclearing' with GST beads. Track 5 
shows proteins co-immune precipitated with exogenously added Vmw110 from an 
extract precleared with GST and GEXE52 beads. Tracks 6-10: reciprocal experiment to 
that shown in tracks 1-5. A radiolabelled BHK cell dounce soluble extract was made 
(Meredith et a/., 1994) and split into two. A standard GST 'pull-down' assay was carried 
out with one sample, using GEXE52 beads. Vmw110 was added to the other sample 
and immune precipitated with monoclonal antibody 11060 before addition of GEXE52 
beads for a 'pull-down' assay. Track 6 shows a sample of radiolabelled dounce 
extracted proteins. Track 7 shows proteins eluted from GST beads with reduced 
glutathione. Track 8 shows proteins eluted from GEXE52 beads. Track 9 shows 
proteins eluted from GEXE52 beads following an immune-precipitation with added 
Vmw110 and 11060. Track 10 shows proteins co-immune precipitated from a dounce 
soluble extract with Vmw110 using 11060. The radiolabelled BHK cell and BHK dounce 
soluble extracts were made in different buffers so it was necessary to alter the NaCI 
concentration of extracts as the experiment proceeded. The position of the 135kD 
protein is marked.
3A10 Discussion
The results in this Section show that Vmwl 10 strongly and specifically interacts with a 
135kD cellular protein via residues in its C-terminal portion: intact Vmwl 10 co-immune 
precipitates with a 135kD protein from both BHK and WS HeLa cell extracts (Meredith 
et al., 1994) and GEXE52 binds a protein of identical size which is likely to be the same. 
The Vmwl 10 residues involved in this interaction are between 594-775 and residues 594- 
646 are sufficient. The GEXE52 protein interacted with a 135kD protein in all cell types 
tested which is perhaps surprising considering the cell lines were not all derived from the 
same species. Characterisation of these 135kD proteins, in the first instance with a 
suitable panel of anti-135kD antibodies and then by comparison of their encoding DNA 
sequences, would clarify whether or not any structural similarities existed. In WS HeLa 
cells, the protein was shown to have a half-life of at least 12 hours and to be present in 
both the nucleus and cytoplasm. The significance of these observations is unknown but 
could possibly be elucidated if the encoding DNA sequence was found to be similar to
that of a well characterised protein.
The GEXE52 protein also interacted with a 150kD protein from BHK and HFL cell 
extracts. From the data shown, it was concluded that Vmwl 10 residues 633-680 were 
necessary for this interaction. Time constraints did not allow as extensive an 
investigation of this protein as the 135kD protein, but it is possible that its interaction 
with C-terminal residues of Vmwl 10 is significant. It could be speculated that it is a
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precursor of the 135kD protein and that the metabolic peculiarities of some cell types 
allow its accumulation.
It is likely that other cellular proteins interact with Vmwl 10. For example, the two 
bands marked ■ in Figure 3A4(ii) were present in a number of experiments although their 
intensities varied. These proteins may have been present in lower amounts than either the 
135kD or 150kD proteins, or their interactions with Vmwl 10 may have been transient. 
Specific interactions with very low amounts of protein would have been obscured by the 
high background. A study of some of these proteins may be amenable by altering the 
conditions of the GST 'pull-down' assay. An alteration of immune-precipitation 
conditions might also uncover further interactions and, at least in principle, the use of an 
antibody other than 11060 might reveal a protein which interacts with residues close to 
the 11060 epitope. Use of the yeast Two-Hybrid System would be an efficient way of 
detecting proteins which interact transiently with Vmwl 10 (Fields and Song, 1989).
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3B Expression of C-terminal residues of VmwllO from a T7 vector and a physical 
analysis of their nature 
3B1 Introduction
The aim of the experiments in this section was to analyse the physical nature of the C- 
terminal domain of Vmwl 10. Intact Vmwl 10 has been shown to exist as a multimer in 
solution (Everett et al., 1991b; Chen et al., 1992) and a multimerisation domain has been 
mapped to the C-terminal end of the protein (Ciufo et al., 1994) (Section ID 11). The 
domain was mapped in a series of experiments to residues 617-711: the experiments 
involved immuneprecipitation and cross-linking of in vitro translated domains of 
VmwllO as well as far-Western blotting. As this region overlapped residues 594-633 
which were found to be involved in binding the 135kD protein (Section 3A6), it was of 
interest to determine whether or not the residues responsible for these two properties of 
VmwllO were the same. The ability of the C-terminal domain of VmwllO to 
multimerise was investigated by the more direct and traditional biochemical methods of 
gel filtration chromatography and glycerol gradient centrifugation using purified proteins 
expressed from a T7 vector.
The VmwllO sequences from pGEXE52 (residues 594-775) and pGEXE58 
(residues 633-775) were cloned into T7 expression vectors and the expressed proteins 
were purified by ion exchange chromatography. Gel filtration chromatography and 
glycerol gradient centrifugation showed that the T7E52 and T7E58 proteins existed in 
multimeric form. In an attempt to resolve the nature of the multimers, glutaraldehyde 
cross-linking experiments were also carried out.
3B2 Construction of pT7E52 and pT7E58
The T7 expression vectors were originally made by cloning fragments of T7 DNA into 
the unique BamHI site of pBR322 (Studier et al., 1990). The T7 fragments were the gene 
010 promoter plus the slO translation initiation region for the gene 10 protein and the T0 
transcription termination signal. Linker sequences, giving rise to a number of different 
vectors, were inserted between the slO translation initiation region and the T 0 terminaton 
signal. Plasmid p585T7a was derived from pET8c via an intermediate, p585.4 (Section 
2A1), such that the pUC19 MCR was inserted between the T7 slO initiation and T0 
termination signals. Plasmid p585T7b is similar to p585T7a except a frameshift has been 
introduced prior to the MCR.
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Figure 3B2 Construction of pT7E52 and pT7E58. Panel A shows pT7E52 from which 
the T7E52 protein was expressed. Restriction enzyme sites relevent to the cloning are 
shown (see text) as well as others present in p585T7a (Figure 2A1(iv)). The T7 
promoter region encodes the transcriptional initiation signal of the T7 gene <P10 promoter 
and the gene s10 translation initiation signal. Transcription is terminated by the 
downstream T7 terminator sequences and translation is terminated by the normal 
Vmw110 stop codon. The E52 coding sequence in T7E52 is preceeded by five vector- 
encoded residues, MARIR. Panel B shows the structure of pT7E58 from the T7 
promoter sequence to the Kpnl site; the remainder of the plasmid is as for pT7E52. 
Again, the E58 coding sequence in T7E58 is preceded by five vector-coded residues, 
MARIR.
Plasmid pT7E52 was constructed by ligating the Ncol-Kpnl fragment of pGEXE52 
to the Ncol-Kpnl fragment of p585T7a (Figure 3B2(A)). Initiation for transcription is 
from the gene 010 promoter and the termination signal is encoded by the T0 termination 
sequence. Translation is initiated from the gene slO translation initiation region and 
terminated by Vmwl 10 sequences. The expressed protein, T7E52, consists of Vmwl 10 
residues 594 to 775 preceded by five vector-encoded amino acids, MARIR.
Plasmid pT7E58 is similar in structure to pT7E52 in that the transcription and 
translation initiation and termination signals are the same. The plasmid was constructed 
in a three fragment ligation reaction: EcoRI-Kpnl of p585T7b2, EcoRI-Sall of pll0E58 
and KpnI-Sall of pGEXE52 (Figure 3B2(B)). The expressed protein, T7E58, consists of 
Vmwl 10 residues 633-775 preceded by five amino acids, MARIR.
3B3 Expression and purification of T7E52 and T7E58
Plasmids pT7E52 and pT7E58 were transformed into the E.coli strain BL21(DE3)pLysS 
(Section 2B1.7). Cultures were grown and protein expression induced from the T7 
promoter by addition of IPTG, then soluble protein extracts were prepared from bacterial 
lysates (Section 2B4.1). Extracts were subjected to ion exchange chromatography to 
purify the T7E52 and T7E58 proteins. The initial column matrix was chosen on the basis 
of the predicted charge of the expressed proteins, so that the expressed proteins would not 
bind to the column. The T7E52 and T7E58 proteins flowed through these columns and 
were purified away from a large number of bacterial proteins which were eluted on a 
NaCl gradient. Pooled flow-through fractions from the first column were taken and 
loaded onto a column of opposite charge and the T7 expressed proteins were eluted from 
the column on a 0.05-1.0M NaCl gradient (Section 2B4.2).
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Figure 3B3 Purification of T7E52 and T7E58 proteins. (A) T7E52: a 2ml bacterial 
extract containing T7E52 was subjected to anion exchange chromatography on a 20ml 
Mono-Q column and pooled flow-through fractions (6ml total volume) loaded on a 20ml 
Mono-S column (Section 2B4.2). Fractions (2ml) were collected and 10pl samples were 
analysed by SDS PAGE on a 12.5% tricine gel - tracks 1-10. Standard molecular weight 
proteins, MW, whose sizes are marked were run. An 'input' sample, 5pl of pooled flow 
through fractions from the Mono-Q column, was also run. The position of T7E52 in 
tracks 8 and 9 is marked. (B) T7E58: bacterial extract (0.5ml) containing protein T7E58 
was subjected to cation exchange chromatography on a 1 ml Mono-S column and pooled 
flow-through fractions (6ml) were loaded on a 1 ml Mono-Q column (Section 2B4.2). 
Fractions (2ml) were collected and 10pl samples analysed by SDS PAGE on a 12.5% 
tricine gel. Samples in tracks 1 -3 were the first three collected and show proteins which 
did not bind to theMono*Q column. The position of T7E58 in these fractions is shown. 
MW' indicates a track with molecular weight markers and the 'input' track contains a 
sample of the pooled flow-through fractions from the Mono-S column.
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Based on its amino acid composition, T7E52 was predicted to be positively charged. 
Bacterial extracts containing this protein were subjected to anion exchange 
chromatography on a Mono-Q column and pooled flow-through fractions containing 
T7E52 (as indicated by SDS PAGE analysis) were loaded on a Mono-S column for cation 
exchange chromatography. The T7E52 protein bound to this column and was separated 
from bacterial proteins on a 0.05-1.0M NaCl gradient. Analysis of samples of fractions 
by SDS PAGE indicated those which contained the purified protein which was of the 
predicted size at approximately 20kD (tracks 8 and 9 of Figure 3B3(A)).
Protein T7E58 had a predicted overall negative charge on the basis of its amino acid 
composition and so the purification procedure for T7E52 was carried out in reverse: the 
bacterial extract was loaded onto a Mono-S column and pooled flow-through fractions 
subjected to anion exchange chromatography on a Mono-Q column. Surprisingly, T7E58 
did not bind to the Mono-Q column at the input ionic strength and pH chosen. Tracks 1-3 
of Figure 3B3(B)) show samples of flow-through fractions: the size of the major band in 
these tracks at 16kD is that predicted for T7E58. The T7E58 protein in track 1, having 
had the majority of bacterial proteins removed, was considered to be sufficiently purified 
for analysis of its physical nature.
3B4 Gel filtration chromatography of T7E52 and T7E58
Purified T7E52 and T7E58 protein samples were analysed by gel filtration 
chromatography on a Superdex 75 column in order to determine their molecular sizes 
(Figure 3B4). These were calculated by comparing the T7E52 and T7E58 elution 
volumes with those of the size standards bovine serum albumin (BSA) and carbonic 
anhydrase (CA) which were analysed as a mixture (Figure 3B4(A)). The presence of 
particular proteins in peak fractions was determined by SDS PAGE (results not shown).
Peak 2 in Figure 3B4(A) corresponds with the exclusion volume of the column and 
contains the dimer of BSA (MW 132kD). Peak 3 at 9.66ml and peak 4 at 11.90ml 
correspond to the elution volumes of BSA (MW 66kD) and CA (MW 29kD) respectively. 
T7E52 was eluted at 9.47ml (peak 2 of Figure 3B4(B)) and T7E58 at 9.84ml (peak 3 of 
Figure 3B4(C)). Peak 2 in the T7E58 analysis corresponds with the exclusion volume of 
the column and contained bacterial proteins too large to enter the beads of the column 
matrix. The sizes of the peaks in this run showed that the column was overloaded (Figure 
2 of Meredith et al., 1995 shows a better trace). Based on the elution volumes of the 
standard proteins, T7E52 and T7E58 were calculated to have apparent molecular sizes of 
70kD and 62kD respectively.
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ELgure 3B4 Gel filtration chromatography of T7E52 and T7E58 on a superdex 75 
column. Panel A shows a run with 50|Lig each of the size standards bovine serum 
albumin (66kD) and carbonic anhydrase (29kD). Peak 2 at 8.10ml corresponds to the 
void volume of the column and contains the BSA dimer. Peak 3 at 9.68ml corresponds 
to monomeric BSA and peak 4 at 11.92ml corresponds to CA. B and C show runs with 
purified T7E52 and T7E58 proteins; 300pl aliquots of purified proteins from the ion 
exchange chromatography were run. T7E52 was eluted at 9.47ml, giving a molecular 
weight of 70kD and T7E58 at 9.84ml giving a molecular weight of 62kD. These were 
much larger than the predicted monomeric molecular weights of 19.9kD and 16.0kD 
respectively.
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As the predicted molecular weights of T7E52 and T7E58 are 19.9kD and 16.0kD 
respectively (Section 3B4) it was concluded that these proteins existed as multimers in 
solution. These were likely to be of higher order than dimers but it was not possible from 
the data to to conclude whether they were tri- or tetrameric. The fact that the proteins 
were found in single, dominant peaks showed that the multimers were stable and not in an 
equilibrium between different species.
3B5 Glycerol gradient centrifugation of T7E52 and T7E58
As further confirmation of the multimeric nature of T7E52 and T7E58, purified samples 
of the proteins from the ion exchange chromatography columns were subjected to 
centrifugation on 10-30% glycerol gradients with the size standards BSA and CA 
(Section 2B4.4). Fractions were collected from the gradients and samples subjected to 
SDS PAGE analysis to determine the migration positions of the proteins (results not 
shown). The positions of T7E52 and T7E58 on the gradient were confirmed by dot blot 
analysis (Figure 3B5) with the monoclonal antibody 10503 which recognises a Vmwl 10 
epitope in the C-terminal end of the protein.
The results showed that most of the T7E52 protein was contained in fractions 9-13 
and most of the T7E58 protein was in fractions 8-14, whilst the control proteins BSA and
CA migrated between fractions 10-14 and 7-9 respectively. This confirmed the
multimeric nature of these proteins as concluded from the gel filtration analyses: 
monomeric T7E52 and T7E58, at predicted molecular weights of 19.9kD and 16.0kD, 
would have sedimented more slowly than CA of molecular weight 29.0kD. However, as 
this method was more crude than the gel filtration analyses, the precise nature of the 
multimers could not be determined accurately.
pT7 expressed and column purified E52 and E58 proteins : dot blots of glycerol gradient fractions 
Positive
control 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
T7E52
T7E58 B  a  « « • • • • • • *
< < >-
CA BSA
T7E52 - MARIR-594-(Vmw110)-775 
T7E58 - MARIR-633-(Vmw110)-775
Figure 3Bfi Glycerol gradient centrifugation of T7E52 and T7E58. Approximately 25pg 
column purified T7E52 or T7E58 were centrifuged down a 5ml 10-30% glycerol gradient
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with 20jig each of the size standards carbonic anhydrase (CA) and bovine serum 
albumin (BSA) at 40krpm for 48hr (Section 2B4.4). Fractions (200pJ) (1-23) were taken 
from the top of the gradient and samples analysed by SDS PAGE to determine the 
migration positions of CA and BSA (results not shown). Aliquots (50jil) were dot blotted 
onto nitrocellulose and T7 expressed Vmw110 sequences detected by ECL as for 
Western blotting (Section 2B3.3); the primary antibody was the monoclonal antibody 
10503. The positive controls show samples of a dilution of the gradient input aliquot.
3B6 Glutaraldehyde cross-linking of T7E52 and T7E58
In an attempt to resolve the question of the multimeric nature of T7E52 and T7E58, 
glutaraldehyde cross-linking experiments were carried out with samples of the purified 
proteins eluted from the Superdex 75 column (Section 2B4.3). Cross-linked proteins 
were analysed by SDS PAGE and detected by Coomassie staining when high 
concentrations of protein were used (approximately 250pg/ml) or by Western blotting 
following electrophoresis, using the MAb 10503 when low concentrations of protein were 
used (approximately 50pg/ml).
In Figure 2B5(A) it can be seen that T7E58 was readily cross-linked when present 
at 250pg/ml, particularly with increasing concentrations of glutaraldehyde. A control 
experiment with carbonic anhydrase (CA) present at a similar concentration was carried 
out to show that the cross-linking seen was not an artifact of high protein concentrations. 
These results were confirmed in an experiment in which smaller amounts of T7E52 and 
T7E58 (50p.g/ml) were cross-linked in the presence of increasing concentrations of 
glutaraldehyde and the products analysed by Western blotting (Panel B). The blot shows 
that both proteins readily formed multimers but that there was an absence of a dominant 
species. Consequently, this method did not resolve the question of the precise physical 
nature of T7E52 and T7E58. This will require a more sophisticated biophysical analysis, 
such as NMR spectroscopy, X-ray crystallography or light scattering analysis.
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Figure 3B6 Glutaraldehyde cross-linking of T7E52 and T7E58. Samples of T7E52 and 
T7E58 purified from the Superdex 75 column were incubated in 20pl volumes at 
250pg/ml (Panel A) or 50pg/ml (Panel B) with glutaraldehyde at 0.001 %-0.01 % (tracks 1 - 
5) for 30min at 20*C. The reactions were stopped by addition of glycine to a final 
concentration of 50mM. Panel A shows a Coomassie stained gel of an experiment 
carried out with T7E58 at the higher protein concentration. The control protein used was 
carbonic anhydrase which is a monomeric at concentrations between 50pg/ml and 
250pg/ml. The 'c' tracks in both experiments show proteins which were not cross-linked 
with glutaraldehyde. Panel B shows a Western blot of cross-linked products in a similar 
experiment to that in Panel A but with lower protein concentrations.
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3B7 Discussion
Expression and purification of the C-terminal domain of VmwllO has enabled the 
analysis of the physical nature of this domain by the methods described in Sections 3B4, 
3B5 and 3B6. All of these indicate that the T7E52 and T7E58 proteins exist as multimers 
of higher order than dimers in solution. These results clearly separate the residues that 
are essential for binding the 135kD protein (594-633) from those which are sufficient for 
multimerisation of the C-terminal domain (633-775).
The possibility of Vmwl 10 residues outside 594-633 contributing to the efficiency 
of 135kD binding or of those outside 633-775 contributing to multimerisation was not 
eliminated by the experiments described in this Thesis. It was clear, however, that the 
essential residues for these two properties of Vmwl 10 were different.
It was intriguing that the precise multimeric natures of T7E52 and T7E58 remained 
elusive. One inconsistency in the investigations was that the results from the gel filtration 
column indicated that these proteins were tri- or tetrameric whilst higher order multimers 
were apparent in the glutaraldehyde cross-linking experiments. It would have been of 
value to carry out the experiment shown in Figure 3B6(B) with a much lower 
concentration of protein to completely eliminate the possibility of artifactual cross- 
linking.
Whilst the experiments in this Section showed that T7E52 and T7E58 existed as 
multimers in solution, it remained a possibility that these isolated domains may not have 
been behaving as they do in the intact protein. However, the results of glycerol gradient 
analysis of the VmwllO proteins expressed by the E52X and D12 mutant viruses 
(residues 594-775 and 594-633 deleted respectively) indicate that this is unlikely 
(Meredith etal., 1995): Vmwl 10 protein from the wild-type and D12 viruses sedimented 
at similar rates whilst the Vmwl 10 protein from the E52X virus sedimented much more 
slowly. This showed that the fast sedimentation rate of Vmw 110 was not due primarily to 
the formation of a complex with the 135kD protein and was consistent with the idea that 
Vmwl 10 residues 594-633 are not required for multimerisation. It is possible that the 
sedimentation rates of Vmwl 10 expressed from the wild-type and from the D12 viruses 
are affected by the formation of a complex with a cellular protein which interacts with 
Vmwl 10 residues between 633-775. However, in conjunction with the data presented in 
this Thesis, it is reasonable to conclude that multimerisation is a property of the C- 
terminal domain of Vmwl 10. Additionally, the consistency between the observation that 
the Vmwl 10 protein of the D 12 virus does not co-immune precipitate the 135kD protein 
and the data from 'pull-down' assays with GEXE52 and GEXE58 proteins, lends itself to 
the assurance that the C-terminal domain of Vmwl 10 folds correctly when expressed in 
isolation.
The results of the experiments presented in this Section are also consistent with 
those of Ciufo et al. (1994) who mapped a Vmwl 10 multimerisation domain to residues
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between 617-711 with adjacent residues on either side of these contributing to the 
efficiency of multimer formation in some of their assays. It is likely that in mapping the 
domain to between residues 633-775 in the direct biochemical analyses presented here, 
the N-terminal boundary has been more clearly defined.
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3C Purification of the WS HeLa cell 135kD protein 
3C1 Introduction
In view of the potential biological significance of the interaction of VmwllO with the 
135kD protein, it became necessary to identify the cellular protein so that the interaction 
could be investigated further. The experiments in this section describe the purification of 
the 135kD protein from WS HeLa cells and subsequent microsequence analysis. The 
sequence information was used to raise antipeptide sera as well as in the design of 
redundant PCR primers for use in cloning a cDNA (Sections 3C4 and 3C5). It was 
quickly found that although the amounts of 135kD protein pulled down in a standard GST 
’pull-down' assay were visible on a Coomassie stained gel, the quantities were too low for 
microsequence analysis. The yield was increased by scaling up the 'pull-down' assay. 
Proteins were subjected to SDS PAGE and blotted to a PVDF membrane (Problott™) 
which was stained to show the position of the 135kD protein. The protein was submitted 
for sequence analysis by Dr. Matsudaira (MIT).
3C2 The 135kD protein in BHK cells is visible on a Coomassie stained protein gel
In order to obtain microsequence information from bands of protein immobilised on 
Problott™ membrane, it was necessary to blot microgram quantities from a 
polyacrylamide gel. The quantity of 135kD protein pulled down by GEXE52 beads from 
BHK cell extracts in a standard GST 'pull-down' assay was investigated by Coomassie 
staining the analytical polyacrylamide gel. The gel was vacuum dried and exposed to 
Kodak X-OMAT S film (Figure 3C2).
Careful positioning of the autoradiograph on the dried, stained gel showed that the 135kD 
protein was visible as a faintly stained band which precisely migrated with the 
radiolabelled 135kD band (compare the A tracks of Panels A and B). The protein was 
absent from all of the control tracks, 'control', 'B' and 'C'. The proteins in the tracks 
marked 'control' show those eluted from GST beads in the usual control experiment. 
Proteins in the 'B' tracks were eluted from GEXE52 beads in an experiment in which the 
beads were mixed with the BHK cell resuspension buffer instead of radiolabelled BHK 
cell proteins. These tracks show bacterial proteins which bind to the fusion protein and it 
is evident that there are no major bacterial bands in the region of the 135kD protein. This 
meant that the 135kD protein could be purified by isolation from a gel or blot as it would 
be unlikely to contain large quantities of contaminating proteins. In another control, 
proteins were eluted from glutathione agarose beads which had been mixed with 
radiolabelled proteins ('C' tracks). This ensured that the 135kD cellular protein was 
eluted from GEXE52 beads because it bound to the fusion protein and not to the beads 
themselves. The only band present in these tracks was mammalian GST.
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Figure 3C2 Visualisation of the 135kD protein from BHK cells on a Coomassie 
stained polyacrylamide gel. A standard GST 'pull-down' assay was carried out and 
proteins eluted from the beads analysed by SDS PAGE on a 12.5% polyacrylamide gel 
(Section 2B3.4). The gel was stained with Coomassie blue and destained (Panel A) and 
vacuum dried and exposed to Kodak X-OMAT S film to give the autoradiograph shown in 
Panel B. The 'ex' track shows a sample of the radiolabelled BHK cell proteins whose 
sizes are indicated. The remaining tracks which are in pairs marked 1,2 show proteins 
eluted from beads in two successive steps with reduced glutathione. Proteins eluted 
from GST beads were run in the control tracks and those eluted from GEXE52 beads in 
the A tracks. A comparison of the autoradiograph with the stained gel shows the 
presence of a faintly stained 135kD band, marked •, in the A tracks. The B tracks show 
proteins eluted from GEXE52 beads in a control experiment in which GEXE52 beads 
were mixed with BHK cell resuspension buffer; consequently these tracks are blank in 
Panel B. In the C tracks, the proteins shown are those eluted in a control experiment 
from glutathione agarose beads alone which had been mixed with a radiolabelled cellular 
©xtract. The major band present in these tracks is mammalian GST.
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As the 135kD band was stainable, it was thought that there may be enough for 
microsequence analysis. The experiment was repeated and electrophoresed proteins 
blotted onto Problott™ membrane for 3 hours (See Section 2B3.5(ii) for details of 
buffers). Both the blot and the gel were stained with Coomassie blue. It was found that 
the quantity of 135kD protein on the gel was too small for analysis and that the blotting 
procedure was inefficient, as approximately 50% of the protein remained on the gel. It 
was also advised that for eventual microsequence analysis, the blot should be stained with 
Ponceau S. This is a less sensitive stain than Coomassie blue, but the procedure does not 
interfere with microsequence analysis. As a consequence of this experiment, the blotting 
time was increased to 6 hours and investigations into increasing the yield of 135kD 
protein in the 'pull-down' experiments were made.
3C3 The limiting factor in the GEXE52-135kD interaction is the amount of 135kD 
protein present in cell extracts
Before scaling up the standard GST 'pull-down' assay for isolation of microgram 
quantities of the 135kD protein, an experiment was carried out to determine whether or 
not the limiting factor in the GEXE52-135kD protein:protein interaction was the amount 
of 135kD protein present in cell extracts (Figure 3C3). The experiment was carried out 
using a radiolabelled WS HeLa cell extract. It was previously decided to purify the 
protein from this cell type because these cells were derived from human tissue and the 
protein appeared to be most abundant in this extract (Section 3A5).
In the left hand panel of Figure 3C3, the results of a standard GST 'pull-down' assay 
are shown. As usual, the 135kD protein was eluted from GEXE52 beads but not from 
control GST beads. A second quantity of GEXE52 beads were mixed with the 135kD 
protein 'pre-cleared' extract and proteins eluted from these beads are shown in the 'A' 
tracks of the right hand panel. This result showed that incubating radiolabelled extracts 
with GEXE52 beads considerably depleted the levels of 135kD protein present. In a 
converse experiment, proteins were eluted from GEXE52 beads which had been 
incubated successively in two aliquots of radiolabelled WS HeLa cell proteins that had 
been 'pre-cleared' with GST beads ('B' tracks). In comparison with the standard assay, 
similar amounts of the 135kD protein were eluted from these beads. The conclusion 
drawn from this experiment was that the limiting factor in the GEXE52-135kD 
protein:protein interaction was the small quantity of 135kD protein present in cell 
extracts.
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Figure 3C3 An investigation of the limiting factor in the GEXE52-135kD proteinrprotein 
interaction. A standard 'pull-down' assay was carried out and proteins eluted from GST 
and GEXE52 beads loaded on a 10% polyacrylamide gel (left-hand panel). In both gels, 
the 'ex' tracks show samples of the ^5S-methionine radiolabelled cell extracts used in 
these experiments. In each group of three tracks, 1,2 show proteins eluted from beads 
in two successive steps with reduced glutathione and in the 'b* tracks, the beads were 
run. The position of the 135kD protein is indicated. The experiment under A shows 
proteins eluted from GEXE52 beads which were mixed with an extract which had been 
preincubated with GEXE52 beads as well as GST beads. The 135kD protein is present 
in smaller amounts compared to the standard assay. Proteins in the B tracks were 
eluted from GEXE52 beads which were passed through two aliquots of the WS HeLa cell 
extract. Greater amounts of the 135kD protein were present in this eluate compared with 
the standard eluate.
Based on this result, attempts were made to isolate sufficient quantities of the 
135kD protein for microsequencing by increasing the amounts of cell extract used in the 
experiments. In one experiment, an unlabelled extract was prepared from a roller bottle 
of WS HeLa cells in a final volume of 5ml. The extract was 'pre-cleared' for three hours 
with 50pl GST beads and incubated overnight, with end over end shaking, with 20pl 
GEXE52 beads. Proteins eluted from the beads were subjected to SDS PAGE and blotted 
onto Problott™ membrane and stained with Ponceau S. A 135kD band was not visible 
(results not shown) so a number of subsequent experiments were carried out in which 
small quantities of GEXE52 beads (up to 50jli1) were passed through cell extracts from up ] 
to 10 roller bottles of WS HeLa cells. These attempts were also unsuccessful and led to 
experiments in which the amounts of GEXE52 beads were also increased (Section 3C4). 
The reasons for the problems encountered in these latter experiments were unknown: it 
may have been that the GEXE52 beads were saturated with the 135kD protein at levels
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not much higher than those present in the volume of extracts used in standard 'pull-down' 
assays.
3C4 Purification of the 135kD protein in a large scale GST 'pull down1 experiment
Attempts were made to purify the 135kD protein in a number of pull-down' experiments 
of larger scale than the standard assay: up to 500jil GEXE52 beads and up to 10 roller 
bottles of WS HeLa cell extract were used (results not shown). These attempts were 
unsuccessful and an investigative experiment was carried out in which the volume of 
GEXE52 beads was increased further; 1ml 50% slurry GEXE52 beads were mixed with 
20ml WS HeLa cell extract made from 5 roller bottles of cells. The extract was 'pre- 
cleared with 1ml 50% slurry GST beads by end over end mixing for three hours and then 
incubated with the GEXE52 beads overnight. Following washing of the beads three times 
in 5ml 0.5M NaCl wash buffer, proteins were eluted from the beads twice in 0.5ml 50mM 
reduced glutathione to give a final volume of 1ml. The eluate was concentrated by 
centrifugation at 5krpm in a Centricon 50 centrifugation unit such that the volume was 
reduced to 40jnl. The sample was run on a 10% polyacrylamide gel with appropriate 
controls (Figure 3C4(i)). The results showed that the 135kD protein was efficiently 
concentrated by this method and did not break down (track 1) and that it was not present 
in any of the control tracks: track 2 shows an experiment in which the GEXE52 beads 
were incubated with the cell extract resuspension buffer and track 3 shows proteins eluted 
from GST beads. A sample of the GEXE52 bacterial protein extract was run in track 4 to 
show that there were no major bacterial bands of 135kD.
This experiment was repeated on a larger scale (Section 2B3.5): 4ml GEXE52 
beads were used to bind the 135kD protein from 60ml unlabelled WS HeLa cell extract 
made from cells grown in 25 roller bottles (Section 2B2.3). The extract was 'pre-cleared' 
with GST beads and incubated with the GEXE52 beads for 40 hours. During this period, 
proteins were eluted from 20|Ltl samples of the GEXE52 beads to ascertain that the 135kD 
protein had bound (results not shown). After washing the beads in the 0.5M NaCl wash, 
proteins were eluted from the beads in two stages with reduced glutathione and the eluate 
volume was reduced to 200(il as in the previous experiment. The sample was mixed with 
radiolabelled proteins eluted from GEXE52 beads in a standard GST 'pull-down' assay 
and subjected to SDS PAGE with appropriate control samples on a 10% polyacrylamide 
gel. The gel was run at 50V rather than the usual 100V (Section 2B3.2) to minimise band 
smearing. Electrophoresed proteins were blotted onto Problott™ membrane which was 
stained with Ponceau S which revealed a heavily stained high molecular weight band 
(Figure 3C4(ii)A). An overnight exposure of the blot to Kodak X-OMAT S film 
confirmed that this was the 135kD protein (compare panels A and B of Figure 3C4(ii)). 
The blot was sent to MIT for microsequence analysis of the 135kD protein by Dr. 
Matsudaira.
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Figure 3C4(i) An investigative GST 'pull-down' experiment for purification of the 135kD 
protein. A 1ml slurry of GST and GEXE52 beads were made by mixing 1ml glutathione 
agarose beads with 3ml of the relevent bacterial extracts for 1 hr at 4‘C. A WS HeLa cell 
extract (20ml), made from 5 roller bottles of cells, was 'pre-cleared' for 3hr with the GST 
beads and then incubated with GEXE52 beads overnught. GST and GEXE52 beads 
were washed three times in 5ml 0.5M NaCl wash buffer (Section 2A10) and proteins 
eluted in two 15min incubations with 0.5ml 50mM reduced glutathione. The elution 
volumes were concentrated to 40(il and the proteins were electrophoresed on a 10% 
polyacrylamide gel. Track 1 shows proteins eluted from the GEXE52 beads and track 3 
those from GST beads. A parallel control experiment was carried out in which GST and 
GEXE52 beads were incubated with WS HeLa cell resusupension buffer. Protein eluted 
from the GEXE52 beads were run in track 2. In track 4 a sample of the GEXE52 
bacterial extract was run. The MW track shows standard proteins whose sizes are 
indicated. The position of the 135kD protein is marked; this protein is present only in 
track 1 and not in any of the control tracks.
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Figure 3C4(in Purification of the 135kD protein. Purification of the 135kD protein was 
carried out as described in Section 2B3.5. The concentrated GEXE52 eluate was mixed 
with proteins eluted from GEXE52 beads in a standard 'pull-down' assay carried out with 
radiolabelled cell extrac and electrophoresed on a 10% polyacrylamide gel (tracks 1 and 
3). Track 2 shows proteins eluted from GEXE52 beads in a standard 'pull-down' assay. 
The heavily stained high molecular weight band in tracks 1 and 3 on the Problott 
membrane (Panel A) was ascertained as being the 135kD protein by comparison with an 
autoradiograph of the blot (Panel B).
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3C5 Peptide sequences
The 135kD protein was eluted from the Problott™ membrane and fragmented by 
digestion with Achromobacter protease, which cuts at lysine residues, prior to analysis. A 
number of fragments were sequenced and the results are shown in Figure 3C5. The 
sequences were used to screen the available database but initially no match was found 
(see Appendix).
In order to obtain a cDNA clone, it was therefore necessary to utilise the sequence 
information experimentally. Antipeptide antisera were raised for use in screening a cDNA 
expression library (Section 3B4) and redundant primers were made for cloning from 
cDNA using a PCR method (Section 3B5). Details of these approaches and the problems 
encountered are discussed in the relevant sections. In summary, it was found that short 
sequences and unknown residues within a sequence limited the usefulness of a particular 
peptide. In addition the antipeptide sera might not recognise the intact 135kD protein 
efficiently. For the PCR experiments it was necessary to use primers with minimal 
redundancy to prevent non-specific priming events so unknown residues (X) were 
problematic. This meant that peptides Glasgow 39, 40 and 23 were not very useful.
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Figure 3C5
G la s g o w  39
E P T P G N M S X P X P X L G L D X F N K
GAAC C AAC AC C AGGAAATATGTC AAAAC C AAAAC CAAAAC TTGGAC TTGATAAATTT AATAAA 
G C C C C C AGTCCC CCCC CCCCT A CT A CCCC C C G
G G G G AGCGGG GGGG GGGGT G GT G GGG
T T T T GTTT TTTT TTTT C T C TTT
G la s g o w  45
V T F E V F V Q A D A P I G V A P D Q K
GTAACATTTGAAGTATTTGTACAAGCAGATGCACCAATTGGAGTAGCACCAGATCAAAAA
C C C G C C C G C C C C C C C C C C G G
G G  G G G G G A G G G G
T T  T T T T T  T T T T
G la s g o w  52
N D R F E F P X Q L P L D E F L Q K  
AATGATCGCTTTGAATTTCCAAAACAACTTCCACTTGATGAATTTCTTCAAAAA 
C CA A C G C CCCC GT A CT A C G CT A G G
G A GGGG T G GT G T G
T TTTT C T C C
G la s g o w  5 2 / 2
I F E X F V D Y V A V E Q L D G D N K  
ATTTTTGAAAAATTTGTAGATTATGTAGCAGTAGAACAACTTGATGGAGATAATAAA 
C C GCCC C C C C C C C G  GT A C C C C G 
A GGG G G G G  T G G
TTT T T T T  C T
G la s g o w  40
A F D E L I X H L F N V K  
GCATTTGATGAACTTATTAAACATCTTTTTAATGTAAAA 
C C C GT A CCCC CT A C C C G
G A T G AGGG T G G
T C TTT C T
G la s g o w  23  
L Y Y Q Q L K
CTTTATTATCAACAACTTAAA 
T A C C G G T A G  
T G T G
C C
Figure 135kD peptide sequences. T h e  s e q u e n c e s  of the six peptides are shown 
using the single letter amino acid symbols (See Abbreviations). All potential codons for 
each amino acid are also shown, indicating the level of redundancy for design of PCR 
primers.
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3C6 Discussion
The results shown in this Section describe investigative experiments which led to the 
purification of the 135kD cellular protein that interacts with the C-terminal domain of 
Vmw 110. Amino acid sequences of peptide fragments were obtained.
It is intriguing that the experiment shown in Figure 3C3 indicated that the limiting 
factor in the GEXE52-135kD proteimprotein interaction was the level of the 135kD 
protein present in cell extracts, yet it was not possible to purify larger amounts by 
incubating small quantities of GEXE52 beads with larger volumes of cell extracts. As the 
intensities of the 135kD bands in this experiment were not quantified, it is possible that 
the GEXE52 beads which were passed through two aliquots of the radiolabelled cell 
extract did not bind twice the amount of 135kD protein compared with the standard assay, 
i.e. the 135kD protein binding capacity of the GEXE52 beads is almost reached in a 
standard 'pull-down' assay.
A criticism of the purification procedure described is the possibility of having 
obtained peptide sequence from a contaminating protein of either mammalian or bacterial 
origin. In the case of mammalian protein contamination, the autoradiograph in Figure 
3C4(ii) showed that the 135kD protein did not migrate with any major band of similar 
molecular weight. The control experiment in Figure 3C4(i) (track 2) showed that there 
were no major contaminating bacterial bands of 135kD. It is therefore unlikely that 
contaminating bands of either origin would have been present in the microgram quantities 
necessary for microsequence analysis. However, in order to show conclusively that these 
peptide sequences were derived from the 135kD protein, it would be necessary to show 
all six encoded within one cDNA whose translated product gives a size of approximately 
135kD (allowing for post-translational modification). Antibodies to this protein should 
result in co-immune precipitation of Vmw 110 from HSV-1 infected cell extracts.
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3D1 Introduction
The experiments in this section describe attempts to identify an anti-135kD antibody from 
an existing panel of antibodies which were known to detect various ND10 antigens and to 
raise an anti-135kD antipeptide serum in rabbits. A strong, specific monoclonal antibody 
or an antiserum which detected the 135kD protein in Western blots was required for 
further investigation of the VmwllO-135kD interaction: firstly, in screening a cDNA 
expression library to obtain a clone; secondly in immune precipitation experiments; and 
thirdly in immunofluorescence experiments.
3D2 Screening anti-NDIO monoclonal antibodies
It was thought that the 135kD protein may be an ND10 protein because it interacted with 
the C-terminal end of Vmw 110 (Section 3A). Residues in the C-terminal end of 
Vmwl 10 were shown in immunofluorescence experiments to be required for targetting 
Vmwl 10 to these domains (Section 1D9.3). Antibodies which detected ND10 antigens in 
immunofluorescence experiments were used in Western blot analyses of standard GST 
'pull-down' assays in an attempt to identify an anti-135kD protein antibody.
Two monoclonal antibodies, iMAb 1150 and MAb 5E10, which detect ND10 
antigens of 55kD and 126kD respectively (Ascoli and Maul, 1991; Stuurman et al.y
1992), were obtained from Professor G. Maul (Wistar Institute) and used to screen 
Western blots of standard GST 'pull-down' assays. The 126kD protein has been identified 
as an isoform of PML (Dyck et al., 1994). It was considered unlikely that MAb 1150 
would interact with the 135kD protein, unless the 55kD ND10 antigen was a 135kD 
protein breakdown product, but it was possible that 5E10 may have done and that the size 
discrepancy between the 126kD antigen and the 135kD protein had arisen from 
experimental error.
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As expected, MAb 1150 did not detect the 135kD band in the GEXE52 eluate 
(results not shown). The results with MAb 5E10 are shown in Figure 3D2. Panel A 
shows the Western blot and B an autoradiograph of the same blot after it was stripped to 
remove any remaining chemiluminescence and reunited with the portion containing lower 
molecular weight proteins (Section 2B3.3). Due to the small amounts of antibody 
available, only a strip of the blot was probed. Proteins eluted from GEXE52 beads were 
run in track 2 and the 135kD protein is clearly visible in the autoradiograph (B). There is 
a high molecular weight band in the corresponding track of the Western blot (A) which, 
as with the autoradiograph, is not present in any of the control tracks 1, 4 and 5 (see 
figure legend). However, a careful comparison of the two original films indicated that the 
135kD protein and the major band in track 2 of the Western blot had different mobilities. 
As discussed in Section 3A10 it is possible that the C-terminal 180 residues of Vmwl 10 
interact with other cellular proteins which are not pulled down in sufficient quantities to 
be consistently visible on an autoradiograph. The protein detected by monoclonal 5E10 
in this experiment may be an example and it is possible that this is PML. Unfortunately, 
time constraints and the unavailability of alternative antibodies prevented further 
investigation.
3D3 Antipeptide sera
Rabbits were immunised with eight-branch peptides which were based on the Glasgow 52 
and Glasgow 45 peptide sequences (Figure 3D3(i)). The author wishes to acknowledge 
G. McVey for carrying out this work.
Peptides 441A and 44IB were designed from the Glasgow 52 sequence and 
peptides 442A, 442B and 442C were based upon the Glasgow 45 sequence. Peptide 
44IB utilises the first seven residues of Glasgow 52. Insertion of a glycine residue at the 
unknown position (X) enabled use of more Glasgow 52 residues in peptide 441 A. It was 
hoped that by inserting a small uncharged amino acid at this position, the spacing 
between the P and Q residues would reflect that in the intact protein which would increase 
the chances of raising a good antiserum. Peptides 442A and 442B were insoluble and 
therefore not of any use in raising antisera. Two rabbits were immunised with each of the 
soluble branched peptides at intervals of approximately 2 weeks. Blood samples were 
taken 1 week following the fourth immunisation as well as after the sixth and tenth 
immunisations. Rabbits 661 and 662 were immunised with peptide 441 A, rabbits 663 
and 664 were immunised with peptide 44IB and rabbits 665 and 666 were immunised
with peptide 442C.
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Glasgow 52 
NDRFEFPXQLPLDEFLQK 
441 A. (NDRFEFPGQLPLDEFL)8 K7 soluble (in water)
441B: (NDRFEFP)8K7 soluble
B. Glasgow 45
VTFEVFVQADAPIGVAAPDQK 
442A: (VTFEVFVQADAPIGVA)8 K7 insoluble
442B: (VTFEVFVQ)8K7 insoluble
442C: (ADAPIGVA)8K7 soluble
C Peptide Rabbit numbers
441A r661,r662
44IB r663, r664
442C r665, r666
Figure 3D3(i) Peptides designed for raising antisera to the 135kD protein in rabbits. 
Panel A shows the amino acid composition of peptides 441A and 441B which were 
based on the sequence of the Glasgow 52 peptide. Peptide 441A contains a glycine 
residue (G) at the unknown position (X). Panel B shows the structures of the three 
peptides designed from the sequence information of the Glasgow 45 peptide. Peptides 
used for raising antisera were those which were soluble in water and the numbers of the 
rabbits immunised with these peptides are shown in Panel C.
Standard 'pull-down' experiments were carried out with appropriate controls and 
gels were Western blotted and blots probed with the rabbit antisera. Initially, the antisera 
were used at dilutions of 1/100 to 1/1000 and then at dilutions as low as 1/ 10, without 
successful detection of the 135kD protein. It was possible that the quantities of 135kD 
protein on the blots were too low to be detected by the antisera so a larger scale 'pull­
down' experiment was carried out using the method described in Figure 3C4(i). The 
concentrated GEXE52 eluate was mixed with a small quantity of radiolabelled proteins 
from a standard assay, and samples were electrophoresed and Western blotted. Each 
serum was tested and the blot stripped between each experiment. One serum, r664 which 
raised against peptide 44 IB, detected the 135kD protein in the GEXE52 eluate 
(compare tracks 4 and 5 of Figure 3D3(ii)) at dilutions as low as 1/5000. The 135kD
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protein was not picked up in the control GEXE52 eluate (track 3) or the GEXE52 
bacterial extract (track 2). The serum did not detect a 135kD protein in the WS HeLa cell 
protein extract, giving instead weak detection of multiple cell proteins (track 1). This 
confirmed that the interaction of this antiserum with the 135kD protein was weak at best. 
Further immunisation of the rabbit with the 44IB peptide did not improve the quality of 
the serum. An attempt was made by A. Orr to improve its quality by passing 10ml of the 
serum, diluted 1/10 with lOmM Tris.HCl (pH 7.5) to give 100ml, through a column 
containing the 44IB peptide coupled to CNBr-activated Sepharose 4B (Pharmacia). 
Proteins which interacted with the column were eluted with lOOmM glycine, pH 2.5 and 
then with lOOmM triethylamine, pH 11.5. Unfortunately, this procedure did not improve 
the quality of the antibody sufficiently: the eluate failed to interact with the 135kD protein 
on Western blots of standard 'pull-down' assays.
Although the r664 serum did not detect low levels of the 135kD protein on Western 
blots, it was used to screen the A.ZAPII WS HeLa cell cDNA expression library (Section 
2B5.2). It was thought that high local peptide concentrations would make this approach 
to cloning a cDNA feasible. Variations on the standard protocol were carried out but 
specific clones were not detected.
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1 2 3 4 5
^  135kD ^ _
Figure 3D3(ii) Western blot of a GST 'pull-down1 assay with rabbit 664 serum raised 
against 441B. A GST 'pull-down' experiment was carried out such that 1ml GEXE52 
beads bound the 135kD protein from a cell extract prepared from five roller bottles of WS 
HeLa cells (Section 3C4(i)). The rabbit 664 serum was used at a dilution of 1/5000 in the 
Western blot shown in the left-hand panel. In track 1, 20|il of the GEXE52 bacterial 
extract were run and in track 2 a 20pl sample of the WS HeLa cell extract. Tracks 3 and 
4 show proteins eluted from GEXE52 beads (the eluates were concentrated in a 
Centricon 50 unit) with track 3 being the control as the beads were mixed with WS HeLa 
cell resuspension buffer. The track 4 eluate was mixed with proteins eluted from 
GEXE52 in a standard assay and track 5 shows an autoradiograph of track 4 following 
stripping of the blot. A comparison of tracks 4 and 5 confirmed that the high molecular 
weight band detected in track 4 was the 135kD protein.
3D4 Immunofluorescence
The r664 serum was used in immunofluorescence experiments in an attempt to 
investigate the location of the 135kD protein in WS HeLa cells (Section 2B2.5). While 
the lack of a strong interaction between the r664 serum and the 135kD protein on Western 
blots suggested that these experiments might be difficult or inconclusive, it was thought 
worthwhile to make an attempt as the antibody might have been more specific or stronger 
in immunofluorescence experiments, particularly if the 135kD protein was present in 
locally high concentrations.
The location of the 135kD protein in untransfected cells was investigated by 
probing cells with serum obtained from rabbit 664 prior to immunisation with the 441B 
peptide and with the r664 antiserum (Figure 3D4A, left and right hand panels 
respectively). Unfortunately, there was no significant difference between the results 
obtained with the pre-immune and anti-peptide antisera and no conclusion as to the 
normal intracellular location of the 135kD protein could be drawn.
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In another series of experiments, cells were transfected with plasmids encoding 
Vmwl 10 sequences (Section 2B2.4). These plasmids were p i l l ,  encoding intact 
Vmwl 10 protein, pi 10D12, encoding Vmwl 10 with residues 594-633 deleted, pi 10FXE, 
encoding Vmwl 10 with residues 106-150 (zinc binding domain) deleted and pi 10E52X, 
encoding Vmw 110 residues 1-593 (Figure 3D4F). Intact Vmwl 10 localised to punctate 
domains in the nucleus (Figure 3D4B); these have been shown to be ND10 (Maul et al.,
1993). The protein product of pi 10D12 was found to be localised to punctate domains in 
the nucleus (Figure 3D4C). The Vmwl 10 protein expressed from pi 10 FXE located to 
punctate nuclear domains in some cells and in others was found in the cytoplasm (Figure 
3D4D). The product of the pi 10E52X plasmid was diffusely spread through the nucleus 
(Figure 3D4E).
In cells transfected with plasmid p i l l ,  the r664 serum gave a signal which 
colocalised with Vmwl 10 at discrete sites within the nucleus (Figure 3D4B). The pre- 
immune serum did not give such a signal (results not shown). Control experiments were 
carried out to check that the TRITC conjugated goat anti-rabbit antibody was not non- 
specifically binding MAb 11060 and that FITC conjugated goat anti-mouse antibody was 
not binding to rabbit antibodies.
Similar colocalisation of the signal from the r664 serum was also obtained with 
Vmwl 10 expressed from pi 10D12, at ND10 (Figure 3D4C). This was surprising as the 
Vmwl 10 protein expressed from this plasmid lacks the residues shown to be necessary 
for interacting with the 135kD protein (594-633): this was shown in GST 'pull-down' 
assays (Section 3A6) and in immune precipitation experiments with intact Vmwl 10 
(Section 3A9). It is possible that Vmwl 10 residues other than 594-633 also interact with 
the 135kD protein, and that conditions within the cell are more favourable for this 
interaction than those in immune precipitation reactions. An alternative explanation is 
that the r664 serum non-specifically detects Vmwl 10. This problem has been 
encountered previously with an entirely different rabbit serum (R. Everett, personal 
communication) (r414) which had been raised against a human PML peptide sequence. 
Anti-serum r414 detected ND10 in the presence of Vmwl 10 in all cell types tested, 
including a PML deficient cell line. Like r664, r414 also gave non-specific diffuse 
fluorescence in untransfected cells. This indicates that extreme caution should be taken 
regarding the interpretation of immunofluorescence experiments carried out with rabbit 
sera, especially when high concentrations of Vmw 110 are present.
The r664 serum gave a signal which very weakly colocalised with Vmwl 10 
expressed from pi 10FXE (Figure 3D4D). The distribution of the RING finger mutant 
Vmwl 10 in these experiments was unusual, in that in some cells the protein was present 
in the cytoplasm while it is usually located at ND10 within the nucleus (compare the two 
different phenotypes in Figure 3D4D, left hand panel). The reasons for the altered 
distribution are unknown but they correlate with the amount of protein present. While the
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r664 signal was easily seen to colocalise with wild type Vmwl 10 in punctate nuclear 
dots, this was not evident with the RING finger mutant.
As expected, co-localisation between Vmwl 10 expressed from pi 10E52X and the 
135kD protein was not seen (Figure 3D4E).
These results are difficult to interpret, particularly with the knowledge that the r664 
serum may be detecting Vmwl 10 non-specifically, although this was not obvious from 
channel cross-over control experiments or Western blots (R. Everett, personal 
communication). If the non-specific interaction was weak, this would explain the 
apparent lack of colocalisation of the r664 signal with Vmwl 10 expressed from 
pllOE52X as the Vmwl 10 protein is not concentrated in punctate domains. Before 
conclusions as to the normal cellular location of the 135kD protein can be drawn, it is 
necessary to repeat these experiments with a stronger anti-135kD serum, or even better, a 
monoclonal antibody.
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Figure 3D4 Immunofluorescence experiments carried out using the anti-135kD 
antipeptide serum r664. WS HeLa cells were seeded in 24 well Nunc Linbro plates at 
0.5X105 cells per well in 1ml medium and transfected with the relevent plasmids as 
described in Section 2B2.4. Immunofluorescence was carried out as described in 
Section 2B2.4; monoclonal antibody 11060 was used at a dilution of 1/2000 and r664 at 
1/100 (lower dilutions did not improve the results). FITC labelled goat anti-mouse IgG 
was used to detect 11060 binding and TRITC labelled goat anti-rabbit igG to detect r664 
binding. Panel A shows untransfected cells probed with the preimmune serum at 1/100 
dilution (left-hand panel) and r664 (right-hand panel). Panel B shows cells transfected 
with p111, from which wild type Vmw110 is expressed; the left-hand panel was probed 
with 11060 and the right-hand panel shows the same field of cells probed with r664. 
Panel C shows cells transfected with p110D12, expressing Vmw110 with residues 594- 
633 deleted; the left-hand panel shows 11060 immunofluorescence and the right-hand 
panel r664 fluorescence. Panel D shows cells transfected with p110FXE (A 106-150) and 
Panel E cells transfected with p110E52X (A594-775), again, the left-hand panels 
showing cells probed with 11060 and the right-hand panels the same fields of cells 
probed with r664.
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3D5 Discussion
The results in this Section show attempts to identify a monoclonal antibody or a rabbit 
antiserum to the 135kD protein. Unfortunately, neither of the monoclonal antibodies 
raised against ND10 antigens detected the 135kD protein in Western blots of standard 
GST 'pull-down' assays. Of the rabbit anti-sera raised against 135kD peptides, only r664 
gave a positive result and this was obtained only when large amounts of the 135kD 
protein were present. This meant that the serum was very weak and explains why a 
cDNA clone was not detected on screening the cDNA expression library. Also, it may 
well have been the case that any clones identified in the library would have been detected 
as a result of non-specific interactions between the serum and expressed peptides. This 
would not have been discovered until several rounds of plaque purification had been 
carried out and the clone sequenced. The weak reactivity of the r664 serum also explains 
why the normal cellular location of the 135kD protein could not be established in 
immunofluorescence experiments. The precedence of the potential problems of non­
specific binding indicated by the r414 serum made it difficult to draw conclusions from 
these experiments.
It is possible that other peptide sequences would have been more immunogenic, but 
the possibility that some rabbit sera non-specifically detect Vmwl 10 in 
immunofluorescence experiments did not make further attempts at raising an antipeptide 
rabbit serum attractive. Therefore, attempts to clone a cDNA by other means were made 
(Section 3E).
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3E1 Introduction
The experiments in this section describe experimental approaches that were taken to clone 
a cDNA encoding the 135kD protein. In one approach, redundant primers were designed 
from peptide sequence information (Section 3C5) for PCR with a cDNA template. 
Another approach involved screening the AZAPII library with a 53 base probe designed 
from one of the longer peptide sequences.
3E2 PCR cloning
A schematic diagram of the PCR cloning method is outlined in Figure 3E2(i). PolyA+ 
RNA was isolated from WS HeLa cell extracts and reverse transcribed (Section 2B1.10). 
The cDNA was used as a template in PCR reactions with redundant primers designed 
from peptide sequence information (Section 2B1.13). As the order of the peptides within 
the 135kD protein sequence was unknown, pairs of redundant primers in the forward and 
reverse orientations were made so that in attempting to make interpeptide PCR products, 
only one of two primer combinations should give a specific product. PCR products were 
cloned into a vector (Section 2B1.5(v)) and sequenced (Section 2B1.14). Products 
encoding 135kD sequence could be identified by translating sequences following the 
primer sequences to check that they matched those predicted from the peptides. These 
clones could then be used to obtain the remainder of the cDNA clone by further PCR or 
by screening a cDNA library.
A number of redundant PCR primers were made based upon peptide sequence 
information (Figure 3E2(ii)). In designing primers, it was important to keep the level of 
redundancy as low as possible to avoid non-specific priming events. The length was also 
important as the shorter a primer is, the greater is its ability to hybridise non-specifically 
to DNA. Restriction enzyme sites were incorporated at the 5' ends of some primers to aid 
the cloning of PCR products. To increase the chances of priming from correct sequences, 
the redundancies of the 3' ends of primers were kept to a minimum, i.e. primers did not 
finish at redundant positions. Partial guess 20mer primers were made initially (P3, P3r, 
P4 and P4r) but it was found that random priming events occurred, as numerous products 
were yielded from any one pair in PCR amplifications. Fully redundant primers were 
designed to avoid highly redundant codons such as those of lysine or serine residues. An 
examination of the peptide sequences showed that Glasgow 45 was the most useful as it 
contained no lysine, serine or unknown residues. Two of the lowest redundancy primers, 
RP4 and RP4/r with a redundancy of 1/256, were designed from this peptide. Other 
primers of this type, RP5 and RP5r, RP11 and RP1 lr, RP7 and RP7r, RP10 and RPlOr 
and RP3 and RP3r, had redundancies of 1/1024, 1/1536, 1/512, 1/1024 and 1/256 
respectively.
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Figure 3E2(i)
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Figure 3E;2(i) Outline of the PCR cloning strategy. PolyA* RNA was obtained from WS 
HeLa cells and reverse transcribed (Section 2B1.10). PCR was carried out using either 
Pfu polymerase or Taq polymerase and products were cloned into pUC9 in the former 
case or pCR™ll in the latter. The cloned products were sequenced (Sections 2B1.13, 
2B5(v) and 2B1.14). The aim was to identify correct products by translating sequence 
downstream of the primer sequence. Such products could be used to design new 
primers for PCR or to screen a cDNA library by hybridisation.
A number of problems were encountered with this cloning approach. Pfu 
polymerase was utilised initially in the experiments as its proofreading activity would 
increase the quality of any specific products. It was found, however, that 2 or 3 bases at 
the 3' ends of primers were often absent in cloned PCR products which was probably a 
result of the proofreading activity of the enzyme. Taq polymerase then became the 
enzyme of choice, but it was surprising to observe the production of many more reaction 
products with this enzyme compared with Pfu polymerase under similar conditions 
(results not shown). A major problem encountered was the amplification of products in 
reactions with single primers and another problem was the amplification of large numbers 
of products in reactions with pairs of primers (See Figure 3E2(iii)). This showed the high 
occurrence of non-specific priming events. Attempts were made to clone reaction 
products which were unique to reactions carried out with pairs of primers. Attempts were 
also made to improve the quality of the cDNA template : as well as using a dT primer 
(Figure 5.2A), random hexamers or reverse PCR primers were used to ensure adequate 
representation of the 5' ends of mRNAs. The efficiency of reverse transcription was 
increased by incubating reactions at 42°C rather than 37°C. Amplified AZAPII library
DNA was also used as a template.
To decrease the number of non-specific bands produced in PCR amplifications a 
number of strategies, all of which were unsuccessful, were employed. A wide range of 
reaction conditions were used in which primer, template and magnesium concentrations 
were varied, as well as cycling conditions. In an attempt to minimise the number of 
possible primer combinations in interpeptide amplifications, a 5 RNA extension assay 
was carried out in an attempt to order the primers on the cDNA (Section 2B1.12). This 
was also unsucessful (results not shown). Both hot start and nested PCR techniques 
were used to try, in the former case, to minimise non-specific primer annealing at 
temperatures lower than the set annealing temperature and, in the latter case, to amplify 
correct sequences in a second round of PCR. Thin-walled reaction tubes and small 
reaction volumes (1 Ojn.1) were used to allow very rapid temperature changes through 
reaction mixes, which minimised non-specific priming and extension during ramping.
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Figure 3E2(ii)
G l a s g o w  5 2 / 2
I F E X F V D Y V A V E Q L D G D N K  
ATTTTTGAAAAATTTGTAGATTATGTAGCAGTAGAACAACTTGATGGAGATAATAAA 
C C GCCC C C C C C C C G  GT A C C C C G 
A  GGG G G G G  T  G G
T T T  T  T T T  C T
C g G g atccT T T G T N G A T T A T G T N G C N G T  3 ' R P7 
C C C
A A A C A N C TG A TA C A N C G N C A C tTaaggc 5 '  R P 7 r  
G A G
c g G g a t c  cTATGTNGCNGTNGAGCAGCT 3 '  R P 1 0  
C A AT
A TA C A N C G N CA N CTTG TCG A CtTA aggC 5 ' R P l O r  
G C TA
I P 1  3 8 m e r  5 ’ T T T G T IG A T T A T G T IG C IG T IG A A C A A C T IG A T G G IG A
C G G
I P l n  3 8 - m e r  5 ' G A T T A T G T IG C IG T IG A A C A A C T IG A TG G IG A T A A T A A
C G G C C
I P l r  3 8 - m e r  C T A A T A C A IC G IC A IC T T G T T G A IC T A C C IC T A T T A T T 5 '
G C C G G
I P l n r  3 8 m e r  A A A C A IC T A A T A C A IC G IC A IC T T G T T G A IC T A C C IC T  5 ’
G C C
G l a s g o w  3 9
E P T P G N M S X P X P X L G L D X F N K  
GAACCAACACCAGGAAATATGTCAAAACCAAAACCAAAACTTGGACTTGATAAATTTAATAAA 
G C C C C C AGTCCC CCCC CCCCT A C T A CCCC C C G
G G G G  AGCGGG GGGG GGGGT G GT G GGG
T T  t  T  G TTT T T T T  T T T T  C T  C T T T
c g g g a t c c
GAACCNACNCCNGGNAATATG 3 '  R P6 
G C
CTTGGNTGNGGNCCNTTATACctTaagGc 5 ' R P 6 r
C G
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G la s g o w  45
V T F E V F V Q A D A P  I G V A P D Q K  
GTAACATTTGAAGTATTTGTACAAGCAGATGCACCAATTGGAGTAGCACCAGATCAAAAA 
C C C G C C C G C C C C C C C C C C G G  
G G G G G G G A G G G G
T T  T T T T T  T T T T
GTGACCTTTGAGGTGTTTGT 3 '  RP8 
C A A C
GTNACNTTTcAGGTNTTTGT 3 ' RP9 
C A C
TTTGAGGTATTTGTGCAGGC 3 '  P4 
T T A
AAACTTCATAAACAGGTTCG 5 '  P 4 r  
G A G T
c g G g a tC c
TTTGAGGTNTTTGTNCAGGC 3 '  RP4 
C A C A
AAACTCCANAAACANGTCCGctTAaGgc 5 ' R P 4r  
G A G A
cGGgaTcCGTNCAGGCNGATGCNCCNAT 3 '  R P 5  
A C
CANGTCCG N CTA CG N G G N TA c11A aggC 5 1 R P 5 r  
T G
cgggatC cG A T G C N C C N A T T G G N G T N G C  3 '  R P 1 1  
C C
A
CTACGNGGNTATCCNCANCGcttaaggc 5 ' R P l l r  
G G
A
R P 8r 5 1 CCGCACCGGGGTCTGGTCTT 
C T A A 
A
R P 9r 5 '  CCNCANCGNGGNCTGGTCTT
A T
I P 2  5 1 TTTGAAGTITTTGTICAAGCIGATGCICCIATTGGIGTIGCICC 4 4 - m e r  
A G  G A
I P n 2  4 4 - m e r  5 ' tTTGTICAAGCIGATGCICCIATTGGIGTIGCICCIGATCAAAA
G A C G
I P 2 r  AAACAIGTTCGICTACGIGGITAACCICAICGIGGICTAGTTTT
5 ’
C T G C
I P 2 n r  AAACTTCAIAAACAIGTTCGICTACGIGGITAACCICAICGIGG 5 '
T C C T
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G l a s g o w  5 2
N D R F E F P X Q L P L D E F L Q K
AATGATCGC TTTG A A TTTC C AAAAC AACTTCCACTTGATGAATTTC TTC AAAAA 
C CA A C G C CCCC GT A CT A C G CT A G G
G A GGGG T G GT G T G
T T T T T  C T C C
AATGATAGATTTGAGTTTCC 3 ' P3 
C T A C
G
c g g g a t c c
AATGATAGNTTTGAGTTTCC 3 ' R P3 
C CC C A C
TTACTATCTAAGCTTAAGGG 5 1 P 3 r  
G GG A
G
T T A C T A T C N A A G C T T A A A G G g cttaA g g c  5 '  R P 3 r  
G GG A C G
Figure 3E2(ii) The PCR primers designed from the peptide sequences Glasgow 5 2 /2 , 
39, 4 5  and 5 2  are shown. All except the inosine primers are 20mers and some have
an additional 8bp at the 5' end incorporating either a BamHI or EcoRI restriction
enzyme site; these bases are in lower case lettering except where they correspond to 
bases in the peptide sequence. The 5' extensions of RP3, RP4 and RP6 are shown on 
the line above the primer sequence to simplify the layout of the diagram. The sites 
were used for cloning PCR products into pUC9 when Pfu polymerase was used for the 
reactions; this was unnecessary when Taq polymerase was used as the products have 
5' A overhangs which enable the cloning of products into the pCR™ll vector. Primers 
P3, P3r, P4 and P4r are partially redundant and RP4, RP4r, RP5,RP5r, RP6, RP6r, 
r p j  rpyr, RP9, RP9r, RP10, RP10r, RP11 and RP11r are fully redundant. Primers 
RP8 and RP8r were designed to minimise the level of redundancy by taking into 
account the optimum codon usage in the human genome (Lathe, 1983). The longer 
inosine primers were designed to minimise non-specific priming events and have 
inosine residues at positions of four-fold redundancy.
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Chapter 3 Results
The primers RP8, RP8r, RP9 and RP9r were designed to amplify the sequence of 
approximately 60bp encoding the Glasgow 45 peptide. The aim was to make a precise 
primer hybridising to this region and to use it in a PCR amplification with a second 
primer hybridising to an arm of the template A.ZAP DNA. In designing the RP8 and RP8r 
primers optimum codon usage in the human genome was considered (Lathe, 1985) to 
minimise the level of redundancy. RP9 and RP9r were fully redundant. Unfortunately, 
this strategy was also unsuccessful.
Finally, longer primers incorporating inosine at positions of redundancy were 
designed from peptides Glasgow 45 and Glasgow 52/2. Amplification of WS HeLa cell 
cDNA was carried out with IP1 and IP2r and a second round with IP In and IP2nr. 
Converse amplifications were also performed. These PCR reactions gave a number of 
candidate bands which were visible by ethidium bromide staining, but cloning and 
sequencing indicated again that none were correct. However, it later transpired that this 
experiment had been at least partially successful (see Appendix).
3E3 Library screening
The A.ZAPII WS HeLa cDNA library was screened in two ways in attempts to isolate a 
135kD clone. The library was screened as an expression library with an antipeptide 
antiserum (Section 3D3) and by DNA hybridisation with a probe designed from peptide 
sequence information (see below). The former method was unsuccessful, probably 
because the antiserum was too weak.
Clones have been successfully isolated in the past by designing probes from peptide 
sequence, taking into account the Lathe rules which define optimum codon usage in the 
human genome (Lathe, 1985). In this case, a probe was designed based on the least 
redundant peptide sequence, Glasgow 45 (Figure 3E3). Taking, for example, the codon 
for proline which is CCN, C would be chosen for the third position as it is used with a 
frequency of 41 % compared to 24% for T and A and 11 % for G. Additionally, eukaryotic 
DNA shows a selective deficiency in CG dinucleotides, as methylation of the C in this 
environment leads to instability and consequent elimination of CG pairs (Josse et al., 
1961). Therefore, in the design of the probe used in these experiments, C was not used in 
the third codon position when the next codon began with G. It was important that the 
probe was as long as possible to give the highest chance of efficient binding to the correct 
sequence. In this case the probe was limited to 53 bases by the the length of the Glasgow 
45 peptide. Taking the Lathe rules into account meant that the probe ought to have been
at least 80% homologous to the correct sequence (see Section 3E4).
The 53 base probe was labelled at the 5' end with y32P-ATP and used to screen blots 
lifted from agar plates onto which the XZAPH cDNA library had been titrated (Sections 
2B5.1 and 2B5.3). Initial screening was unsuccessful and at this point the constraints of
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time necessitated that these experiments were discontinued. However, this approach later 
turned out to be successful, as detailed in the Appendix.
Glasgow 45
V T F E V F V Q A D A P I G V A P D Q K  
GTAACATTTGAAGTATTTGTACAAGCAGATGCACCAATTGGAGTAGCACCAGATCAAAAA 
C C C G C C C G C C C C C C C C C C G G  
G G G G G G G A G G G G
T T  T T T T T  T T T T
5 ' TTTGAGGTCTTTGTGCAGGCTGATGCCCCCATTGGTGTGGCCCCTGACCAGAA
Figure 3E3 Sequence of the 'guessmer1 oligonucleotide used to screen the cDNA AZAP library. 
The sequence and back translation of Glasgow 45 are shown with the sequence of the 
53 base 'guessmer'.
3E4 Discussion
The results described in this Section highlight the difficulties of cloning from peptide 
sequence information. In particular, the redundancies of the PCR primers meant that high 
levels of non-specific binding to template sequences occurred, giving rise to large 
numbers of reaction products during amplification. The presence of incorrect residues in 
some of the peptide sequences (see Appendix) meant that some primers, particularly those 
designed from the C-terminal end of Glasgow 45 (RP11, R P llr, RP8r and RP9r), had 
little, if any, chance of annealing to correct sequences.
It is evident that the most productive and least time consuming approach to isolating 
a clone was screening a cDNA library with a 'guessmer' probe. Peptide sequences of at 
least 17-20 residues, uninterrupted by unknown or ambiguous residues, are required for 
designing a probe long enough for successful use. As mentioned in Section 5E3, given 
entirely correct peptide sequence information, the homology of a genuine probe can be 
over 80%. This is lower when microsequence information is not entirely correct; the 
guessmer' based on Glasgow 45 was later found to have a homology of only 70% to the 
actual DNA sequence.
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The HSV-1 IE protein VmwllO is a potent and promiscuous transactivator of gene 
expression in transfection assays both alone and in synergy with Vmwl75. Although it 
is a non-essential viral protein, both in tissue culture and in mice, viruses which fail to 
express Vmw 110 show a marked cell-type and multiplicity-dependent defect in plaque 
formation as a result of the failure to initiate viral gene expression (Sections 1D6 and 
1D7). In tissue culture, VmwllO null mutant viruses readily enter a quiescent state 
from which they can be reactivated by the addition of Vmw 110 (Section 1D7). Mouse 
latency models have shown that Vmwl 10 plays a role in the efficient establishment of 
and reactivation from latent infection (Section 1D7). As the condition of the infected 
cell is likely to be a determining factor in whether or not lytic or latent infection is 
established (Section 1C3), there must be molecular interactions between the virus and 
the cell. These observations indicated that any interactions which might occur between 
Vmwl 10 and cellular proteins were potentially important in understanding the biology 
of HSV-1; the aim of the research presented in this Thesis was to identify and 
characterise any such proteins. Any hypothesis or theory proposing a mechanism of 
action for Vmwl 10 needs to account for its non-essential nature in virus infection and 
its non-specific transactivation properties. The necessity for Vmw 175 in the presence of 
Vmwl 10 in viral infection also needs to be considered.
4.1 The interaction of VmwllO with a 135kD cellular protein
The C-terminal 180 residues of Vmwl 10 were investigated because a deletion in this 
region (D14 A680-720) affected the localisation of VmwllO to ND10 (nuclear 
structures containing cellular proteins; Section 1D9.3) and reduced the ability of 
VmwllO to transactivate gene expression in transient transfection assays (Section 
1D9.5). In addition, a run of serine residues ending at residue 591 might indicate the 
presence of a possible domain boundary.
When expressed as a GST fusion protein, Vmwl 10 residues 594-775 (GEXE52) 
bound a 135kD cellular protein from a number of different whole cell extracts (Section 
3A). The fact that the 135kD protein was not visible as a discrete band in the whole cell 
protein profile indicated that this protein was present in small amounts in the cell and 
that the interaction between the C-terminal end of Vmwl 10 and the 135kD protein was 
strong and specific. GEXE58, containing Vmwl 10 residues 633-775, did not bind the 
135kD protein in this assay so it was concluded that residues 594-633 were necessary 
for the interaction in this system. VmwllO residues 594-646 were found to be 
sufficient for the interaction as GEXE52AvaI bound the 135kD protein (Section 3A6).
As the GST 'pull-down' assay involved the use of isolated domains of Vmwl 10, it 
was possible that the Vmwl 10 residues had not folded correctly and that the interaction
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with the 135kD protein was therefore artifactual. The fact that a 135kD protein could 
be coimmune precipitated in a complex with VmwllO from infected cell extracts 
showed that this was unlikely. The reciprocal depletion experiment indicated that the 
135kD proteins in the two systems were likely to be the same (Section 3A9). 
Additional coimmune precipitation experiments have been carried out by other 
members of the group using infected cell extracts; the Vmwl 10 protein in a wild type 
infected cell extract coimmune precipitated with a 135kD cellular protein but the 
Vmwl 10 protein of the deletion mutant virus D12 (A594-633) did not, confirming the 
necessity of VmwllO residues between 594-633 for the interaction with the 135kD 
protein in infected cell extracts (Meredith et a l., 1994; 1995). Although these 
experiments indicate that C-terminal residues of Vmwl 10 fold in a manner reflecting 
that of the intact protein when expressed as GST fusion proteins, it is likely that residues 
immediately adjacent to GST sequences are unable to behave as they would in the intact 
protein by virtue of being juxtaposed to foreign residues. This means that the N- 
terminal boundary of the residues necessary for interacting with the 135kD protein is 
downstream of residue 594. Even though Vmwl 10 residues 594-646 are necessary and 
sufficient for the interaction of Vmwl 10 with the 135kD protein, these experiments do 
not exclude the possibility of the involvement of further but non-essential residues of 
Vmw 110 in the interaction.
The Vmwl 10 sequence between 594-633 is approximately 70% conserved in the 
equivalent HSV-2 protein but there is little conservation in the equivalent proteins of the 
other a-herpesviruses. This raises the question of the importance of the interaction in 
the life-cycle of a-herpesviruses in general. However, the Vmwl 10 mutant virus D12 
(missing VmwllO residues 594-633) exhibits an impaired growth ability in tissue 
culture (Meredith et al., 1995), indicating that the interaction is significant in the life 
cycle of HSV-1. It is possible that this interaction is specific to HSV-1 although motifs 
in the equivalent proteins of the other a-herpesviruses may interact with the 135kD 
protein in a different way to Vmwl 10. It is evident that different viruses disrupt ND10 
in different ways (Section 1D9.2) and it is possible that the Vmwl 10-135kD interaction 
is connected with this. Therefore, the Vmwl 10 equivalent of other a-herpesviruses 
may interact with other cellular proteins which results in the same ultimate effect on 
ND10; that of their disruption. It would be of interest to investigate in GST 'pull-down' 
assays or in immune precipitation experiments whether or not the Vmwl 10 homologues 
of HSV-2 or other a-herpesviruses or any other viral protein that interacts with ND10 
interacts with a cellular protein the same as or similar to the 135kD protein. This would 
answer the question of whether or not the 135kD protein was involved generally in 
ND10 disruption during virus infection. If this was the case, then the interaction of this 
cellular protein with viral proteins may present a target for general anti-viral
chemotherapy.
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It is possible that a proline-rich sequence between VmwllO residues 594-633 is 
responsible for the interaction of Vmwl 10 with the 135kD protein. The PXXP motif, a 
copy of which is present in the proline-rich region, is contained within protein domains 
recognised by SH3 domain proteins (Ren et a l., 1993; Yu et al., 1994). The SH3 
domain is a 50-60 amino acid domain which is important for the involvement of 
proteins containing the domain in cell signal transduction. Whilst the 135kD protein 
does not contain an SH3 domain (see Appendix), it is still possible that the 
Vmwl 10:135kD protein interaction is mediated by these residues in Vmwl 10. There 
are two mutant Vmwl 10 proteins, E4 and E9, which contain four amino acid insertions 
in the proline-rich region (Everett, 1987a). The PXXP domain of E4 is intact but is 
displaced and this protein has a slightly reduced ability to transactivate gene expression 
in the absence of Vmw 175 in transient transactivation assays (approximately 80% of 
wild type levels), whilst the PXXP domain of E9 is unaltered and the protein has near 
wild type transactivating activity. However, in the presence of Vmw 175, the ability of 
E9 Vmwl 10 to transactivate gene expression is much reduced compared with the level 
of wild type Vmwl 10 and Vmw 175. It is therefore possible that two GPR repeats in the 
proline-rich region are important; one of these is lost in E9 Vmwl 10. Both GPR repeats 
are present in the E4 insertion mutant protein which shows only a slight reduction in 
transactivating ability in the presence of Vmw 175 (approximately 80% of wild type 
levels). Whether or not the proline-rich sequence is important for the interaction with 
the 135kD protein could be more fully investigated by point mutating various residues 
in this region and using the GST 'pull-down' assay to investigate 135kD binding.
4.2 The interaction of VmwllO with a 135kD cellular protein from a number of 
different cell types
It is intriguing that a 135kD protein was pulled down from all the cell types tested, 
given that some of the cell lines were derived from different species (human, hamster, 
rat). It would have been less surprising to observe different sized but related proteins. 
A knowledge of the degree of similarity between these proteins will come by cloning 
and analysing the relevant cDNAs, although a suitable panel of antibodies to the human 
135kD protein may show the degree of cross-reactivity with these proteins. If these 
proteins were very similar in different species, it could indicate the importance of the
role of the 135kD protein in the cell.
The ND7 cell line, a neuronal line originally obtained by the fusion of 
neuroblastoma cells with primary rat sensory neurons (Wood et al., 1990), was 
examined to ascertain whether or not the 135kD protein was present in both 
undifferentiated and differentiated cells. Although these cells are not true neuronal 
cells, it is possible that the pattern of gene expression in differentiated ND7 cells may 
reflect that of neurons. It was thought that if the protein was absent from differentiated
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cells, this may be an alternative explanation to those already put forward by other 
investigators (Section 1B3) as to the relative non-permissivity of these cells to virus 
infection. It may be that in the absence of the 135kD protein, VmwllO cannot 
efficiently transactivate gene expression and the virus behaves as a VmwllO null 
mutant, thus entering latency more efficiently. The idea of differential gene expression 
in neurons playing a role in HSV-1 latency has also been proposed by Latchman's 
group; they suggested that the presence of particular isoforms of Oct-2 in neurons 
prevents transactivation of IE genes (Section 1B3). Aside from the technical difficulties 
encountered with this experiment (Section 3A5), the presence of the 135kD protein in 
both undifferentiated and differentiated ND7 cell extracts could have been a result of the 
fact that differentiated ND7 cells do not truly reflect the characteristics of neurons 
regarding gene expression.
One method by which the presence or absence of the 135kD protein in neurons 
could be ascertained is by staining a section of neuronal ganglia with a suitable 135kD 
antibody. However, a result showing the presence of the 135kD protein in neuronal 
cells may not necessarily mean that it is present in similar quantities in vivo; if it is 
involved in an interaction with Vmwl 10 that is linked to the reactivation of latent virus, 
its expression may be rapidly induced in the latent to lytic switch. Therefore, it is 
possible that its expression could arise as a stress or shock response during or following 
the death of the host but prior to fixing the cells for staining.
It would be informative to observe the effects of HSV-1 infection on a 135kD 
protein 'knock out' cell line. If HSV-1 plaqued on a 135kD negative cell line with the 
efficiency of a Vmwl 10 null mutant on the parental cell line, this would suggest that the 
interaction between VmwllO and the 135kD protein is important for the function of 
VmwllO in lytic growth. As the alternative to lytic infection is latency, this would 
provide circumstantial evidence for the necessity of the Vmwll0:135kD protein 
interaction in the reactivation of latent infection. However, solving the role played by 
VmwllO in infection, particularly with regard to latency, may not answer the 
fundamental question of the mechanism by which HSV-1 establishes and reactivates 
from latent infection; the activity of Vmwl 10, which may be intricately connected with 
the 135kD protein, whilst contributing to the efficiency of the process might only 
complement a mechanism mediated via another viral protein.
4.3 Is the 135kD protein an ND10 component?
Of interest is the fact that the 135kD protein was found to be present in both nuclear and 
cytoplasmic extracts in GST 'pull-down assays (Section 3A8). Unfortunately, the r664 
antipeptide serum, which was raised to a 135kD peptide (Section 3D3), was too weak to 
confirm this in immunofluorescence assays. The presence of the 135kD protein in the 
cytoplasm in quantities too large to suggest that there was leakage of the 135kD protein
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from nuclei indicates that this is of functional significance. This suggested that the 
135kD protein was not an ND10 protein as it would have been expected to be present 
predominantly in the nuclear extract. The cytoplasmic location of the 135kD protein 
may be connected to observations of Everett and Maul (1994) who showed in 
immunofluorescence experiments that VmwllO becomes located in the cytoplasm as 
well as in the nucleus during the course of infection.
4.4 The potential involvement of VmwllO and the 135kD protein in a transport 
process
Prior to knowledge of the 135kD cDNA sequence (see Appendix), it was thought that 
Vmwl 10 and the 135kD protein were involved in a transport process; it was possible 
that one was responsible for the transport of the other from the nucleus to the cytoplasm 
or that both were linked in the cotransportation of other proteins. The nature of such a 
transport process could only be speculated.
(i) The proposed transport process
The 135kD protein might act at the pretranscriptional level to locate transcription 
factors translated in the cytoplasm to the nucleus for storage in ND10. VmwllO 
consequently would disrupt this arrangement by dispersing ND10 proteins which could 
result in communication between the nucleus and cytoplasm signalling that the ND10 
'stores' were empty. According to this model, the cell would then direct cytoplasmically 
sequestered transcription factors to the nucleus immediately upon translation which 
would be favourable for viral gene transcription; they would not enter ND10 due to the 
presence of Vmwl 10. This would complement the shut-off of host cell macromolecular 
synthesis by the virus (Section 1B2.5). It is important to consider how such a proposed 
process could explain other known properties of VmwllO, such as its synergistic 
activation of gene expression with Vmwl75 in transient transfection assays and its 
apparent involvement in latency.
(ii) Relating the proposed transport process to other properties of VmwllO
In the above scenario, the synergistic transactivation of gene expression by VmwllO 
and Vmw 175 in transfection assays could be explained if the gene encoding the 135kD 
protein was transactivated by Vmwl75; the effects of VmwllO on ND10 disruption 
would be increased if Vmwl 10 bound the 135kD protein in a process which allowed the 
transport of transcription factors into the nucleus but prevented their localisation to 
ND10. The fact that Vmw 175 null mutant viruses are non-viable despite expressing a 
functional VmwllO protein could be explained if Vmwl 10-mediated transactivation 
depended on a threshold level of the 135kD protein; although Vmwl 10 transactivates 
gene expression to a degree by itself in transient transfection assays, this activity may
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not be sufficiently high to induce lytic infection in the viral context. This phenomenon 
could be investigated by examining the levels of gene expression in cells transfected 
with plasmids encoding VmwllO only, and VmwllO and the 135kD protein. In 
addition, provided there was a low level of IE gene expression during latency (Section 
lC3(iv)), the involvement of Vmwl 10 in reactivation could be explained; the low level 
of expression of Vmw 175 during latency may be increased on a stimulus for 
reactivation and this would result in increased 135kD protein levels so that the 
synergistic activation of gene expression of VmwllO and Vmw 175 would come into 
play.
(iii) Problems
A major drawback of the model explained above is that none of the three ND10 proteins 
cloned to date have been shown to activate gene expression in transfection assays, 
which suggests they are not transcription factors (Section 1D9.2) although they could 
indirectly regulate transcription. In addition, the sequence of the 135kD protein 
indicates that it is a member of a family of ubiquitin C-terminal carboxy hydrolases (see 
Appendix) which somewhat negates the hypothesis of its involvement in a transport 
process with Vmwl 10. It is an attractive proposition that the 135kD protein is substrate 
specific in that it acts on a small number of proteins connected somehow with the 
regulation of gene expression. This being the case, it would have been less surprising if 
it was located only in the nucleus. Its location throughout the cell suggests that it may 
be a general deubiquitinating enzyme. VmwllO may, by virtue of interacting with 
other proteins, specifically direct its activity.
4.5 The interaction of VmwllO with ND10
The observation that D12 VmwllO (A594-633) localises to ND10 in 
immunofluorescence assays raises the question of which residues are responsible for its 
localisation to these domains. If the 135kD protein was an ND10 protein, it could be 
that residues other than 594-633 of VmwllO interact with the 135kD protein for the 
localisation of VmwllO to ND10 and that these interactions were undetectable in 
immune precipitation reactions as the assay conditions were unsuitable. However, the 
localisation of the 135kD protein in both the nucleus and the cytoplasm, suggesting that 
it is unlikely to be an ND10 protein, means that C-terminal residues of Vmwl 10 other 
than 594-633 are responsible for the initial interaction of Vmwl 10 with ND10. For 
example, D14 Vmwl 10 which lacks residues 680-720 gives diffuse nuclear staining in 
the viral and plasmid context whilst GEXE52D14 (which includes the same deletion) 
binds the 135kD protein. An obvious alternative candidate ND10 protein with which 
Vmwl 10 C-terminal residues could interact is PML. It would be of value to repeat the 
Western blot of the GEXE52 'pull-down' experiment in Section 3D2 to ascertain
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whether or not the protein apparently detected by the monoclonal antibody 5E10 is 
PML. It could be that some of the lower molecular weight proteins occasionally seen in 
the GST pull-down' experiments (Section 3A4) were PML isoforms; they may also 
have been other ND10 proteins.
The immunofluorescence experiments presented in this Thesis show that the r664 
serum, raised against a 135kD peptide in rabbits, detects ND10 in the presence of wild 
type Vmw 110. This could be interpreted as meaning that Vmwl 10 recruits the 135kD 
protein into ND10. However, D12 Vmwl 10 gave a similar result, which means either 
that the 135kD protein interacts with VmwllO residues outside of 594-633 in this 
recruitment process or that r664 cross-reacts with Vmwl 10 (this is not supported by the 
results of Western blots but is thought to have occurred with another rabbit antiserum, 
r414 (Section 3D4)). As VmwllO and the 135kD proteins are large it would not be 
surprising to find that !35kD protein contacts were made with VmwllO residues 
outside 594-633. The use of a specific monoclonal antibody to the 135kD protein will 
clarify the localisation of the 135kD protein in the presence of VmwllO and in 
uninfected cells.
If Vmwl 10 is responsible for recruiting the 135kD protein into ND10, this could 
be an important step in the disruption of ND10. The proposed enzymatic activity of the 
135kD protein predicted from its sequence may be responsible for ND10 disruption, 
although it is difficult to envisage how an enzymic activity known to counteract the 
ubiquitination of proteins targeted for degradation could act to disrupt a multiprotein 
complex. It is possible that the interaction between Vmwl 10 and the 135kD protein is 
unrelated to the disruption of ND10; the fact that D12 VmwllO has a different 
disruptive effect on ND10 compared to wild type Vmwl 10 may be due to a structural 
alteration in VmwllO rather than being an effect of the altered Vmwll0:135kD 
protein:protein interaction. This could be tested in an immunofluorescence assay by 
looking at the effects of wild type VmwllO on ND10 in a 135kD~ cell line. If the 
Vmwl 10:135kD proteimprotein interaction is unconnected with the disruption of ND10 
by VmwllO, it may be that following ND10 disruption VmwllO binds the 135kD 
protein and directs its deubiquitinating activity towards one or more ND10 proteins 
which are now exposed to ubiquitinating enzymes and targeted for degradation.
As Vmwl 10 is a large protein, it would not be surprising to find that it is involved 
in two or more unrelated processes, all of which contribute to its efficient function. In 
support of this is the observation that the growth of the D12 virus in tissue culture is less 
gffjcjgnt than wild type virus but more efficient than the deletion mutant d ll403. The 
fact that the FXE deletion mutant vims grows almost as inefficiently as dl 1403 in tissue 
culture could be because the RING finger is necessary for the correct folding of more 
than one functional domain of Vmwl 10, for example regions 2, 3, and 4 (Section 1D5). 
Vmwl 10 C-terminal residues may be required for the initial interaction of VmwllO
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with ND10 and a domain dependent on the correct folding of the RING finger may aid 
in ND10 disruption. This is consistent with the fact that, so far, a cellular protein which 
interacts with the RING finger has not been identified. The possibility that the 
VmwllO RING finger domain interacts with other regions of VmwllO could be 
investigated by carrying out GST 'pull-down' experiments with the RING finger domain 
and various Vmwl 10 polypeptides. The RING finger dependent activity of Vmwl 10 
required for normal ND10 disruption could therefore be separate from that required for 
its transactivation properties (Section 1D5) if two functional domains fold around the 
RING finger. It is equally possible though, that the RING finger could be an exposed 
functional domain whose individual activity is essential for Vmwl 10 function but is 
enhanced by other regions of Vmwl 10. This would mean that it is important to identify 
cellular proteins with which this domain interacts in order to fully understand ND10 
disruption.
It is unlikely that the localisation property of C-terminal residues of Vmwl 10 to 
ND10 and the involvement of those residues in the synergistic activation of gene 
expression with Vmw 175 are unrelated properties because the residues involved are 
probably too close together to be employed in different functions. However, if ND10 
proteins are not transcription factors or indirect activators of gene expression, the 
connection between ND10 disruption and the increase in gene expression seen in 
transfection assays is difficult to explain. It is possible that disruption of ND10 is a 
general virus phenomenon which circumvents a vital cellular defence mechanism. 
Another explanation is that, as ND10 may be connected with sites of viral replication 
(Section lD9.2(iii)), the scaffold around which the proteins are structured may be an 
essential anchor for viral replication.
4.6 Multimerisation of the C-terminal end of VmwllO
A multimerisation domain has been mapped to the C-terminal region of Vmwl 10. This 
has been shown indirectly in immunofluorescence assays, in in vitro translation assays 
and in glutaraldehyde cross-linking experiments (Ciufo et al., 1994) as well as directly 
in biochemical assays (Section 3B). The experiments presented in this Thesis show that 
both T7E52 (VmwllO residues 594-775) and T7E58 (VmwllO residues 633-775) 
readily multimerised in all assays tested, although it was not possible to resolve the 
nature of these multimers. This result clearly separates the residues that are essential for 
binding the 135kD protein (594-633) from those which are sufficient for 
multimerisation. As was the case with the GST fusion proteins, it is unlikely that 
residues in immediate proximity to the vector-encoded MARIR residues at the N- 
terminal ends of the polypeptides fold correctly which means that the minimal 
multimerisation interface begins downstream of residue 633.
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The data of Ciufo et al. (1994) indicates that C-terminal polypeptides of Vmwl 10 
form dimers in in vitro translation experiments and that these multimers form only when 
the polypeptides are cotranslated and not simply mixed together. This suggests that the 
multimerisation interaction is strong and is unlikely to be easily disrupted, supporting 
the evidence that the VmwllO multimerisation and 135kD interaction interfaces are 
separate.
Whilst essential residues for 135kD binding are not necessary for the localisation 
of VmwllO to ND10, it is possible that the VmwllO multimerisation domain is a 
requirement. It would be of value to express C-terminal segments of Vmwl 10 smaller 
than those encompassed by T7E52 and T7E58 in the T7 expression system to narrow 
down the multimerisation domain. In conjunction with immunofluorescence 
experiments using VmwllO truncation mutants, the multimerisation of Vmwl 10 as a 
prerequisite for ND10 localisation could be determined.
4.7 The multiple protein:protein interactions of VmwllO C-terminal residues
It is difficult to envisage how Vmwl 10 can multimerise in the presence of the 135kD 
protein when the domains necessary for both are in such close proximity and 
particularly when Vmwl 10 is located at ND10; steric hindrance might be expected to 
prevent one or the other from occurring. It is possible that Vm w l 10 binds the 135kD 
protein with a stoichiometry so that functional complexes contain 3-4 VmwllO 
molecules and one 135kD protein molecule. This complex could form prior to 
Vmwl 10 interacting with ND10, or Vmwl 10 multimers may bind ND10 and undergo a 
conformational change which enables the binding of the 135kD protein; both 
hypotheses fit in with the idea of VmwllO recruiting the 135kD protein to ND10. 
There is also the question of the number of Vmwl 10 multimers which localise to ND10 
during virus infection; this is likely to be more than one because one or two molecules 
would be unlikely to be detected in immunofluorescence and the amount of Vmwl 10 
produced would mean that VmwllO would be diffusely spread in the nucleus 
throughout infection, even at early times. ND10 may contain a number of VmwllO 
'docking' sites and be disrupted physically by Vmwl 10 binding. However, the possible 
recruitment of the 135kD protein could mean that disruption occurs as a biochemical 
interaction, a question which should be resolved when the 135kD protein substrate is 
known. It may also be the case that there is a minimal number of Vmwl 10 binding sites 
and that when VmwllO multimers bind, others are recruited to form higher order 
VmwllO complexes which result in the physical disruption of ND10; this would 
explain the difficulty in determining the precise physical nature of the VmwllO 
multimers in the experiments described in this Thesis (Section 3B). It may be that 
recruitment of the 135kD protein stabilises multimer interactions, either by altering the
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conformation of multimers or by inhibiting their degradation in the ubiquitin dependent 
pathway.
The GST fusion protein GEXE52AvaI, expressing VmwllO residues 594-646, 
binds the 135kD protein in 'pull-down' assays. As the data presented in this Thesis 
suggests that sequences essential for multimerisation exist between residues 633-775, it 
is unlikely that the GEXE52AvaI protein could multimerise in the normal way. The 
data of Ciufo et al. (1994) indicates that the multimerisation domain lies between 
residues 617-711 with residues N- and C-terminal of these contributing to the efficiency 
of multimerisation. Whilst this region overlaps the Vmwl 10 residues of GEXE52AvaI 
by 29 residues, the fact that the overlap is so small indicates that these residues may not 
be sufficient for VmwllO multimerisation. To be completely sure of this, it is 
necessary to express Vmwl 10 residues 594-646 in a T7 system for purification and 
biochemical analysis. It is likely, therefore, that multimerisation is not a prerequisite for 
135kD protein binding so that the stoichiometry of the Vmwl 10-135kD interaction is 
1:1. Due to the large sizes of Vmwl 10 and the 135kD proteins it is even more difficult 
to envisage how Vmwl 10 could multimerise and this complex bind a number of 135kD 
protein molecules when the binding domains for each property of Vmwl 10 are so close 
together. In addition, it is likely that Vmwl 10 interacts with another cellular protein via 
its C-terminal end in initially binding to ND10 (Section 4.5). A 1:1 stoichiometry of the 
Vmwl 10:135kD protein complex suggests also that the 135kD protein, due to its large 
size, must contact VmwllO residues other than those between 594-633 and possibly 
interact with itself; multiple protein:protein contacts might stabilise the Vmwl 10:135kD 
protein complex. It would be of interest to determine the minimal 135kD binding 
region and to obtain structural information regarding the interaction. The expression of 
peptides encoding VmwllO residues 594-646 and the 135kD protein residues which 
contact these should result in the formation of stable heterodimers.
In addition to its interaction with the 135kD protein and with itself, the C-terminal 
end of Vmwl 10 probably interacts with at least one other cellular protein (Section 4.5). 
The interaction of Vmwl 10 with a 150kD protein (Section 3A6) has not been observed 
in coimmune precipitations with Vmwl 10 which could mean that this interaction is an 
artifact of the GST 'pull-down' experiments. It is also intriguing that the 150kD protein 
was not present in all cell extracts. Whether or not it is a precursor of the 135kD protein 
could possibly be determined in Western blot experiments with a good panel of 135kD 
antibodies. Vmwl 10 residues 633-680 were shown to be necessary for binding this 
protein in BHK cells (Section 3A6). This means that it is probably unrelated to the 
135kD protein, unless VmwllO residues between 594-680 all contribute to the 
Vmwl 1 0 :135kD/150kD interaction and, on processing of the proposed precursor 
protein, the essential residues for the interaction become slightly different. As Vmwl 10 
residues 633-775 can interact with a 150kD cellular protein in GST 'pull-down' assays,
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while residues 680-775 do not, it is possible that the Vmwl 10 multimerisation domain 
is downstream of residue 680 as it is unlikely that Vmwl 10 binds other proteins via its 
multimerisation domain (Section 4.5).
On the other hand, it may be that VmwllO residues 633-680 contain the 
multimerisation domain; dimerisation of the GST portion of the fusion proteins (Section 
3A3) may prevent the self interaction of these VmwllO residues so that they are 
exposed to cellular proteins in the GST 'pull-down' assay. In experiments with intact 
VmwllO multimerisation via these residues would prevent the 150kD protein from 
binding. However, if the multimerisation domain is downstream of Vmwl 10 residue 
680, this would appear to make the potential formation of a Vmwl 10:135kD protein 
complex physically more feasible. Once formed, this complex may exclude the binding 
of the 150kD protein; in the GST 'pull-down' assay the Vmwl 10;150kD protein:protein 
interaction may still occur in the presence of the VmwllO:135kD protein:protein 
interaction because the Vmwl 10 residues do not multimerise.
4.8 Interactions between viral and cellular proteins
As discussed above, it is likely that Vmwl l O interacts with proteins other than the 
135kD protein, via residues which require correct folding of the RING finger and also 
via C-terminal residues other than those necessary for the 135kD interaction or 
multimerisation. This could be predicted on the basis of Vmw 110 being a large protein 
and on its inability to bind directly to DNA whilst it has profound effects on gene 
expression. It is also supported genetically by the observation discussed above, that 
various VmwllO deletion mutant viruses exhibit a range of reduced growth abilities 
which are often not as severe as that of d ll403. FXE is the only mutant virus which 
exhibits a disability as severe as that of dl 1403; this could be because the RING finger 
carries out an essential function facilitated by other regions of the protein or, as 
discussed above, because mutations in the RING finger have a marked effect on the 
folding of the entire protein.
Vmw65 also interacts with cellular proteins (Section 1C 1.1) and it is unlikely that 
these interactions and that of Vmwl 10 with the 135kD protein are the only virusxell 
interactions as the life cycle of the virus involves so many gene products. The work 
presented in this Thesis provides a potentially interesting insight and route of pursuance 
for understanding the role VmwllO plays in virus infection. As well as aiding in 
uncovering the mechanism of one of the fundamental biological properties of the virus, 
namely the lytic-latent switch, the Vmwl 10:135kD protein interaction will help in the 
understanding of the potentially important role played by ND10 in the cell.
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Cloning the cDNA encoding the 135kD protein
All of this work, apart from the RT PCR which was performed by the author, was 
carried out by R. Everett.
The A, ZAP II WS HeLa cDNA library was screened using the 53 base 'guessmer' 
probe designed from the sequence of peptide Glasgow 45 (Section 3E3). The method 
was based on the hybridisation screening method detailed in Section 2B5.3. Two 
clones, 1142 and 1131, were isolated and sequence analysis showed that they were 
partially overlapping; sequence encoding peptide Glasgow 45 was found in the 
overlapping region. Interestingly, three amino acid residues towards the C-terminal end 
of Glasgow 45 did not correspond to the sequence in the cDNA clones (Figure A). The 
fact that peptide Glasgow 52 was also contained within clone 1142 was strong evidence 
that the correct cDNA had been isolated and not that encoding a related protein. The 
presence of these incorrect residues in Glasgow 45 would have meant that primers 
designed from the sequence of the C-terminal end of Glasgow 45 (RP5r, RP11, RP1 lr, 
RP8r, RP9r; Section 3E 2) would have had much less homology than expected to the 
correct sequence. The production of correct PCR products using these primers would 
therefore have been very unlikely.
Clone 1131 was also used to screen the PCR products of reactions carried out with 
the 38 and 44 base inosine-containing primers in a Southern blot experiment. It was 
found that clone 1131 hybridised to a band which was not visible upon ethidium 
bromide staining. Following the cloning of the complete cDNA sequence of the 135kD 
protein and the identification of the positions of the inosine-containing primers, the size 
of the band recognised by clone 1131 in this experiment was found to be correct. It is 
possible that correct but invisible products were also produced in other PCR 
experiments. Consequently, it should have been possible to identify a correct PCR 
product by cloning and sequencing every product from each reaction. Unfortunately, 
this would have been too time consuming to be a reasonable approach to obtaining a 
clone, which was why the method was abandoned in favour of hybridisation screening.
During the cloning procedure described above, the peptide sequences were used 
regularly to screen the data base of the Washington University Merck Expressed 
Sequence Tag (EST) Project using the NCBI BLAST E-mail service. The EST Project 
aims to produce sequences of approximately 300-400 bases at the 5' and 3' ends of about 
200,000 cDNA clones over an 18 month period (October '94-March ’96). Over 8,000 
unedited sequences are entered into the database weekly. The screening procedure 
resulted in the identification of clone 80922 which contained a sequence encoding 
peptide Glasgow 39.
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Clone 80922, encoding the 3’ end of a cDNA was linked to clone 1142 using RT 
PCR with an exact primer to a sequence at the 3’ end of clone 1142 (primer 1782) and 
an exact primer to a sequence at the 5' end of clone 80922 (primer G39R).
A PCR product of clone 1142 was used to rescreen the A. ZAP II WS HeLa cDNA 
library. Twelve clones were isolated and sequenced to give a single contiguous cDNA 
encoding the 135kD protein.
The cDNA encodes a 1102 residue protein of predicted molecular weight 128kD. 
Sequence analysis has shown that the protein contains two blocks of residues 
characteristic of the ubiquitin specific protease (USP) family of enzymes. These 
enzymes are found in a wide range of eukaryotic organisms, including not only humans 
but also yeast, mouse, Drosophila and C. elegans. Ubiquitin specific proteases, also 
known as deubiquitinating enzymes or isopeptidases are thiol proteases (E.C. 3.1.2.15) 
that recognise and cleave the amide bond at the C-terminal glycine of ubiquitin (Tobias 
and Varshavsky, 1991; Baker et al., 1992). There is little significant homology of 
members of the family outside the two regions thought to be involved in catalytic 
activity.
The ubiquitin proteolytic pathway is a tightly regulated biochemical system in 
which target proteins are 'marked' for degradation by ubiquitinylation (reviewed by 
Wilkinson, 1995). The most renowned role in which the pathway is involved is in 
increasing the rates of intracellular proteolysis in the response of a cell to stress stimuli 
such as starvation. The result is energy production and the release of amino acids for de 
novo protein synthesis. The pathway is also involved in cell cycle regulation with 
respect to the selective degradation of specific cyclins (reviewed by Wilkinson, 1995).
USPs are involved in the ubiquitin pathway at four different stages; (i) they cleave 
ubiquitin from a precursor protein, (ii) they de-ubiquitinylate some proteins targeted for 
degradation, (iii) they cleave polyubiquitin chains from the peptide remnants of 
degraded proteins and (iv) they degrade polyubiquitin chains to ubiquitin monomers. 
The specificity of the pathway is not fully understood; it has been suggested that 
proteins are randomly ubiquitinated and deubiquitinated (by USPs) but if a protein is 
damaged, the bound ubiquitin undergoes a conformational change which results in the 
polyubiquitinylation that targets it for degradation. The fact that at least 15 ubiquitin 
specific proteases exist in yeast and that there are many more in Drosophila, mice and 
humans suggests that these enzymes may have specific target proteins.
The interaction of Vmwl 10 with a USP has led to speculations of the mechanism 
of action of VmwllO. It is possible that in interacting with the 135kD protein, 
VmwllO sequesters a protein whose normal function is to remove ubiquitin from a 
protein targeted for proteolysis. The result of this could be activation of one or more of 
a number of cellular transcription factors which would explain the potent and 
promiscuous transactivation of gene expression induced by VmwllO in transfection
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assays (Section 1D5); activation of the transcription factor NFkB occurs in response to 
external stimuli which result in the specific ubiquitinylation and subsequent degradation 
of a bound inhibitor, IkB, thus allowing NFkB to move into the nucleus (Palombella et 
al., 1994). The targeting of the 135kD protein by Vmwl 10 to ND10 may result in the 
degradation of one or more ND10 proteins normally sequestered from this pathway; this 
mechanism could be responsible for the subsequent disintegration of these structures 
observed in immunofluorescence assays.
Vmw 175 induces the expression of a class of ubiquitin encoding genes (Latchman 
et al., 1987; Kemp et al., 1988) required for efficient ribosomal biogenesis (Finley et 
al., 1989); their induction leads to an enhancement of both protein synthesis and protein 
degradation. Sequestration of the 135kD protein by VmwllO could counteract the 
Vmw 175 induced protein degradation processes by preventing the release of free 
ubiquitin which would act as a limiting factor in the ubiquitin dependent proteolytic 
pathway. This would result in a general increase in protein levels and may explain the 
synergistic activity of VmwllO and Vmwl75 (which requires the Vmwll0:135kD 
interaction domain). This model is valid only if the majority of free ubiquitin is 
released from ubiquitinated proteins by the 135kD protein; this is feasible in virus 
infected cells when the majority of cellular gene expression is inhibited but is more 
difficult to explain in transfection assay systems. Identification of the target of the 
135kD protein would be useful in further understanding the role of Vmwl 10 in virus 
infection.
Figure A The 135kD protein and cDNA sequences. The protein sequence denoted by 
the single letter amino acid code is shown above the cDNA sequence. The peptide 
sequences which were derived from the 135kD protein are shown above the relevant 
stretch of protein sequence, incorrect or unknown residues (X) being shown in bold.
The start and stop positions of selected cDNA clones, marked I  and ----- 1
respectively, are shown directly below the relevant points in the cDNA sequence. The 
positions of the primers 1782 and G39R are also shown directly below the cDNA 
sequence.
179
Appendix
Figure A
AGTACGTGCGCGTCTCCCTGCCGCCGCCGCCGCCCGCCGCGGGCCGCCCCGGGGCCGCCG 6 0
TCGCCGACGACGCGCGGGAGGAGGAGGAGGAGGCCGCCCCGCCGCCGCCGCCGCCGCCGC 1 2 0
CGCCCCGGCTCGCCGCCGCCCGCCCGCCGGGCTCGCAGCCCCGGCCCCCGGCCGCAGGCG 1 8 0
M N H Q Q Q Q Q Q Q K A G  13
AGGCCCAGGCCGCGGCCGACATGAACCACCAGCAGCAGCAGCAGCAGCAGAAAGCGGGCG 2 4 0
E Q Q L S E P E D M E M E A G D T D D P  33  
AGC AGC AGTTGAGC GAGC C C GAGGAC ATGGAGATGGAAGC GGG AGATAC AGATGACCC AC 3 0 0
I— start of clone 1142  
P R I T Q N P V I N G N V A L S D G H N  53 
C AAGAATT AC TC AGAAC C C TGTGATC AATGGGAATGTGGC CCTGAGTGATGGAC AC AAC A 3 6 0
T A E E D M E D D T S W R S E A T F Q F  73  
CCGCGGAGGAGGACATGGAGGATGACACCAGTTGGCGCTCCGAGGCAACCTTTCAGTTCA 4 2 0
T V E R F S R L S E S V L S P P C F V R  93  
CTGTGGAGCGCTTCAGCAGACTGAGTGAGTCGGTCCTTAGCCCTCCGTGTTTTGTGCGAA 4 8 0
start of clone 1131 I—
N L P W K I M V M P R F Y P D R P H Q K  113  
ATCTGCCATGGAAGATTATGGTGATGCCACGCTTTTATCCAGACAGACCACACCAAAAAA 5 4 0
S V G F F L Q C N A E S D S T S W S C H  133  
GCGTAGGATTCTTTCTCCAGTGCAATGCTGAATCTGATTCCACGTCATGGTCTTGCCATG 6 0 0
( p r o b a b le )  G la s g o w  40 K A F D E L 
A Q A V L K I I N Y R D D E K S F S R R  1 5 3  
CACAAGCAGTGCTGAAGATAATAAATTACAGAGATGATGAAAAGTCGTTCAGTCGTCGTA 6 6 0  
I X H L F N V K
I  S H L F F H K E N D W G F S N F M A W  1 7 3
TTAGTCATTTGTTCTTCCATAAAGAAAATGATTGGGGATTTTCCAATTTTATGGCCTGGA 7 2 0
G la s g o w  45 K V T F E V 
S E V T D P E K G F I D D D K V T F E V  1 9 3
GTGAAGTGACCGATCCTGAGAAAGGATTTATAGATGATGACAAAGTTACCTTTGAAGTCT 7 8 0  
F V Q A D A P I G V A P D Q K
F V Q A D A P H G V A W D S K K H T G Y  2 1 3  
TTGTACAGGCGGATGCTCCCCATGGAGTTGCGTGGGATTCAAAGAAGCACACAGGCTACG 8 4 0
V G L K N Q G A T C Y M N S L L Q T L F  2 3 3  
TCGGCTTAAAGAATCAGGGAGCGACTTGTTACATGAACAGCCTGCTACAGACGTTATTTT ' 9 0 0
F T N Q L R K A V Y M M P T E G D D S S  2 5 3  
TCACGAATCAGCTACGAAAGGCTGTGTACATGATGCCAACCGAGGGGGATGATTCGTCTA 9 6 0
K S V P L A L Q R V F Y E L Q H S D K P  2 7 3  
AAAGCGTCCCTTTAGCATTACAAAGAGTGTTCTATGAATTACAGCATAGTGATAAACCTG 1 0 2 0
V G T K K L T K S F G W E T L D S F M Q  2 9 3  
TAGGAACAAAAAAGTTAACAAAGTCATTTGGGTGGGAAACTTTAGATAGCTTCATGCAAC 1 0 8 0  
end of clone 1311 homology — I 
H D V Q E L C R V L L D N V E N K M K G  3 1 3  
ATGATGTTCAGGAGCTTTGTCGAGTGTTGCTCGATAATGTGGAAAATAAGATGAAAGGCA 1 1 4 0
T C V E G T I P K L F R G K M V S Y I Q  3 3 3  
CCTGTGTAGAGGGCACCATACCCAAATTATTCCGCGGCAAAATGGTGTCCTATATCCAGT 1 2 0 0
C K E V D Y R S D R R E D Y Y D I Q L S  3 5 3  
GTAAAGAAGTAGACTATCGGTCTGATAGAAGAGAAGATTATTATGATATCCAGCTAAGTA 1 2 6 0
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K N / T  I  F E X F V D Y V A V E Q L  
I K G K K N I F E S F V D Y V A V E Q L  3 7 3  
TCAAAGGAAAGAAAAATATATTTGAATCATTTGTGGATTATGTGGCAGTAGAACAGCTCG 1 3 2 0  
D G D N K G la s g o w  5 2 / 2
D G D N K Y D A G E H G L Q E A E K G V  39 3  
ATGGGGACAATAAATACGACGCTGGGGAACATGGCTTACAGGAAGCAGAGAAAGGTGTGA 1 3 8 0
K F L T L P P V L H L Q L M R F M Y D P  413  
AATTCCTAACATTGCCACCAGTGTTACATCTACAACTGATGAGATTTATGTATGACCCTC 1 4 4 0  
G la s g o w  5 2 K X N D R F E F P X Q L P L  
Q T D Q N I K I N D R F E F P E Q L P L  4 3 3  
AGACGGACCAAAATATCAAGATCAATGATAGGTTTGAATTCCCAGAGCAGTTACCACTTG 1 5 0 0
D E F L Q K I------------------------ primer 1782---------------- >
D E F L Q K T D P K D P A N Y I L H A V  45 3  
ATGAATTTTTGCAAAAAACAGATCCTAAGGACCCTGCAAATTATATTCTTCATGCAGTCC 1 5 6 0  
end of clone 1142 homology— I 
L V H S G D N H G G H Y V V Y L N P K G  473  
TGGTTCATAGTGGAGATAATCATGGTGGACATTATGTGGTTTATCTAAACCCCAAAGGGG 1 6 2 0
D G K W C K F D D D V V S R C T K E E A  493  
ATGGC AAATGGTGT AAATTTGATGAC GAC GTGGTGTC AAGGTGTAC T AAAG AGGAAGC AA 1 6 8 0
I  E H N Y G G H D D D L S V R H C T N A  513
TTGAGCACAATTATGGGGGTCACGATGACGACCTGTCTGTTCGACACTGCACTAATGCTT 1 7 4 0
Y M L V Y I R E S K L S E V L Q A V T D  533  
ACATGTTAGTCTACATCAGGGAATCAAAACTGAGTGAAGTTTTACAGGCGGTCACCGACC 1 8 0 0
H D I  P Q Q L V E R L Q E E K R I  E A Q 553
ATGATATTCCTCAGCAGTTGGTGGAGCGATTACAAGAAGAGAAAAGGATCGAGGCTCAGA 1 8 6 0
K R K E R Q E A H L Y M Q V Q  I V A E D  573
AGCGGAAGGAGCGGCAGGAAGCCCATCTCTATATGCAAGTGCAGATAGTCGCAGAGGACC 1 9 2 0
Q F C G H Q G N D M Y D E E K V K Y T V  593  
AGTTTTGTGGCCACCAAGGGAATGACATGTACGATGAAGAAAAAGTGAAATACACTGTGT 1 9 8 0
F K V L K N S S L A E F V Q S L S Q T M  613  
TCAAAGTATTGAAGAACTCCTCGCTTGCTGAGTTTGTTCAGAGCCTCTCTCAGACCATGG 2 0 4 0
G F P Q D Q I R L W P M Q A R S N G T K  633  
GATTTCCACAAGATCAAATTCGATTGTGGCCCATGCAAGCAAGGAGTAATGGAACAAAAC 2 1 0 0
R P A M L D N E A D G N K T M I E L S D  653  
GACCAGCAATGTTAGATAATGAAGCCGACGGCAATAAAACAATGATTGAGCTCAGTGATA 2 1 6 0
N E N P W T I F L E T V D P E L A A S G  673  
ATGAAAAC C C TTGGACAATATTCC TGGAAACAGTTGATCC CGAGCTGGC TGCTAGTGGAG 2 2 2 0
A T L P K F D K D H D V M L F L K M Y D  693  
CGACCTTACCCAAGTTTGATAAAGATCATGATGTAATGTTATTTTTGAAGATGTATGATC 2 2 8 0
P K T R S L N Y C G H I Y T P I S C K I  7 1 3  
CCAAAACGCGGAGCTTGAATTACTGTGGGCATATCTACACACCAATATCCTGTAAAATAC 2 3 4 0
R D L L P V M C D R A G F I Q D T S L I  73 3  
GTGACTTGCTCCCAGTTATGTGTGACAGAGCAGGATTTATTCAAGATACTAGCCTTATCC 2 4 0 0
L Y E E V K P N L T E R I Q D Y D V S L  7 5 3  
TCTATGAGGAAGTTAAACCGAATTTAACAGAGAGAATTCAGGACTATGACGTGTCTCTTG 2 4 6 0
D K A L D E L M D G D I I V F Q K D D P  7 7 3  
ATAAAGC C CTTGATGAAC TAATGGATGGTGACATCATAGTATTTCAGAAGGATGACCC TG 2 5 2 0
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E N D N S E L P T A K E Y F R D L Y H R  7 9 3  
AAAATGATAACAGTGAATTACCCACCGCAAAGGAGTATTTCCGAGATCTCTACCACCGCG 2 5 8 0
V D V I F C D K T I P N D P G F V V T L  813  
TTGATGTCATTTTCTGTGATAAAACAATCCCTAATGATCCTGGATTTGTGGTTACGTTAT 2 6 4 0
S N R M N Y F Q V A K T V A Q R L N T D  83 3  
CAAATAGAATGAATTATTTTCAGGTTGCAAAGACAGTTGCACAGAGGCTCAACACAGATC 2 7 0 0
P M L L Q F F K S Q G Y R D G P G N P L  853  
CAATGTTGCTGCAGTTTTTCAAGTCTCAAGGTTATAGGGATGGCCCAGGTAATCCTCTTA 2 7 6 0
R H N Y E G T L R D L L Q F F K P R Q P  873  
GACATAATTATGAAGGTACTTTAAGAGATCTTCTACAGTTCTTCAAGCCTAGACAACCTA 2 8 2 0  
K L Y Y Q Q L K  G la s g o w  23  
K K L Y Y Q Q L K M K I T D F E N R R S  893  
AGAAACTTTACTATCAGCAGCTTAAGATGAAAATCACAGACTTTGAGAACAGGCGAAGTT 2 8 8 0
F K C  I W L N S Q F R E E E I T L Y P D  913
TTAAATGTATATGGTTAAACAGCCAATTTAGGGAAGAGGAAATAACACTATATCCAGACA 2 9 4 0
K H G C V R D L L E E C K K A V E L G E  933  
AGCATGGGTGTGTCCGGGACCTGTTAGAAGAATGTAAAAAGGCCGTGGAGCTTGGGGAGA 3 0 0 0
K A S G K L R L L E I V S Y K I  I G V H  953
AAGCATCAGGGAAACTTAGGCTGCTAGAAATTGTAAGCTACAAAATCATTGGTGTTCATC 3 06 0
Q E D E L L E C L S P A T S R T F R I E  973  
AAGAAGATGAACTATTAGAATGTTTATCTCCTGCAACGAGCCGGACGTTTCGAATAGAGG 3 1 2  0
E l  P L D Q V D I  D K E N E M L V T V A  993
AAATCCCTTTGGACCAGGTGGACATAGACAAAGAGAATGAGATGCTTGTCACAGTGGCGC 3 1 8 0
H F H K E V F G T F G I P F L L R I H Q  1 0 1 3  
ATTTCCACAAAGAGGTCTTCGGAACGTTCGGAATCCCGTTTTTGCTGAGGATACACCAGG 3 2 4 0
G E H F R E V M K R I Q S L L D I Q E K  1 0 3 3  
GCGAGCATTTTCGAGAAGTGATGAAGCGAATCCAGAGCCTGCTGGACATCCAGGAGAAGG 3 3 0 0
E F E K F K F A I V M T G R H Q Y I N E  1 0 5 3  
AGTTTGAGAAGTTTAAATTTGCAATTGTAATGACGGGCCGACACCAGTACATAAATGAAG 33 60
end of clone 80922 homology I—
G la s g o w  39 K D / S F / S  E P T P G N M S X P  
D E Y E V N L K D F E P Q P G N M S H P  1 0 7 3  
ACGAGTATGAAGTAAATTTGAAAGACTTTGAGCCACAGCCCGGTAATATGTCTCATCCTC 3 4 2 0  
X P X L G L D X F N K
R P W L G L D H F N K A P K R S R Y T Y  1 0 9 3  
GGCCTTGGCTAGGGCTCGACCACTTCAACAAAGCCCCAAAGAGGAGTCGCTACACTTACC 3 4 8 0
<---------- Primer G39R----------- 1
L E K A I K I H N -  1 1 0 2
TTGAAAAGGCCATTAAAATCCATAACTGATTTCCAAGCTGGTGTGTTCAAGGCGAGGACG 3 5 4 0
GTGTGTGGGTGGCCCCTTAACAGCCTAGAACTTTGGTGCACGTGCCCTCTAGCCGAAGTC 3 6 0 0
TTCAGCAAGAGGATTCGCTGCTGGTGTTAATTTTATTTTATTGAGGCTGTTCAGTTTGGC 3 6 6 0
TTCTCTGTATCTATTGACTGCCCTTTTTGAGCAAAATGAAGATGTTTTTATAAAGCTT 3 7 1 8
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